



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

Robert M. Grant, M.D., M.P.H., Javier R. Lama, M.D., M.P.H., Peter L. Anderson, Pharm.D., Vanessa McMahan, B.S., Albert Y. Liu, M.D., M.P.H., Lorena Vargas, Pedro Goicochea, M.Sc., Martín Casapía, M.D., M.P.H., Juan Vicente Guanira-Carranza, M.D., M.P.H., María E. Ramírez-Cardich, M.D., Orlando Montoya-Herrera, M.Sc., Telmo Fernández, M.D., Valdilea G. Veloso, M.D., Ph.D., Susan P. Buchbinder, M.D., Suwat Chariyalertsak, M.D., Dr.P.H., Mauro Schechter, M.D., Ph.D., Linda-Gail Bekker, M.B., Ch.B., Ph.D., Kenneth H. Mayer, M.D., Esper Georges Kallás, M.D., Ph.D., K. Rivet Amico, Ph.D., Kathleen Mulligan, Ph.D., Lane R. Bushman, B.Chem., Robert J. Hance, A.A., Carmela Ganoza, M.D., Patricia Defechereux, Ph.D., Brian Postle, B.S., Furong Wang, M.D., J. Jeff McConnell, M.A., Jia-Hua Zheng, Ph.D., Jeanny Lee, B.S., James F. Rooney, M.D., Howard S. Jaffe, M.D., Ana I. Martinez, R.Ph., David N. Burns, M.D., M.P.H., and David V. Glidden, Ph.D. for the iPrEx Study Team

N Engl J Med 2010; 363:2587-2599 | December 30, 2010 | DOI: 10.1056/NEJMoa1011205

[Comments](#) open through January 4, 2011

Share:

Abstract

Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.

We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections.

The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; $P=0.005$). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) ($P<0.001$). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group ($P<0.001$). The two groups had similar rates of serious adverse events ($P=0.57$).

Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, [NCT00458393](#).)

Article

A total of 2.7 million new infections with the human immunodeficiency virus (HIV) were diagnosed worldwide in 2008, according to the Joint United Nations Program on HIV/AIDS (UNAIDS). Combination antiretroviral therapy for patients with HIV infection restores health and may decrease the transmission of the virus to uninfected partners.¹ Therapy also decreases mother-to-child transmission.²

Postexposure chemoprophylaxis is recommended after occupational or nonoccupational exposure to HIV-infected fluids.³ The use of such chemoprophylaxis requires that people recognize when they might have been exposed to HIV and that they start therapy within 72 hours. Both challenges are substantial limitations to the use of postexposure chemoprophylaxis.^{4,5}

We selected emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) combination therapy in a single tablet (FTC–TDF) for evaluation of preexposure prophylaxis because of several favorable characteristics.⁶ (Details are provided in the introduction in the [Supplementary Appendix](#), available with the full text of this article at NEJM.org.) The protective activity of FTC and TDF has been shown in mice transplanted with human immune cells⁷ and in nonhuman primates.^{8–10} In these studies, there were increased levels of efficacy when both agents were used together, as compared with the use of either agent alone. The administration of the drug both before and after exposure was important for maximizing the protective benefit.¹¹

Daily preexposure prophylaxis with oral TDF had an acceptable side-effect profile in a trial involving West African women.¹² A tenofovir 1% vaginal gel reduced HIV infection rates by 39% among women.¹³ Men and transgender women who have sex with men are disproportionately affected by the global epidemic.^{14,15} Surveys of such persons in the United States indicate that the current use of preexposure prophylaxis is rare, although the majority would consider such use if evidence of safety and efficacy became available.^{16,17}

In this multinational study, called the Preexposure Prophylaxis Initiative (iPrEx) trial, we aimed to evaluate the safety and efficacy of once-daily oral FTC–TDF as compared with placebo for the prevention of HIV acquisition among men and transgender women who have sex with men.

We developed the concept and protocol for this study using methods that came to be approved as “good participatory practices” by UNAIDS.¹⁸ The development of the protocol was sponsored by the National Institute of Health’s Division of Acquired Immunodeficiency Syndrome (DAIDS). The protocol was approved by national government public health authorities in Peru, Ecuador, South Africa, Brazil, Thailand, and the United States and by the ethics committee at each site. All subjects provided written informed consent. The study coordinator vouches for the fidelity of the report to the protocol. The study [protocol](#) is available at NEJM.org, and a detailed description of the methods is provided in the [Supplementary Appendix](#).

Inclusion criteria were male sex at birth, an age of 18 years or older, HIV-seronegative status, and evidence of high risk for acquisition of HIV infection. Subject codes were randomly assigned in blocks of 10, stratified according to site. The subject codes were assigned consecutively at the study sites to eligible subjects at the time of the first dispensation of a study drug. Serologic testing for hepatitis B was performed at screening.

Study visits were scheduled every 4 weeks after enrollment. Each 4-week visit included drug dispensation, pill count, adherence counseling, rapid testing for HIV antibodies, and taking of a medical history. Chemical and hematologic analyses were performed at weeks 4, 8, 12, 16, and 24 and every 12 weeks thereafter. During screening, a computer-assisted structured interview collected information about education level, self-identified sex, and alcohol use, along with subjects’ perceived study-group assignment at week 12. High-risk behavior was assessed by interview every 12 weeks, and physical examinations and evaluations for sexually transmitted infections were performed at least every 24 weeks. Visits through May 1, 2010, are included in this report of the primary analysis of safety and efficacy. The visit cutoff date was set by the study sponsor without any access to interim findings and was intended to ensure observation of the targeted number of seroconversion events (85). The use of study drugs was intensively monitored and promoted (for details, see Methods in the [Supplementary Appendix](#)).

At every scheduled visit, subjects received a comprehensive package of prevention services, including HIV testing, risk-reduction counseling, condoms, and diagnosis and treatment of symptomatic sexually transmitted infections, including gonorrhea and chlamydia urethritis, syphilis, and herpes simplex virus type 2 (HSV-2). In addition, at 24-week intervals, subjects were screened for asymptomatic urethritis, syphilis, antibodies to HSV-2, and genital warts and ulcers; treatment was provided when indicated. Sexual partners were offered treatment of sexually transmitted infections that were diagnosed in the subject. Subjects were linked to local prevention and treatment services when required to receive standard-of-care services. All subjects were instructed to protect themselves from HIV with conventional methods, since they were unaware of their study-group assignment. Subjects who reported a recent unprotected exposure to an HIV-infected partner were referred for postexposure prophylaxis (at sites where such therapy was available), and the administration of a study drug was temporarily suspended. Vaccination against hepatitis B virus (HBV) was offered to all susceptible subjects.

Testing for HIV antibody was performed on whole blood with the use of two different rapid tests at every scheduled visit, and reactive rapid tests were tested with the use of Western blot analysis of serum (Figure S1 in the [Supplementary Appendix](#)). Subjects with failed rapid tests were retested during the visit. HIV plasma RNA testing with the use of an assay with a lower limit of quantitation of 40 copies per milliliter was performed if seroconversion was detected within 12 weeks after enrollment. RNA testing was also used to identify the first date of laboratory evidence of infection for the as-treated analysis. Testing for drug-resistance genotyping and phenotyping was performed with the use of clinically validated assays on the basis of the viral load at the seroconversion visit.

A prespecified subgroup analysis was performed to investigate whether drug levels correlated with protective effect. Subjects with HIV infection were matched with two control subjects, one from each study group who were selected from among seronegative subjects, according to study site (Figure S5 in the [Supplementary Appendix](#)). Plasma was tested for the presence of FTC and tenofovir (TFV), and peripheral-blood mononuclear cells were tested for FTC triphosphate (FTC-TP) and TFV diphosphate (TFV-DP), which are the active intracellular metabolites of FTC and TFV, respectively, with the use of validated liquid chromatography and tandem mass spectrometry assays.

The study was designed by four of the investigators in collaboration with all the site investigators and communities. DAIDS reviewers approved the protocol, which was developed by the study investigators, and monitored the conduct of the trial at study sites. The Bill and Melinda Gates Foundation also provided funding but did not have a role in protocol development or site monitoring. Gilead Sciences donated both FTC-TDF and placebo tablets and provided travel-related support for meetings conducted by non-Gilead investigators. The role of Gilead Sciences in the development of the protocol was limited to sections regarding the handling of the study drugs. Neither Gilead Sciences nor any of its employees had a role in the accrual or analysis of the data or in the preparation of the manuscript. DAIDS agreed to give Gilead 30 days to comment on the manuscript, but there was no agreement to accept suggestions. The first author wrote the first draft of the manuscript (except for the drug-level sections, which were drafted by another investigator) and decided to submit the manuscript for publication. The protocol statistician and data manager vouch for the accuracy of the data, and the protocol chair and site investigators vouch for the completeness of the reported data.

Data were collected on case-report forms and faxed to a DataFax server at DF/Net Research. It was determined that the observation of 85 incident HIV infections would yield a power of at least 80% with a one-sided alpha level of 0.05 to reject a null hypothesis of efficacy of 30% or less if the true efficacy were 60% or more. The modified intention-to-treat analysis included available data for all subjects except those with HIV RNA detected in their enrollment sample. The as-treated analysis used a time-dependent covariate indication as to whether the subject was known to fall below the prespecified level of study-drug compliance (50%) on any of the following: records of study-drug dispensation alone, pill-use calculation on the basis of study-drug dispensation and returns, and subjects' self-report. For the as-treated analysis, pills from unreturned bottles were assumed to have been taken, and late visits were included in the analysis if the last dispensation allowed pill use on 50% or more of days. Safety analyses included all subjects.


Of 4905 subjects who were screened, 2499 were enrolled in the study from July 10, 2007, through December 17, 2009, at 11 sites in six countries (Figure 1). The baseline characteristics of the two study groups were similar (Table 1). All subjects were born male, although 29 (1%) reported their current gender identity as female. The ages of the subjects ranged from 18 to 67 years; the FTC-TDF group was on average 9 months older than the placebo group (mean age, 27.5 vs. 26.8 years; $P=0.04$).

Among HBV-susceptible subjects at screening, 94% accepted HBV vaccination. We enrolled 13 subjects with chronic HBV infection that was detected at screening, and acute HBV infection was reported as an adverse event in 3 additional subjects (2 in the FTC-TDF group and 1 in the placebo group) after enrollment when elevated liver aminotransferase levels were observed. All the HBV infections resolved with detectable levels of immunity.

The cohort was followed for 3324 person-years with a variable duration of observation (median, 1.2 years; maximum, 2.8 years) ([Figure 1](#)). There were no significant trends in visit completion rates over time. Most subjects said they did not know their study-group assignment at week 12, and those who guessed their assignment were evenly distributed between the two groups (Table S3 in the [Supplementary Appendix](#)). No subjects were told their study-group assignment during the course of the trial. A study drug was temporarily discontinued in 21 subjects (8 in the FTC-TDF group and 13 in the placebo group) so that they could receive postexposure prophylaxis for HIV ($P=0.28$).

The rate of self-reported pill use was lower in the FTC-TDF group than in the placebo group at week 4 (mean, 89% vs. 92%; $P<0.001$) and at week 8 (mean, 93% vs. 94%; $P=0.006$) but was similar thereafter (mean, 95% in the two groups). At each visit, a portion of subjects (approximately 6%) did not report the number of pills missed. The percentage of pill bottles returned was 66% by 30 days and 86% by 60 days. The rate of pill use that was estimated according to pill count also increased during the first 8 weeks and then remained stable at a median ranging from 89 to 95%, depending on whether pills from unreturned bottles were counted as having been taken or not taken. On the basis of pill-dispensation dates and quantities, the rate of pill use decreased during the first year, from 99% to 91%, a trend that contrasted with pill counts and self-report, which indicated an increased rate of use.

FIGURE 1



Enrollment and Outcomes.

TABLE 1

Baseline Characteristics of the Subjects.

Sexual practices were similar in the two groups at all time points ($P=0.97$) (Figure S2 in the [Supplementary Appendix](#)). The total numbers of sexual partners with whom the respondent had receptive anal intercourse decreased, and the percentage of those partners who used a condom increased after subjects enrolled in the study. There were no significant between-group differences in the numbers of subjects with syphilis ($P=0.49$), gonorrhea ($P=0.74$), chlamydia ($P=0.43$), genital warts ($P=0.53$), or genital ulcers ($P=0.62$) during follow-up (Table S4 in the [Supplementary Appendix](#)).

In testing for elevations in serum creatinine levels, there were 41 instances of elevations that were at least 1.1 times the upper limit of the normal range or more than 1.5 times the baseline level. Of these elevations, 26 (2%) were in the FTC-TDF group and 15 (1%) were in the placebo group ($P=0.08$). Two of these elevations increased in grade, accounting for a total of 43 creatinine adverse events (Table 2, and Table S9 in the *Supplementary Appendix*). Overall, 18 creatinine elevations (44%) remained in the normal range, and 36 (88%) were not confirmed on the next test. A total of 10 elevations led to discontinuation of a study drug (7 in the FTC-TDF group and 3 in the placebo group); study drugs were restarted in 9 subjects. Serum creatinine levels were elevated at more than one consecutive test in 5 subjects in the FTC-TDF group (<1%) and in none of the subjects in the placebo group. All elevations in the serum creatinine level resolved after the discontinuation of a study drug, within 4 weeks in 3 subjects, within 12 weeks in 1 subject, and within 20 weeks in 1 subject. Four of the subjects resumed taking FTC-TDF without recurrence of the elevation.


TABLE 2

Adverse Events

Moderate nausea (grade 2 and above) was reported more frequently in the FTC-TDF group than in the placebo group (22 vs. 10 events, $P=0.04$), as was unintentional weight loss of 5% or more (34 vs. 19 events, $P=0.04$) (for details, see Table S10 in the [Supplementary Appendix](#)).

HIV rapid testing was performed at 39,613 visits, during which there were false reactive tests for 3 subjects at 7 visits; each subject had multiple negative tests afterward. HIV seroconversion was observed in 110 persons, of whom 10 had plasma HIV RNA subsequently detected in specimens obtained at the enrollment visit. A finding of fewer than 40 copies per milliliter of plasma HIV RNA was documented for the other 100 HIV-infected subjects before seroconversion. Among the 100 subjects with emergent HIV infection, 36 occurred in the FTC-TDF group, and 64 occurred in the placebo group, representing a relative reduction of 44% in incidence in the modified intention-to-treat population (95% confidence interval [CI], 15 to 63; $P=0.005$) ([Figure 2](#)). After adjustment for the difference in age between the two groups, the efficacy was 43% (95% CI, 14 to 62). The rate of pill use on 50% or more of days was recorded on the basis of pill counts, self-report, and dispensation records at 81% of visits on which efficacy was 50% (95% CI, 18 to 70; $P=0.006$). This rate did not differ significantly ($P=0.48$) from the efficacy at visits with less than 50% pill use of 32% (95% CI, -41 to 67%) ([Figure 3](#)). Efficacy of less than 30% could not be ruled out in the modified intention-to-treat analysis ($P=0.15$) or in the prespecified as-treated analysis at 50% pill use ($P=0.09$). There was no evidence of a change in HIV efficacy with longer follow-up ($P=0.44$).


FIGURE 2



Kaplan–Meier Estimates of Time to HIV Infection (Modified Intention-to-Treat Population)

In prespecified analyses of efficacy according to subgroup, efficacy was higher among subjects who reported at screening that they had previously had unprotected receptive anal intercourse than among those who did not (efficacy, 58%; 95% CI, 32 to 74) (**Figure 3**). There was no significant between-group difference in protection on the basis of region, race or ethnic group, male circumcision, level of education, alcohol use, or age. In post hoc analyses, pill use on 90% or more of days was recorded at 49% of visits on which efficacy was 73% (95% CI, 41 to 88; $P<0.001$). Among all subjects, without exclusion for HIV infection at enrollment or the degree of compliance to the drug regimen, the efficacy was 47% (95% CI, 22 to 64; $P=0.001$).

FIGURE 3



HIV Incidence among Subjects Receiving FTC-TDF, According to Subgroup.

Among the 10 subjects in whom plasma HIV RNA was subsequently detected in specimens obtained at enrollment, 5 had symptoms of an acute viral syndrome at enrollment, 2 had symptoms 1 week later (prompting an interim study visit), 1 had an anal sore, and 2 had leukopenia at enrollment. In these subjects, the clinicians did not suspect acute HIV infection, because the symptoms were attributed to an upper respiratory tract infection, sinusitis, or other non-HIV cause.

Of the preexisting HIV infections at enrollment, two occurred in the FTC-TDF group and eight in the placebo group ($P=0.06$). Among subjects who were infected after enrollment, the numbers with detectable plasma HIV RNA before seroconversion were 5 of 36 (14%) in the FTC-TDF group and 7 of 64 (11%) in the placebo group ($P=0.75$). The time to seroconversion after RNA detection was similar in the two groups ($P=0.55$). After the discontinuation of a study drug, seroconversion rates were similar among 320 subjects (161 in the FTC-TDF group and 159 in the placebo group) ($P=0.42$). These subjects had a total of 1173 visits for HIV testing after the discontinuation of a study drug (642 in the FTC-TDF group and 531 in the placebo group). During

these visits, 5 seroconversions were observed (2 in the FTC–TDF group and 3 in the placebo group).

Among subjects who became infected with HIV, the median time between the tested specimen date and the last uninfected visit was 35 days (interquartile range, 28 to 56). No drug was detected in any plasma or cell specimens from subjects in the placebo group. Among subjects in the FTC–TDF group, at least one of the study-drug components was detected in 3 of 34 subjects with HIV infection (9%) and in 22 of 43 seronegative control subjects (51%) (Figure 4). Of the 3 HIV-infected subjects with a detectable level of a study drug, none had cell-associated drug levels higher than the median for the 22 seronegative control subjects in whom a study-drug component was detected. Only 8% of subjects with HIV infection and 54% of control subjects who were considered “on treatment” on more than 50% of days had a detectable level of a study drug in plasma or peripheral-blood mononuclear cells (Table S8 in the [Supplementary Appendix](#)). Detection of the different drug components was more than 95% concordant (Table S6 in the [Supplementary Appendix](#)).

In the FTC–TDF group, among subjects with a detectable study-drug level, as compared with those without a detectable level, the odds of HIV infection were lower by a factor of 12.9 (95% CI, 1.7 to 99.3; $P<0.001$), corresponding to a relative reduction in HIV risk of 92% (95% CI, 40 to 99; $P<0.001$). After adjustment for reported unprotected receptive anal intercourse, the relative risk reduction was 95% (95% CI, 70 to 99; $P<0.001$).

Plasma HIV RNA levels and CD4+ T-cell counts were similar among subjects with seroconversion in the two groups (Figure S4 in the [Supplementary Appendix](#)). Among the 10 subjects who were infected at enrollment, 3 had FTC-resistant infections (2 of 2 in the FTC–TDF group and 1 of 8 in the placebo group) (Table S5 in the [Supplementary Appendix](#)). No TDF-resistant infections were observed. Among 36 subjects in the FTC–TDF group and 64 subjects in the placebo group who became infected with HIV during the trial, no FTC or TDF resistance was detected.


Once-daily oral FTC–TDF provided 44% additional protection from HIV among men or transgender women who have sex with men who also received a comprehensive package of prevention services. The protective effect of FTC–TDF was significant but not as high as originally hypothesized during the design of the study. Although reported pill use was high, drug exposure that was measured objectively was substantially lower. The intracellular assay that was used in this study is expected to detect TFV-DP for 14 days or more after the last dose of TDF is taken (see Methods in the [Supplementary Appendix](#)). Other evidence of low drug exposure included the lack of drug resistance observed among emergent infections and the absence of suppression of the HIV RNA level in plasma at the seroconversion visit. There was no evidence of delayed seroconversion among subjects who were infected in the FTC–TDF group. More information will be available after the entire cohort stops receiving the study drug.

The estimate of biologic activity of FTC–TDF persists after adjustment for high-risk sexual practice, suggesting that the correlation between drug detection and protection is primarily due to the drug and not to other characteristics of subjects that may link poor adherence with higher risk. The testing of a larger number of specimens, from more subjects at more times, is needed to better define the minimum protective drug concentration. Protective drug levels may differ according to the type of exposure (rectal vs. penile). Drug level may have a role in monitoring trials, programs, and individual users. Methods for inexpensively measuring long-term drug exposure, such as that afforded by analysis of hair,¹⁹ would be helpful once such a method is fully validated.

Side effects may have contributed to low pill use among some subjects. As with treatment of HIV infection and the use of FTC–TDF in postexposure prophylaxis,²⁰ the initiation of FTC–TDF preexposure prophylaxis was associated with self-limited start-up symptoms in a few subjects. The trial design involving a placebo may also have contributed to lower-than-expected pill use. All subjects were counseled that the study pill might be a placebo or an active drug having no proven benefit. Open-label research and program development could provide users with clearer information about expected benefits and risks, which might increase the use and efficacy of preexposure prophylaxis. Engagement with communities and additional behavioral research are needed to develop methods of counseling that better support such use.

The initiation of chemoprophylaxis either before or after exposure should be deferred in patients with signs or symptoms of a viral syndrome, which are often present during acute HIV infection.^{21,22} The initiation of postexposure prophylaxis in patients who are RNA-positive but antibody-negative has been linked with acquisition of resistance to FTC and lamivudine (3TC),⁵ as occurred in subjects in the FTC–TDF group who were already infected at enrollment in our trial. Ways to increase recognition of acute HIV infection would include routine measurement of body temperature and testing for HIV antibodies to evaluate viral syndromes, regardless of whether the presentation suggests HIV infection or another cause. Testing for HIV RNA at the time of

FIGURE 4



Levels of Study-Drug Components in Blood of Subjects Receiving FTC–TDF, According to HIV Status.

the initiation of preexposure prophylaxis should be considered where available.

TDF treatment is known to cause decreases in renal function,²³ and there were trends toward more creatinine elevations in the FTC–TDF group than in the placebo group. Most creatinine elevations were self-limited and were not confirmed on repeat testing of a new specimen, as might occur due to dehydration, creatine use, or exercise. The ability to detect safety outcomes, including drug resistance, may have been decreased by lower-than-expected drug exposure. In light of evidence of the efficacy of FTC–TDF, more information is needed about possible subclinical effects that may affect bone mineral density, low-level drug resistance, and proximal renal tubular function. Flares of hepatitis caused by HBV after stopping preexposure prophylaxis with TDF were not seen in West African women,¹² but more information is needed. These issues are being investigated in existing trials of preexposure prophylaxis.

Reported high-risk behavior decreased substantially after enrollment and remained lower than at baseline during the trial. Safer behavior was also observed in a trial of preexposure prophylaxis with TDF in West African women¹² and may reflect the services (e.g., counseling, testing, and dispensing of condoms) that are provided as part of such interventions. In addition, taking a pill a day may have served as a daily reminder of imminent risk and may have promoted planning for sex, which has been associated with lower HIV risk.²⁴ Behavioral changes during future open-label use of preexposure prophylaxis may differ because of an increased expectation of benefits, although such “risk compensation” was not observed during an open-label study of postexposure prophylaxis, during which benefits were expected.²⁵

The optimal regimen for preexposure prophylaxis has not been established, and data from the subjects in our study cannot be applied to other populations. Alternative regimens in different populations are being studied. (Details are available in the Discussion in the [Supplementary Appendix](#) and at www.avac.org.)

In our study, preexposure prophylaxis with oral FTC–TDF among men and transgender women who have sex with men addressed an important unmet need in public health. HIV prevalence is higher in this population than in other groups in almost all countries.¹⁴ In the United States, rates of HIV infection among such men and transgender women have climbed since the early 1990s, affecting in particular black and Hispanic subpopulations.²⁶ Intensive counseling in behavioral risk reduction for such subjects has not been shown to be better than standard counseling.²⁷ Although male circumcision partially protects heterosexual men,^{28–30} penile circumcision is not expected to protect those who are exposed on the rectal mucosa.³¹ Heterosexual women were partially protected by tenofovir 1% vaginal gel,¹³ but the safety and utility of tenofovir topical gels for rectal use is not yet known. In the FTC–TDF group, there was increased efficacy among subjects who reported having unprotected receptive anal intercourse, which is the main mode of HIV transmission among the subjects in our study and increases the risk of heterosexual women who engage in the practice.³² We showed that such subjects with a high risk of exposure to HIV can be mobilized to participate in prevention initiatives and that preexposure prophylaxis is effective for slowing the spread of HIV in this population.

Supported by the Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, as a cooperative agreement (UO1 AI64002, to Dr. Grant) and by the Bill and Melinda Gates Foundation. Study drugs were donated by Gilead Sciences. The pharmacological studies were sponsored by a cooperative agreement with DAIDS (UO1 AI84735, to Dr. Anderson). Support for some specimen handling came from a grant from DAIDS (RO1 AI062333, to Dr. Grant) and by the J. David Gladstone Institutes. Some infrastructure support at the University of California at San Francisco was provided by a grant from the National Institutes of Health (UL1 RR024131).

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

This article (10.1056/NEJMoa1011205) was published on November 23, 2010, and updated on December 1, 2010, at NEJM.org.

Dr. Grant reports receiving support as an advisor to Siemens (the manufacturer of TruGene HIV-1 Genotyping Kit); Dr. Mayer reports receiving grant support from Gilead, Merck, and Bristol-Myers Squibb; Dr. Kallás reports serving on a data and safety monitoring board for Merck; Dr. Schechter reports receiving consulting fees and grants from Gilead; Drs. Liu and Anderson report receiving donations of study drug from Gilead for various PrEP projects; and Drs. Jaffe and Rooney report being employees of Gilead Sciences and owning stock in the company. No other potential conflict of interest relevant to this article was reported.

We thank the study subjects for their dedication to finding new ways to protect communities and for their trust in us; the community advisory boards; the members of the DAIDS multinational independent data and safety monitoring board, Kathy Edwards (chair), Shrikant I. Bangdiwala, KyungMann Kim, W.D. Francois Venter, Alejandro Llanos-Cuentas, Olavo Henrique Munhoz Leite, V.I. Mathan, Carlos Seas, Panpit Suwangool, Wafaa El-Sadr, Gary Maartens, Gabriel Thimonthe, Michael Proschan, and Dennis Dixon; community advocates Mitchell Warren, Julie Davids, Susana Chavez, Jorge (Tito) Bracamonte, and Carlos Caceres; Caitlin Fernandez, Joseph Rower, and Brandon Klein for their analytical pharmacology assistance; Grace Chow and Stephen Becker for their guidance as project officers; John Carroll of the Gladstone Institutes for providing original versions of the figures; Miguel Bernal and Ximena Barra for their print and film work; Mark Aurigemma for developing communication materials; Malu Robles for her assistance in the

preparation of the manuscript; and Mark Wainberg, Mike Youle, Sandra Lehrman, Jose Pilotto, Neptali Arias, Vivian Levy, Kimberly Page, and Renee Ridzon for inspiration and logistical work.

The authors' affiliations are listed in the Appendix.

Address reprint requests to Dr. Grant at the J. David Gladstone Institutes, University of California at San Francisco, 1650 Owens St., San Francisco, CA, 94158, or at robert.grant@ucsf.edu.

Other members of the Preexposure Prophylaxis Initiative (iPrEx) study team are listed in the [Supplementary Appendix](#), available at NEJM.org.

The authors' affiliations are as follows: the Gladstone Institute of Virology and Immunology (R.M.G., V.M., P.G., R.J.H., J.J.M., P.D., J.L.), the University of California, San Francisco (R.M.G., A.Y.L., S.P.B., K.M., F.W., D.V.G.), and the HIV Research Section, San Francisco Department of Public Health (A.Y.L., S.P.B.) — all in San Francisco; Investigaciones Medicas en Salud, Lima (J.R.L., L.V.), Asociación Civil Impacta Salud y Educación, Lima (J.R.L., J.V.G.-C., M.E.R.-C., C.G.), and Asociación Civil Selva Amazónica, Iquitos (M.C.) — all in Peru; the University of Colorado, Denver (P.L.A., L.R.B., J.-H.Z.); Fundación Ecuatoriana Equidad, Guayaquil, Ecuador (O.M.-H., T.F.); Instituto de Pesquisa Clínica Evandro Chagas—Fundação Oswaldo Cruz (V.G.V.), and Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro (M.S.) — both in Rio de Janeiro; Brown University, Providence, RI (K.H.M.); the Fenway Institute, Fenway Health, Boston (K.H.M.); the Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, and Instituto de Investigaçāo em Imunologia — both in São Paulo (E.G.K.); Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand (S.C.); Desmond Tutu HIV Centre and Department of Medicine, University of Cape Town, Cape Town, South Africa (L.-G.B.); Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (A.I.M., D.N.B.); Gilead Sciences, Foster City, CA (J.F.R., H.S.J.); DF/Net Research, Seattle (B.P.); Applied Health Research, Brighton, MI (K.R.A.); and the Center for Health, Intervention, and Prevention, University of Connecticut, Storrs (K.R.A.).

References

- 1 Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet* 2010;375:2092-2098
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 2 Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *N Engl J Med* 1994;331:1173-1180
[Free Full Text](#) | [Web of Science](#) | [Medline](#)
- 3 Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. *MMWR Recomm Rep* 2005;54:1-20
[Medline](#)
- 4 Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. *J Acquir Immune Defic Syndr* 2004;35:519-525
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 5 Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. *Clin Infect Dis* 2005;41:1507-1513
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 6 Grant RM, Buchbinder S, Cates W Jr, et al. AIDS: promote HIV chemoprophylaxis research, don't prevent it. *Science* 2005;309:2170-2171
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 7 Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. *PLoS Med* 2008;5:e16-e16
[CrossRef](#) | [Web of Science](#) | [Medline](#)

- 8 Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. *Science* 1995;270:1197-1199
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 9 Van Rompay KKA, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. *J Infect Dis* 2001;184:429-438
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 10 Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. *PLoS Med* 2008;5:e28-e28
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 11 Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. *Sci Transl Med* 2010;2:14ra4-14ra4
[CrossRef](#) | [Web of Science](#)
- 12 Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. *PLoS Clin Trials* 2007;2:e27-e27
[CrossRef](#) | [Medline](#)
- 13 Abdoor Karim Q, Abdoor Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science* 2010;329:1168-1174
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 14 van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A. The global epidemic of HIV infection among men who have sex with men. *Curr Opin HIV AIDS* 2009;4:300-307
[CrossRef](#) | [Web of Science](#)
- 15 Beyer C, Baral SD, Walker D, Wirtz AL, Johns B, Sifakis F. The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. *Epidemiol Rev* 2010;32:137-151
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 16 Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. *J Acquir Immune Defic Syndr* 2008;47:241-247
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 17 Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. *J Acquir Immune Defic Syndr* 2009;50:77-83
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 18 Good participatory practice: guidelines for biomedical HIV prevention trials. Geneva: UNAIDS, 2007.
- 19 Liu A, Vittinghoff E, Gandhi M, et al. Validating measures of tenofovir drug exposure in a US pre-exposure prophylaxis trial. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 27–March 2, 2010.
- 20 Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center. *J*

Acquir Immune Defic Syndr 2008;47:494-499
[CrossRef](#) | [Web of Science](#) | [Medline](#)

- 21 Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-620
[Web of Science](#) | [Medline](#)
- 22 Hofer CB, Harrison LH, Struchiner CJ, et al. Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. J Acquir Immune Defic Syndr 2000;25:188-191
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 23 Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naïve patients. AIDS 2008;22:2155-2163
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 24 van Griensven F, Thienkrua W, Sukwicha W, et al. Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection. J Int AIDS Soc 2010;13:13-13
[CrossRef](#) | [Web of Science](#)
- 25 Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-792
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 26 Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-529
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 27 Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 2004;364:41-50
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 28 Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298-e298[Erratum, PLoS Med 2006;3(5):e226.]
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 29 Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-656
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 30 Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657-666
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 31 Templeton DJ, Millett GA, Grulich AE. Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Curr Opin Infect Dis 2010;23:45-52
[CrossRef](#) | [Web of Science](#) | [Medline](#)
- 32 Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010;39:1048-1063
[CrossRef](#) | [Web of Science](#) | [Medline](#)

Citing Articles (699)

- 1 Stacey M. Succop, Kathleen M. MacQueen, Francois van Loggerenberg, Nelisile Majola, Quarraisha Abdool Karim, Salim S. Abdool Karim. (2014) Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. *AIDS Care* **26**:12, 1521-1525
[CrossRef](#)
- 2 J. S. Doyle, L. Degenhardt, A. E. Pedrana, E. S. McBryde, R. J. Guy, M. A. Stoove, E. R. Weaver, A. E. Grulich, Y.-R. Lo, M. E. Hellard. (2014) Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases* **59**:10, 1483-1494
[CrossRef](#)
- 3 Rute Nunes, Bruno Sarmento, José das Neves. (2014) Formulation and delivery of anti-HIV rectal microbicides: Advances and challenges. *Journal of Controlled Release* **194**, 278-294
[CrossRef](#)
- 4 Timothy Joseph Sowicz, Anne M. Teitelman, Christopher Lance Coleman, Bridgette M. Brawner. (2014) Considerations for Implementing Oral Preexposure Prophylaxis: A Literature Review. *Journal of the Association of Nurses in AIDS Care* **25**:6, 496-507
[CrossRef](#)
- 5 Kristen Underhill, Dora Dumont, Don Operario. (2014) HIV Prevention for Adults With Criminal Justice Involvement: A Systematic Review of HIV Risk-Reduction Interventions in Incarceration and Community Settings. *American Journal of Public Health* **104**:11, e27-e53
[CrossRef](#)
- 6 Emily A. Krogstad, Kim A. Woodrow. (2014) Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. *International Journal of Pharmaceutics* **475**:1-2, 282-291
[CrossRef](#)
- 7 Jared M Baeten, Deborah Donnell, Nelly R Mugo, Patrick Ndase, Katherine K Thomas, James D Campbell, Jonathan Wangisi, Jordan W Tappero, Elizabeth A Bukusi, Craig R Cohen, Elly Katabira, Allan Ronald, Elioda Tumwesigye, Edwin Were, Kenneth H Fife, James Kiarie, Carey Farquhar, Grace John-Stewart, Lara Kidoguchi, Robert W Coombs, Craig Hendrix, Mark A Marzinke, Lisa Frenkel, Jessica E Haberer, David Bangsberg, Connie Celum. (2014) Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. *The Lancet Infectious Diseases* **14**:11, 1055-1064
[CrossRef](#)
- 8 Susan Buchbinder. (2014) When is good good enough for HIV-1 prophylaxis?. *The Lancet Infectious Diseases* **14**:11, 1024-1025
[CrossRef](#)
- 9 Manjula Gunawardana, Marc M. Baum, Thomas J. Smith, John A. Moss. (2014) An Intravaginal Ring for the Sustained Delivery of Antibodies. *Journal of Pharmaceutical Sciences* **103**:11, 3611-3620
[CrossRef](#)
- 10 Ian McGowan, Charlene Dezzutti, Lisa Rohan. The Development of Rectal Microbicides for HIV-1 Prevention. In: Drug Delivery and Development of Anti-HIV Microbicides. Pan Stanford, 2014:331-375.

[CrossRef](#)

- 11 Osmond D'Cruz, Fatih Uckun. Microbicides for the Prevention of HIV. In: Drug Delivery and Development of Anti-HIV Microbicides. Pan Stanford, 2014:1-54.
[CrossRef](#)
- 12 Elizabeth Tolley, Barbara Friedland, Mitzy Gafos, Rivet Amico, Lut Van Damme, Cynthia Woodsong, Kathleen MacQueen, Leila Mansoor, Sheena McCormack. Socioeconomic and Behavioral Factors Influencing Choice, Adherence, and Success of Microbicide Formulations. In: Drug Delivery and Development of Anti-HIV Microbicides. Pan Stanford, 2014:569-628.
[CrossRef](#)
- 13 Pedro Mesquita, Betsy Herold. HIV Transmission Models: Lessons Learned for Microbicide Formulation Design. In: Drug Delivery and Development of Anti-HIV Microbicides. Pan Stanford, 2014:55-89.
[CrossRef](#)
- 14 John Moss, Marc Baum. Microbicide Intravaginal Rings. In: Drug Delivery and Development of Anti-HIV Microbicides. Pan Stanford, 2014:221-290.
[CrossRef](#)
- 15 T. Liegler, M. Abdel-Mohsen, L. G. Bentley, R. Atchison, T. Schmidt, J. Javier, M. Mehrotra, C. Eden, D. V. Glidden, V. McMahan, P. L. Anderson, P. Li, J. K. Wong, S. Buchbinder, J. V. Guanira, R. M. Grant, . (2014) HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. *Journal of Infectious Diseases* **210**:8, 1217-1227
[CrossRef](#)
- 16 David N. Burns, Cynthia Grossman, Jim Turpin, Vanessa Elharrar, Fulvia Veronese. (2014) Role of Oral Pre-exposure Prophylaxis (PrEP) in Current and Future HIV Prevention Strategies. *Current HIV/AIDS Reports*
[CrossRef](#)
- 17 Aranka Anema, Sarah J. Fielden, Tony Castleman, Nils Grede, Amie Heap, Martin Bloem. (2014) Food Security in the Context of HIV: Towards Harmonized Definitions and Indicators. *AIDS and Behavior* **18**:S5, 476-489
[CrossRef](#)
- 18 M. M. Solomon, K. H. Mayer, D. V. Glidden, A. Y. Liu, V. M. McMahan, J. V. Guanira, S. Chariyalertsak, T. Fernandez, R. M. Grant, L.-G. Bekker, S. Buchbinder, M. Casapia, S. Chariyalertsak, J. Guanira, E. Kallas, J. Lama, K. Mayer, O. Montoya, M. Schechter, V. Veloso, . (2014) Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. *Clinical Infectious Diseases* **59**:7, 1020-1026
[CrossRef](#)
- 19 Carl A. Kirton. (2014) HIV infection and its implication for nurse leaders. *Nursing Management (Springhouse)* **45**:10, 24-31
[CrossRef](#)
- 20 Brian Mustanski, L. Zachary DuBois, Tonya L. Prescott, Michele L. Ybarra. (2014) A Mixed-Methods Study of Condom Use and Decision Making Among Adolescent Gay and Bisexual Males. *AIDS and Behavior* **18**:10, 1955-1969
[CrossRef](#)
- 21 Priya Srinivasan, Chuong Dinh, Jining Zhang, Chou-Pong Pau, Janet M. McNicholl, Yungtai Lo, Betsy C. Herold, Ryan Teller, Patrick Kiser, James M. Smith. (2014) Pharmacokinetic

evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use. *Journal of Medical Primatology* **43**:5, 364-369
[CrossRef](#)

- 22 Norma C. Ware, Emily E. Pisarski, Jessica E. Haberer, Monique A. Wyatt, Elioda Tumwesigye, Jared M. Baeten, Connie L. Celum, David R. Bangsberg. (2014) Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. *AIDS and Behavior*
[CrossRef](#)
- 23 Martin Holt. (2014) Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis. *Culture, Health & Sexuality* **1**-12
[CrossRef](#)
- 24 Paul Goepfert, Anju Bansal. (2014) Human Immunodeficiency Virus Vaccines. *Infectious Disease Clinics of North America*
[CrossRef](#)
- 25 Antons Mozalevskis, Sandra Manzanares-Laya, Patricia García de Olalla, Antonio Moreno, Constanza Jacques-Aviñó, Joan A. Caylà. (2014) Can we rely on the antiretroviral treatment as the only means for human immunodeficiency virus prevention? A Public Health perspective. *Enfermedades Infecciosas y Microbiología Clínica*
[CrossRef](#)
- 26 David Boren, Patrick S. Sullivan, Chris Beyerer, Stefan D. Baral, Linda-Gail Bekker, Ron Brookmeyer. (2014) Stochastic variation in network epidemic models: implications for the design of community level HIV prevention trials. *Statistics in Medicine* **33**:22, 3894-3904
[CrossRef](#)
- 27 Kristen Underhill. (2014) Intimacy, Condom Use, and Pre-Exposure Prophylaxis (PrEP) Acceptability among Men Who Have Sex with Men (MSM) in Primary Partnerships: a Comment on Gamarel and Golub. *Annals of Behavioral Medicine*
[CrossRef](#)
- 28 Jennifer L. Brown, Jessica M. Sales, Ralph J. DiClemente. (2014) Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches. *Current HIV/AIDS Reports*
[CrossRef](#)
- 29 Justin O Parkhurst. (2014) Structural approaches for prevention of sexually transmitted HIV in general populations: definitions and an operational approach. *Journal of the International AIDS Society* **17**:1,
[CrossRef](#)
- 30 Ariane van der Straten, Jonathan Stadler, Ellen Luecke, Nicole Laborde, Miriam Hartmann, Elizabeth T Montgomery. (2014) Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. *Journal of the International AIDS Society* **17**:3(Suppl 2),
[CrossRef](#)
- 31 Sekou Sidibe, Allison P Pack, Elizabeth E Tolley, Elizabeth Ryan, Caroline Mackenzie, Emily Bockh, George Githuka. (2014) Communicating about microbicides with women in mind: tailoring messages for specific audiences. *Journal of the International AIDS Society* **17**:3(Suppl 2),
[CrossRef](#)

- 32 Timothy D Mastro, Nirupama Sista, Quarraisha Abdool-Karim. (2014) ARV-based HIV prevention for women – where we are in 2014. *Journal of the International AIDS Society* **17**:3(Suppl 2),
[CrossRef](#)
- 33 Natasha Mack, Emily M Evens, Elizabeth E Tolley, Kate Brelsford, Caroline Mackenzie, Cecilia Milford, Jennifer A Smit, Joshua Kimani. (2014) The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study. *Journal of the International AIDS Society* **17**:3(Suppl 2),
[CrossRef](#)
- 34 Kathleen M MacQueen, Elizabeth E Tolley, Derek H Owen, K Rivet Amico, Kathleen M Morrow, Thomas Moench, David R Friend, Barbara Friedland. (2014) An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings. *Journal of the International AIDS Society* **17**:3(Suppl 2),
[CrossRef](#)
- 35 Amy H Lin, Tiffany L Breger, Matthew Barnhart, Ann Kim, Charlotte Vangsgaard, Emily Harris. (2014) Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning. *Journal of the International AIDS Society* **17**:3(Suppl 2),
[CrossRef](#)
- 36 Ralph J. DiClemente, Jerrold M. Jackson. (2014) Towards an integrated framework for accelerating the end of the global HIV epidemic among young people. *Sex Education* **14**:5, 609-621
[CrossRef](#)
- 37 H.J. Chang, C.H. Moog, A. Astolfi, P.S. Rivadeneira. (2014) A control systems analysis of HIV prevention model using impulsive input. *Biomedical Signal Processing and Control* **13**, 123-131
[CrossRef](#)
- 38 Michael Stein, Portia Thurmond, Genie Bailey. (2014) Willingness to Use HIV Pre-Exposure Prophylaxis Among Opiate Users. *AIDS and Behavior* **18**:9, 1694-1700
[CrossRef](#)
- 39 Sarah T. Roberts, Renee Heffron, Kenneth Ngure, Connie Celum, Ann Kurth, Kathryn Curran, Nelly Mugo, Jared M. Baeten. (2014) Preferences for Daily or Intermittent Pre-exposure Prophylaxis Regimens and Ability to Anticipate Sex Among HIV Uninfected Members of Kenyan HIV Serodiscordant Couples. *AIDS and Behavior* **18**:9, 1701-1711
[CrossRef](#)
- 40 Brian Mustanski, Daniel T. Ryan, Travis Sanchez, Craig Sineath, Kathryn Macapagal, Patrick S. Sullivan. (2014) Effects of Messaging About Multiple Biomedical and Behavioral HIV Prevention Methods on Intentions to use Among US MSM: Results of an Experimental Messaging Study. *AIDS and Behavior* **18**:9, 1651-1660
[CrossRef](#)
- 41 Douglas Krakower, Norma Ware, Jennifer A. Mitty, Kevin Maloney, Kenneth H. Mayer. (2014) HIV Providers' Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study. *AIDS and Behavior* **18**:9, 1712-1721
[CrossRef](#)
- 42 Helen L. King, Samuel B. Keller, Michael A. Giancola, David A. Rodriguez, Jasmine J. Chau, Jason A. Young, Susan J. Little, Davey M. Smith. (2014) Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE Study). *AIDS and Behavior* **18**:9, 1722-

1725

[CrossRef](#)

- 43 Lynn T. Matthews, Renee Heffron, Nelly R. Mugo, Craig R. Cohen, Craig W. Hendrix, Connie Celum, David R. Bangsberg, Jared M. Baeten. (2014) High Medication Adherence During Periconception Periods Among HIV-1-Uninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **67**:1, 91-97
[CrossRef](#)
- 44 Erica J. Gibson, David L. Bell, Sherine A. Powerful. (2014) Common Sexually Transmitted Infections in Adolescents. *Primary Care: Clinics in Office Practice* **41**:3, 631-650
[CrossRef](#)
- 45 James M. McMahon, Julie E. Myers, Ann E. Kurth, Stephanie E. Cohen, Sharon B. Mannheimer, Janie Simmons, Enrique R. Pouget, Nicole Trabold, Jessica E. Haberer. (2014) Oral Pre-Exposure Prophylaxis (PrEP) for Prevention of HIV in Serodiscordant Heterosexual Couples in the United States: Opportunities and Challenges. *AIDS Patient Care and STDs* **28**:9, 462-474
[CrossRef](#)
- 46 Christopher W. Blackwell. (2014) Preexposure prophylaxis. *The Nurse Practitioner* **39**:9, 50-53
[CrossRef](#)
- 47 J. M. Snowden, C. Wei, W. McFarland, H. F. Raymond. (2014) Prevalence, correlates and trends in seroadaptive behaviours among men who have sex with men from serial cross-sectional surveillance in San Francisco, 2004-2011. *Sexually Transmitted Infections* **90**:6, 498-504
[CrossRef](#)
- 48 A G A Jackson, L J Else, P M M Mesquita, D Egan, D J Back, Z Karolia, L Ringner-Nackter, C J Higgs, B C Herold, B G Gazzard, M Boffito. (2014) A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. *Clinical Pharmacology & Therapeutics* **96**:3, 314-323
[CrossRef](#)
- 49 Raphael J Landovitz, Thomas J Coates. (2014) Moving HIV PrEP from research into practice. *The Lancet Infectious Diseases* **14**:9, 781-783
[CrossRef](#)
- 50 Robert M Grant, Peter L Anderson, Vanessa McMahan, Albert Liu, K Rivet Amico, Megha Mehrotra, Sybil Hosek, Carlos Mosquera, Martin Casapia, Orlando Montoya, Susan Buchbinder, Valdilea G Veloso, Kenneth Mayer, Suwat Chariyalertsak, Linda-Gail Bekker, Esper G Kallas, Mauro Schechter, Juan Guanira, Lane Bushman, David N Burns, James F Rooney, David V Glidden. (2014) Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *The Lancet Infectious Diseases* **14**:9, 820-829
[CrossRef](#)
- 51 Milena Veselinovic, Kuo-Hsiung Yang, Jonathan LeCureux, Craig Sykes, Leila Remling-Mulder, Angela D.M. Kashuba, Ramesh Akkina. (2014) HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. *Virology* **464-465**, 253-263
[CrossRef](#)
- 52 Samir K. Lakhade, Siddappa N. Byrareddy, Mingkui Zhou, Barbara C. Bachler, Shiu-Lok

Hu, Francois Villinger, Shannon Stock, Diego A. Vargas-Inchaustegui, Marjorie Robert-Guroff, Welkin E. Johnson, Victoria R. Polonis, Donald N. Forthal, Erwann P. Loret, Robert A. Rasmussen, Ruth M. Ruprecht. (2014) Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. *Vaccine* [CrossRef](#)

- 53 G. E. Gray, L. Corey. (2014) Reevaluating HIV Vaccine Clinical Trials Policy for Infants. *Journal of Infectious Diseases* [CrossRef](#)
- 54 Kathryn E. Muessig, Myron S. Cohen. (2014) Advances in HIV Prevention for Serodiscordant Couples. *Current HIV/AIDS Reports* [CrossRef](#)
- 55 Kristi E. Gamarel, Sarit A. Golub. (2014) Intimacy Motivations and Pre-exposure Prophylaxis (PrEP) Adoption Intentions Among HIV-Negative Men Who Have Sex with Men (MSM) in Romantic Relationships. *Annals of Behavioral Medicine* [CrossRef](#)
- 56 Kawango Agot, Douglas Taylor, Amy L. Cornelius, Meng Wang, Julie Ambia, Angela D. M. Kashuba, Caleb Parker, Ansley Lemons, Mookho Malahleha, Johan Lombaard, Lut Van Damme. (2014) Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. *AIDS and Behavior* [CrossRef](#)
- 57 Daniel J. Escudero, Thomas Kerr, Evan Wood, Paul Nguyen, Mark N. Lurie, Omar Sued, Brandon D. L. Marshall. (2014) Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting. *AIDS and Behavior* [CrossRef](#)
- 58 K.M. Mitchell, A.M. Foss, H.J. Prudden, Z. Mukandavire, M. Pickles, J.R. Williams, H.C. Johnson, B.M. Ramesh, R. Washington, S. Isac, S. Rajaram, A.E. Phillips, J. Bradley, M. Alary, S. Moses, C.M. Lowndes, C.H. Watts, M.-C. Boily, P. Vickerman. (2014) Who mixes with whom among men who have sex with men? Implications for modelling the HIV epidemic in southern India. *Journal of Theoretical Biology* **355**, 140-150 [CrossRef](#)
- 59 JL Marcus, T Buisseret, T Horvath, KR Amico, JD Fuchs, SP Buchbinder, RM Grant, AY Liu. (2014) Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. *HIV Medicine* **15**:7, 385-395 [CrossRef](#)
- 60 Christina Psaros, Jessica E. Haberer, Elly Katabira, Allan Ronald, Elioda Tumwezigye, James D. Campbell, Jonathan Wangisi, Kenneth Mugwanya, Alex Kintu, Michael Enyakoit, Katherine K. Thomas, Deborah Donnell, Meighan Krows, Lara Kidoguchi, Norma Ware, Jared M. Baeten, Connie Celum, David R. Bangsberg, Steve A. Safren. (2014) An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**:5, 522-529 [CrossRef](#)
- 61 K. Rivet Amico, Julia L. Marcus, Vanessa McMahan, Albert Liu, Kimberly A. Koester, Pedro Goicochea, Peter L. Anderson, David Glidden, Juan Guanira, Robert Grant. (2014) Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**:5, 530-537 [CrossRef](#)

- 62 Margaret C. Snead, Athena P. Kourtis, Johan H. Melendez, Carolyn M. Black, Christine K. Mauck, Ana Penman-Aguilar, Dorothy M. Chaney, Maria F. Gallo, Denise J. Jamieson, Maurizio Macaluso, Gustavo F. Doncel. (2014) Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?. *Contraception* **90**:2, 136-141
[CrossRef](#)
- 63 Edwin O. Were, Renee Heffron, Nelly R. Mugo, Connie Celum, Andrew Mujugira, Elizabeth A. Bukusi, Jared M. Baeten. (2014) Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. *AIDS* **28**:13, 1977-1982
[CrossRef](#)
- 64 Wenya Yu, Lu Wang, Na Han, Xiayan Zhang, Tanmay Mahapatra, Sanchita Mahapatra, Giridhar R. Babu, Weiming Tang, Roger Detels, Jinkou Zhao. (2014) Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?. *Artificial Cells, Nanomedicine, and Biotechnology* **1**:8
[CrossRef](#)
- 65 Ted M. Ross, Lara E. Pereira, Amara Luckay, Janet M. McNicholl, J. Gerardo García-Lerma, Walid Heneine, Hermancia S. Eugene, Brooke R. Pierce-Paul, Jining Zhang, R. Michael Hendry, James M. Smith. (2014) A Polyvalent Clade B Virus-Like Particle HIV Vaccine Combined with Partially Protective Oral Preexposure Prophylaxis Prevents Simian-Human Immunodeficiency Virus Infection in Macaques and Primes for Virus-Amplified Immunity. *AIDS Research and Human Retroviruses* **140729094523001**
[CrossRef](#)
- 66 Bridget Haire. (2014) It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials. *Journal of Bioethical Inquiry*
[CrossRef](#)
- 67 Mark A. Wainberg, Susan Kippax, Marlene Bras, Papa Salif Sow. (2014) The 20th International AIDS Conference: where do we go from here?. *Journal of the International AIDS Society* **17**:1,
[CrossRef](#)
- 68 Senad Handanagic, Jelena Barbaric, Andrew Anglemyer, Ivana Bozicevic, Senad Handanagic. Community mobilization and empowerment interventions for preventing HIV in low and middle income countries. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014.
[CrossRef](#)
- 69 Shayesta Dhalla, Gary Poole. (2014) Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. *Human vaccines & immunotherapeutics* **10**:7,
[CrossRef](#)
- 70 Matthew D. Hickey, Charles R. Salmon, Robert A. Tessler, Dan Omollo, Peter Bacchetti, Richard Magerenge, Brian Mattah, Marcus R. Salmon, Daniel Zoughbie, Kathryn J. Fiorella, Elvin Geng, Betty Njoroge, Chengshi Jin, Yong Huang, Elizabeth A. Bukusi, Craig R. Cohen, Monica Gandhi. (2014) Antiretroviral Concentrations in Small Hair Samples as a Feasible Marker of Adherence in Rural Kenya. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**:3, 311-315
[CrossRef](#)
- 71 Amy L. Cornelius, Jennifer Deese, Meng Wang, Doug Taylor, Khatija Ahmed, Kawango Agot, Johan Lombaard, Rachel Manongi, Saidi Kapiga, Angela Kashuba, Lut Van Damme. (2014) FEM-PrEP. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**:3, 324-331

[CrossRef](#)

- 72 Deborah Donnell, Jared M. Baeten, Namandjé N. Bumpus, Justin Brantley, David R. Bangsberg, Jessica E. Haberer, Andrew Mujugira, Nelly Mugo, Patrick Ndase, Craig Hendrix, Connie Celum. (2014) HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**:3, 340-348
[CrossRef](#)
- 73 Bettina T. Schunter, Wing-Sie Cheng, Megan Kendall, Hein Marais. (2014) Lessons Learned From a Review of Interventions for Adolescent and Young Key Populations in Asia Pacific and Opportunities for Programming. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**, S186-S192
[CrossRef](#)
- 74 Bill G. Kapogiannis, Ken E. Legins, Upjeet Chandan, Sonia Lee. (2014) Evidence-Based Programming for Adolescent HIV Prevention and Care. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **66**, S228-S235
[CrossRef](#)
- 75 M. Boffito, A. Jackson, D. Asboe. (2014) Pharmacology Lessons From Chemoprophylaxis Studies. *Clinical Infectious Diseases* **59**:suppl 1, S52-S54
[CrossRef](#)
- 76 K. H. Mayer. (2014) Antiretroviral Chemoprophylaxis: State of Evidence and the Research Agenda. *Clinical Infectious Diseases* **59**:suppl 1, S47-S51
[CrossRef](#)
- 77 K. R. Amico, M. J. Stirratt. (2014) Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence. *Clinical Infectious Diseases* **59**:suppl 1, S55-S60
[CrossRef](#)
- 78 S. M. McCormack, M. Gafos, M. Desai, M. S. Cohen. (2014) Biomedical Prevention: State of the Science. *Clinical Infectious Diseases* **59**:suppl 1, S41-S46
[CrossRef](#)
- 79 B. Young, J. M. Zuniga, J. Montaner, K. H. Mayer. (2014) Controlling the HIV Epidemic With Antiretrovirals: Moving From Consensus to Implementation. *Clinical Infectious Diseases* **59**:suppl 1, S1-S2
[CrossRef](#)
- 80 M. L. McNairy, W. M. El-Sadr. (2014) A Paradigm Shift: Focus on the HIV Prevention Continuum. *Clinical Infectious Diseases* **59**:suppl 1, S12-S15
[CrossRef](#)
- 81 Christine R. Trezza, Angela D. M. Kashuba. (2014) Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention. *Clinical Pharmacokinetics* **53**:7, 611-624
[CrossRef](#)
- 82 Morenike Oluwatoyin Folayan, Kristin Peterson, Bridget Haire, Brandon Brown, Kadiri Audu, Olumide Makanjuola, Babatunde Pelemo, Vicki Marsh. (2014) Debating Ethics in HIV Research: Gaps between Policy and Practice in Nigeria. *Developing World Bioethics* **n/a**
[CrossRef](#)
- 83 Michele R Decker, Anna-Louise Crago, Sandra K H Chu, Susan G Sherman, Meena S Seshu, Kholi Buthelezi, Mandeep Dhaliwal, Chris Beyer. (2014) Human rights violations

against sex workers: burden and effect on HIV. *The Lancet*
[CrossRef](#)

- 84 Tonia Poteat, Andrea L Wirtz, Anita Radix, Annick Borquez, Alfonso Silva-Santisteban, Madeline B Deutsch, Sharful Islam Khan, Sam Winter, Don Operario. (2014) HIV risk and preventive interventions in transgender women sex workers. *The Lancet*
[CrossRef](#)

- 85 Linda-Gail Bekker, Leigh Johnson, Frances Cowan, Cheryl Overs, Donela Besada, Sharon Hillier, Willard Cates. (2014) Combination HIV prevention for female sex workers: what is the evidence?. *The Lancet*
[CrossRef](#)

- 86 Laura J Else, John Tjia, Akil Jackson, Sujan Dilly Penchala, Deirdre Egan, Marta Boffito, Saye H Khoo, David J Back. (2014) Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography–tandem mass spectrometry. *Bioanalysis* **6**:14, 1907-1921
[CrossRef](#)

- 87 Susanne Doblecki-Lewis, Michael A. Kolber. (2014) Preventing HIV infection: Pre-exposure and postexposure prophylaxis. *IUBMB Life* **66**:7, 453-461
[CrossRef](#)

- 88 Martin Holt, Toby Lea, Dean Murphy, Jeanne Ellard, Marsha Rosengarten, Susan Kippax, John De Wit. (2014) Willingness to use HIV pre-exposure prophylaxis has declined among Australian gay and bisexual men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **1**
[CrossRef](#)

- 89 Gary Maartens, Connie Celum, Sharon R Lewin. (2014) HIV infection: epidemiology, pathogenesis, treatment, and prevention. *The Lancet* **384**:9939, 258-271
[CrossRef](#)

- 90 Alexandra Jones, Ide Cremin, Fareed Abdullah, John Idoko, Peter Cherutich, Nduku Kilonzo, Helen Rees, Timothy Hallett, Kevin O'Reilly, Florence Koechlin, Bernhard Schwartlander, Barbara de Zalduondo, Susan Kim, Jonathan Jay, Jacqueline Huh, Peter Piot, Mark Dybul. (2014) Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. *The Lancet* **384**:9939, 272-279
[CrossRef](#)

- 91 Julia Dickson-Gomez, Jill Owczarzak, Janet St.Lawrence, Cheryl Sitzler, Katherine Quinn, Broderick Pearson, Jeffrey A. Kelly, Yuri A. Amirkhanian. (2014) Beyond the Ball: Implications for HIV Risk and Prevention Among the Constructed Families of African American Men Who Have Sex with Men. *AIDS and Behavior*
[CrossRef](#)

- 92 K. H. Mayer. (2014) Editorial Commentary: The Next Tsunami? HIV Spread in Asian Men Who Have Sex With Men. *Clinical Infectious Diseases* **58**:12, 1760-1762
[CrossRef](#)

- 93 X. Wei, G. Hunt, S. S. Abdool Karim, V. Naranbhai, S. Sibeko, Q. Abdool Karim, J.-f. Li, A. D. M. Kashuba, L. Werner, J.-A. S. Passmore, L. Morris, W. Heneine, J. A. Johnson. (2014) Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. *Journal of Infectious Diseases* **209**:12, 1916-1920
[CrossRef](#)

- 94 Sophia A. Hussen, Karen Andes, Danielle Gilliard, Rana Chakraborty, Carlos del Rio, David J. Malebranche. (2014) Transition to Adulthood and Antiretroviral Adherence Among HIV-Positive Young Black Men Who Have Sex With Men. *American Journal of Public Health* 104:1-7
[CrossRef](#)
- 95 Ted Ross, Lara E. Pereira, Amara Luckay, Janet M McNicholl, Gerardo Garcia-Lerma, Walid Heneine, Hermancia Eugene, Brooke Pierce-Paul, Jining Zhang, R. Michael Hendry, James M. Smith. (2014) A polyvalent clade B VLP HIV vaccine combined with partially protective oral pre-exposure prophylaxis prevents SHIV infection in macaques and primes for virus-amplified immunity. *AIDS Research and Human Retroviruses* 30:10080150004
[CrossRef](#)
- 96 Matthew J. Mimiaga, Jaclyn M. White, Douglas S. Krakower, Katie B. Biello, Kenneth H. Mayer. (2014) Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. *AIDS Care* 26:6, 684-693
[CrossRef](#)
- 97 I. I. Bogoch, E. P. Scully, K. C. Zachary, S. Yawetz, K. H. Mayer, C. M. Bell, J. R. Andrews. (2014) Patient Attrition Between the Emergency Department and Clinic Among Individuals Presenting for HIV Nonoccupational Postexposure Prophylaxis. *Clinical Infectious Diseases* 58:11, 1618-1624
[CrossRef](#)
- 98 J. Stan Lehman, Meredith H. Carr, Allison J. Nichol, Alberto Ruisánchez, David W. Knight, Anne E. Langford, Simone C. Gray, Jonathan H. Mermin. (2014) Prevalence and Public Health Implications of State Laws that Criminalize Potential HIV Exposure in the United States. *AIDS and Behavior* 18:6, 997-1006
[CrossRef](#)
- 99 Andrea R. Thurman, Sharon Anderson, Gustavo F. Doncel. (2014) Effects of Hormonal Contraception on Antiretroviral Drug Metabolism, Pharmacokinetics and Pharmacodynamics. *American Journal of Reproductive Immunology* 71:6, 523-530
[CrossRef](#)
- 100 Ian McGowan. (2014) An Overview of Antiretroviral Pre-Exposure Prophylaxis of HIV Infection. *American Journal of Reproductive Immunology* 71:6, 624-630
[CrossRef](#)
- 101 Jared M Baeten, Renee Heffron. (2014) Pre-exposure prophylaxis to intensify the fight against HIV. *The Lancet Infectious Diseases* 14:6, 443-445
[CrossRef](#)
- 102 Susan P Buchbinder, David V Glidden, Albert Y Liu, Vanessa McMahan, Juan V Guanira, Kenneth H Mayer, Pedro Goicochea, Robert M Grant. (2014) HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. *The Lancet Infectious Diseases* 14:6, 468-475
[CrossRef](#)
- 103 B Vrijens, J Urquhart. (2014) Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials. *Clinical Pharmacology & Therapeutics* 95:6, 617-626
[CrossRef](#)
- 104 Sally Cameron, John Godwin. (2014) Barriers to Legal and Human Rights in Australia in the Era of HIV Treatment as Prevention. *AIDS Education and Prevention* 26:3, 202-213
[CrossRef](#)

- 105 Arielle Lasny, Stephanie L. Sansom, Richard J. Wolitski, Timothy A. Green, Craig B. Borkowf, Pragna Patel, Jonathan Mermin. (2014) HIV sexual transmission risk among serodiscordant couples. *AIDS* **28**:10, 1521-1529
[CrossRef](#)
- 106 LaRon E. Nelson, Ja'Nina J. Walker, Steve N. DuBois, Sulaimon Giwa. (2014) Your blues ain't like mine: considering integrative antiracism in HIV prevention research with black men who have sex with men in Canada and the United States. *Nursing Inquiry*/a-n/a
[CrossRef](#)
- 107 Santiago Moreno, Jorge del Romero, Julia del Amo. (2014) Infección por el virus de la inmunodeficiencia humana en España: es hora de actuar. *Enfermedades Infecciosas y Microbiología Clínica* **32**:6, 339-340
[CrossRef](#)
- 108 P. L. Anderson, D. V. Glidden, L. R. Bushman, W. Heneine, J. G. Garcia-Lerma. (2014) Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. *Journal of Antimicrobial Chemotherapy*
[CrossRef](#)
- 109 M. Martin, S. Vanichseni, P. Suntharasamai, U. Sangkum, P. A. Mock, R. J. Gvetadze, M. E. Curlin, M. Leethochawalit, S. Chiamwongpaet, T. Cherdtrakulkiat, R. Anekvorapong, W. Leelawiwat, N. Chancharojwong, J. M. McNicholl, L. A. Paxton, S. Kittimunkong, K. Choopanya, , K. Choopanya, S. S. Na Ayudhya, S. Chiamwongpaet, K. Kaewnil, P. Kitisin, M. Kukavejworakit, M. Leethochawalit, P. Natrujirote, S. Simakajorn, W. Subhachaturas, S. Vanichseni, B. Prasittipol, U. Sangkum, P. Suntharasamai, R. Anekvorapong, C. Khoomphong, S. Koocharoenprasit, P. Manomaipiboon, S. Manotham, P. Saicheua, P. Smutraprapoot, S. Sonthikaew, L.-O. Srisuwanvilai, S. Tanariyakul, M. Thongsari, W. Wattana, K. Yongvanitjit, S. Angwandee, S. Kittimunkong, W. Aueaksorn, B. Chaipung, N. Chancharojwong, T. Chaowanachan, T. Cherdtrakulkiat, W. Chonwattana, R. Chuachoowong, M. Curlin, P. Disprayoon, K. Kamkong, C. Kittinunvorakoon, W. Leelawiwat, R. Linkins, M. Martin, J. McNicholl, P. Mock, S. Na-Pompet, T. Plipat, A. Sanguansat, P. Sittidech, P. Tararut, R. Thongtew, D. Worrajittanon, C. Utentpitak, A. Warapornmongkholkul, P. Wasinrapee, J. Brannon, M. Brown, R. Gvetadze, L. Harper, L. Paxton, C. Rose, C. Hendrix, M. Marzinke. (2014) Renal Function of Participants in the Bangkok Tenofovir Study--Thailand, 2005-2012. *Clinical Infectious Diseases*
[CrossRef](#)
- 110 Nadia Chanzu, Beatrice Ondondo. (2014) Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. *Frontiers in Immunology* **5**,
[CrossRef](#)
- 111 Yujiang Jia, Debapriya Sengupta, Jenevieve Opoku, Charles Wu, Angelique Griffin, Tiffany West, Rowena Samala, Irshad Shaikh, Gregory Pappas. (2014) Site migration in seeking care services from multiple providers is associated with worse clinical outcomes among HIV-infected individuals in Washington, DC. *AIDS Care*1-6
[CrossRef](#)
- 112 Warunee Thienkrua, Catherine S. Todd, Supaporn Chaikummao, Wichuda Sukwicha, Somsak Yafant, Narongritt Tippaont, Anchalee Varangrat, Pechpailin Khlaimanee, Timothy H. Holtz. (2014) Prevalence and correlates of willingness to participate in a rectal microbicide trial among men who have sex with men in Bangkok. *AIDS Care*1-11
[CrossRef](#)
- 113 Claire J. Forbes, Clare F. Mccoy, Diarmaid J. Murphy, A. David Woolfson, John P. Moore, Abbey Evans, Robin J. Shattock, R. Karl Malcolm. (2014) Modified Silicone Elastomer

Vaginal Gels for Sustained Release of Antiretroviral HIV Microbicides. *Journal of Pharmaceutical Sciences* **103**:5, 1422-1432

[CrossRef](#)

- 114 R. K. Malcolm, D. Lowry, P. Boyd, L. Geer, R. S. Veazey, L. Goldman, P. J. Klasse, R. J. Shattock, J. P. Moore. (2014) Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. *Journal of Antimicrobial Chemotherapy* **69**:5, 1325-1329

[CrossRef](#)

- 115 George K. Lewis. (2014) Role of Fc-mediated antibody function in protective immunity against HIV-1. *Immunology* **142**:1, 46-57

[CrossRef](#)

- 116 Eric C. Tang, Magdalena E. Sobieszczyk, Eileen Shu, Pedro Gonzales, Jorge Sanchez, Javier R. Lama. (2014) Provider Attitudes Toward Oral Preexposure Prophylaxis for HIV Prevention Among High-Risk Men Who Have Sex with Men in Lima, Peru. *AIDS Research and Human Retroviruses* **30**:5, 416-424

[CrossRef](#)

- 117 Angela Coombs, Willi McFarland, Theresa Ick, Vincent Fuqua, Susan P. Buchbinder, Jonathan D. Fuchs. (2014) Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **1**

[CrossRef](#)

- 118 Sarah A. Gutin, Beverley Cummings, Prafulta Jaintialil, Kelly Johnson, Francisco Mbofana, Carol Dawson Rose. (2014) Qualitative evaluation of a Positive Prevention training for health care providers in Mozambique. *Evaluation and Program Planning* **43**, 38-47

[CrossRef](#)

- 119 Maja Kiselinova, Ward De Spiegelaere, Chris Verhofstede, Steven FJ Callens, Linos Vandekerckhove. (2014) Antiretrovirals for HIV prevention: when should they be recommended?. *Expert Review of Anti-infective Therapy* **12**:4, 431-445

[CrossRef](#)

- 120 Heather A. Pines, Pamina M. Gorbach, Robert E. Weiss, Steve Shoptaw, Raphael J. Landovitz, Marjan Javanbakht, David G. Ostrow, Ron D. Stall, Michael Plankey. (2014) Sexual Risk Trajectories Among MSM in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **65**:5, 579-586

[CrossRef](#)

- 121 Catherine A Hankins. (2014) Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?. *Expert Review of Pharmacoeconomics & Outcomes Research* **14**:2, 167-170

[CrossRef](#)

- 122 Seth C. Kalichman, Larissa Zohren, Lisa A. Eaton. (2014) Setting the Bar High or Setting Up to Fail? Interpretations and Implications of The EXPLORE Study (HPTN 015). *AIDS and Behavior* **18**:4, 625-633

[CrossRef](#)

- 123 Beryl A. Koblin, Gordon Mansergh, Margaret Chesney, Thomas Coates. (2014) Moving the Bar to the Right Place: Positioning Interventions in HIV Prevention. *AIDS and Behavior* **18**:4, 634-637

[CrossRef](#)

- 124 Hyman M. Scott, Vincent Fuqua, H. Fisher Raymond. (2014) Utilization of HIV Prevention Services Across Racial/Ethnic Groups Among Men Who Have Sex with Men in San Francisco, California, 2008. *AIDS and Behavior* **18**:S3, 316-323
[CrossRef](#)
- 125 Alia A. Al-Tayyib, Mark W. Thrun, Jason S. Haukoos, N. Eugene Walls. (2014) Knowledge of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men in Denver, Colorado. *AIDS and Behavior* **18**:S3, 340-347
[CrossRef](#)
- 126 K. Schneider, R. T. Gray, D. P. Wilson. (2014) A Cost-effectiveness Analysis of HIV Preexposure Prophylaxis for Men Who Have Sex With Men in Australia. *Clinical Infectious Diseases* **58**:7, 1027-1034
[CrossRef](#)
- 127 M. L. McNairy, W. M. El-Sadr. (2014) Antiretroviral Therapy for the Prevention of HIV Transmission: What Will It Take?. *Clinical Infectious Diseases* **58**:7, 1003-1011
[CrossRef](#)
- 128 Thomas J Coates, Michal Kulich, David D Celentano, Carla E Zelaya, Suwat Chariyalertsak, Alfred Chingono, Glenda Gray, Jessie K K Mbwambo, Stephen F Morin, Linda Richter, Michael Sweat, Heidi van Rooyen, Nuala McGrath, Agnès Fiamma, Oliver Laeyendecker, Estelle Piwowar-Manning, Greg Szekeres, Deborah Donnell, Susan H Eshleman. (2014) Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. *The Lancet Global Health*
[CrossRef](#)
- 129 Kimberley A. Phillips, Karen L. Bales, John P. Capitanio, Alan Conley, Paul W. Czoty, Bert A. 't Hart, William D. Hopkins, Shiu-Lok Hu, Lisa A. Miller, Michael A. Nader, Peter W. Nathanielsz, Jeffrey Rogers, Carol A. Shively, Mary Lou Voytko. (2014) Why primate models matter. *American Journal of Primatology*
[CrossRef](#)
- 130 S.M. Ashrafur Rahman, Naveen K. Vaidya, Xingfu Zou. (2014) Impact of Tenofovir gel as a PrEP on HIV infection: A mathematical model. *Journal of Theoretical Biology* **347**, 151-159
[CrossRef](#)
- 131 Daniel J Escudero, Mark N Lurie, Thomas Kerr, Chanelle J Howe, Brandon DL Marshall. (2014) HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. *Journal of the International AIDS Society* **17**:1,
[CrossRef](#)
- 132 C. Fraser, K. Lythgoe, G. E. Leventhal, G. Shirreff, T. D. Hollingsworth, S. Alizon, S. Bonhoeffer. (2014) Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective. *Science* **343**:6177, 1243727-1243727
[CrossRef](#)
- 133 Leila Essop Mansoor, Quarasha Abduol Karim, Lise Werner, Bernadette Madlala, Nelisiwe Ngcobo, Deborah H. Cornman, K. Rivet Amico, Jeffrey Fisher, William A. Fisher, Kathleen M. MacQueen, Salim S. Abduol Karim. (2014) Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. *AIDS and Behavior*
[CrossRef](#)
- 134 Corbin G. Thompson, Alexander Sedykh, Melanie R. Nicol, Eugene Muratov, Denis Fourches, Alexander Tropsha, Angela D.M. Kashuba. (2014) Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. *AIDS*

Research and Human Retroviruses 140313131359009

[CrossRef](#)

- 135 C. D. Andrews, W. R. Spreen, H. Mohri, L. Moss, S. Ford, A. Gettie, K. Russell-Lodrigue, R. P. Bohm, C. Cheng-Mayer, Z. Hong, M. Markowitz, D. D. Ho. (2014) Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. *Science* **343**:6175, 1151-1154
[CrossRef](#)
- 136 Marie-Claude Boily, Zara Shubber. (2014) Modelling in concentrated epidemics. *Current Opinion in HIV and AIDS* **9**:2, 134-149
[CrossRef](#)
- 137 Tonia Poteat, Sari L. Reisner, Anita Radix. (2014) HIV epidemics among transgender women. *Current Opinion in HIV and AIDS* **9**:2, 168-173
[CrossRef](#)
- 138 Raquel De Boni, Valdilea G. Veloso, Beatriz Grinsztejn. (2014) Epidemiology of HIV in Latin America and the Caribbean. *Current Opinion in HIV and AIDS* **9**:2, 192-198
[CrossRef](#)
- 139 M. Y. Karris, S. E. Beekmann, S. R. Mehta, C. M. Anderson, P. M. Polgreen. (2014) Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada. *Clinical Infectious Diseases* **58**:5, 704-712
[CrossRef](#)
- 140 Brian C. Zanoni, Kenneth H. Mayer. (2014) The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities. *AIDS Patient Care and STDs* **28**:3, 128-135
[CrossRef](#)
- 141 Catherine E. Oldenburg, Katie B. Biello, Donn Colby, Elizabeth F. Closson, Thi Nguyen, Nguyen N.N. Trang, Hang X. Lan, Kenneth H. Mayer, Matthew J. Mimiaga. (2014) Engagement with Peer Health Educators Is Associated with Willingness to Use Pre-Exposure Prophylaxis Among Male Sex Workers in Ho Chi Minh City, Vietnam. *AIDS Patient Care and STDs* **28**:3, 109-112
[CrossRef](#)
- 142 I. Toupin, B. Lebouché, J. Otis, J.-J. Lévy, M. Fernet. (2014) Adhésion au traitement antirétroviral et éthique de la responsabilité : devons-nous prescrire une thérapie antirétrovirale aux personnes non adhérentes ?. *Éthique & Santé* **11**:1, 4-12
[CrossRef](#)
- 143 Chuka Didigu, Robert Doms. (2014) Gene Therapy Targeting HIV Entry. *Viruses* **6**:3, 1395-1409
[CrossRef](#)
- 144 Richard Crosby, Angelica Geter, Ralph DiClemente, Laura Salazar. (2014) Acceptability of Condoms, Circumcision and PrEP among Young Black Men Who Have Sex with Men: A Descriptive Study Based on Effectiveness and Cost. *Vaccines* **2**:1, 129-137
[CrossRef](#)
- 145 Mackenzie L. Cottrell, Angela D.M. Kashuba. (2014) Topical Microbicides and HIV Prevention in the Female Genital Tract. *The Journal of Clinical Pharmacology* n/a
[CrossRef](#)
- 146 Matthew E. Levy, Leo Wilton, Gregory Phillips, Sara Nelson Glick, Irene Kuo, Russell A. Brewer, Ayana Elliott, Christopher Watson, Manya Magnus. (2014) Understanding

Structural Barriers to Accessing HIV Testing and Prevention Services Among Black Men Who Have Sex with Men (BMSM) in the United States. *AIDS and Behavior*
[CrossRef](#)

- 147 Corbin Thompson, Alexander Sedykh, Melanie Nicol, Eugene Muratov, Denis Fournes, Alexander Tropsha, Angela Kashuba. (2014) Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. *AIDS Research and Human Retroviruses* 140210065858006
[CrossRef](#)
- 148 Chris Beyrer. (2014) Strategies to manage the HIV epidemic in gay, bisexual, and other men who have sex with men. *Current Opinion in Infectious Diseases* 27:1, 1-8
[CrossRef](#)
- 149 Catherine E. Oldenburg, Till Bärnighausen, Guy Harling, Matthew J. Mimiaga, Kenneth H. Mayer. (2014) Adherence to Post-Exposure Prophylaxis for Non-forcible Sexual Exposure to HIV: A Systematic Review and Meta-Analysis. *AIDS and Behavior* 18:2, 217-225
[CrossRef](#)
- 150 Sarah K. Calabrese, Valerie A. Earshaw, Kristen Underhill, Nathan B. Hansen, John F. Dovidio. (2014) The Impact of Patient Race on Clinical Decisions Related to Prescribing HIV Pre-Exposure Prophylaxis (PrEP): Assumptions About Sexual Risk Compensation and Implications for Access. *AIDS and Behavior* 18:2, 226-240
[CrossRef](#)
- 151 Marc M. Solomon, Javier R. Lama, David V. Glidden, Kathleen Mulligan, Vanessa McMahan, Albert Y. Liu, Juan Vicente Guanira, Valdilea G. Veloso, Kenneth H. Mayer, Suwat Chariyalertsak, Mauro Schechter, Linda-Gail Bekker, Esper Georges Kallás, David N. Burns, Robert M. Grant. (2014) Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. *AIDS* 28:1
[CrossRef](#)
- 152 C. V. Fletcher, K. Staskus, S. W. Wietgrefe, M. Rothenberger, C. Reilly, J. G. Chipman, G. J. Beilman, A. Khoruts, A. Thorkelson, T. E. Schmidt, J. Anderson, K. Perkey, M. Stevenson, A. S. Perelson, D. C. Douek, A. T. Haase, T. W. Schacker. (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proceedings of the National Academy of Sciences*
[CrossRef](#)
- 153 Benjamin Verboom, Gerardo Melendez-Torres, Christopher P Bonell, Gerardo Melendez-Torres. Combination methods for HIV prevention in men who have sex with men (MSM). In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014.
[CrossRef](#)
- 154 J McAllister, P Read, A McNulty, WWY Tong, A Ingersoll, A Carr. (2014) Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. *HIV Medicine* 15:1, 13-22
[CrossRef](#)
- 155 Steven J. Reynolds, Thomas C. Quinn. HIV/AIDS Prevention. In: Manson's Tropical Infectious Diseases. Elsevier, 2014:100-111.e2.
[CrossRef](#)
- 156 Mark Mirochnick, Taha Taha, Regis Kreitchmann, Karin Nielsen-Saines, Newton Kumwenda, Esau Joao, Jorge Pinto, Breno Santos, Teresa Parsons, Brian Kearney, Lynda Emel, Casey Herron, Paul Richardson, Sarah E. Hudelson, Susan H. Eshleman, Kathleen George, Mary G. Fowler, Paul Sato, Lynne Mofenson. (2014) Pharmacokinetics and Safety

of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **65**:1, 33-41

[CrossRef](#)

- 157 Ian McGowan. (2014) The development of rectal microbicides for HIV prevention. *Expert Opinion on Drug Delivery* **11**:1, 69-82
[CrossRef](#)
- 158 Lovemore I. Chirwa, Jeffrey A. Johnson, Richard W. Niska, Tebogo M. Segolodi, Faith L. Henderson, Charles E. Rose, Jin-fen Li, Michael C. Thigpen, Onkabetse Matlhaba, Lynn A. Paxton, John T. Brooks. (2014) CD4+ cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. *AIDS* **28**:2, 223-226
[CrossRef](#)
- 159 Kirk Fiereck. (2014) Cultural Conundrums: The Ethics of Epidemiology and the Problems of Population in Implementing Pre-Exposure Prophylaxis. *Developing World Bioethics* n/a-n/a
[CrossRef](#)
- 160 Caroline Foster, Susan McDonald, Graham Frize, Sarah Ayers, Sarah Fidler. (2014) "Payment by Results"—Financial Incentives and Motivational Interviewing, Adherence Interventions in Young Adults with Perinatally Acquired HIV-1 Infection: A Pilot Program. *AIDS Patient Care and STDs* **28**:1, 28-32
[CrossRef](#)
- 161 Fern Terris-Prestholt, Anna M Foss, Andrew P Cox, Lori Heise, Gesine Meyer-Rath, Sinead Delany-Moretlwe, Thomas Mertenskoetter, Helen Rees, Peter Vickerman, Charlotte H Watts. (2014) Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. *BMC Infectious Diseases* **14**:1, 14
[CrossRef](#)
- 162 John A. Schneider, A. Ning Zhou, Edward O. Laumann. (2014) A new HIV prevention network approach: Sociometric peer change agent selection. *Social Science & Medicine*
[CrossRef](#)
- 163 Sabina S Alistar, Philip M Grant, Eran Bendavid. (2014) Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. *BMC Medicine* **12**:1, 46
[CrossRef](#)
- 164 Estelle Piwowar-Manning, Jessica M. Fogel, Oliver Laeyendecker, Shauna Wolf, Vanessa Cummings, Mark A. Marzinke, William Clarke, Autumn Bread, Sarah Wendel, Lei Wang, Priscilla Swanson, John Hackett, Sharon Mannheimer, Carlos del Rio, Irene Kuo, Nina T. Harawa, Beryl A. Koblin, Richard Moore, Joel N. Blankson, Susan H. Eshleman. (2014) Failure to Identify HIV-Infected Individuals in a Clinical Trial Using a Single HIV Rapid Test for Screening. *HIV Clinical Trials* **15**:2, 62-68
[CrossRef](#)
- 165 Eric P. F. Chow, Joseph T. F. Lau, Xun Zhuang, Xiaohu Zhang, Yanjie Wang, Lei Zhang. (2014) HIV Prevalence Trends, Risky Behaviours, and Governmental and Community Responses to the Epidemic among Men Who Have Sex with Men in China. *BioMed Research International* **2014**, 1-19
[CrossRef](#)
- 166 Cynthia Cunha, Raquel De Boni, Maria Regina Guimarães, Carolyn Yanavich, Valdilea Veloso, Ronaldo Moreira, Brenda Hoagland, Beatriz Grinsztejn, Ruth Friedman. (2014) Unprotected sex among men who have sex with men living with HIV in Brazil: a cross-

sectional study in Rio de Janeiro. *BMC Public Health* **14**:1, 379
[CrossRef](#)

-
- 167 William A. Fisher, Jeffrey D. Fisher, Paul A. Shuper. Social Psychology and the Fight Against AIDS. Elsevier, 2014:105-193.

[CrossRef](#)

-
- 168 Lisa A. Eaton, Daniel D. Driffin, Harlan Smith, Christopher Conway-Washington, Denise White, Chauncey Cherry. (2014) Psychosocial factors related to willingness to use pre-exposure prophylaxis for HIV prevention among Black men who have sex with men attending a community event. *Sexual Health* **11**:3, 244

[CrossRef](#)

-
- 169 Brian P. Mulhall, Stephen Wright, Debbie Allen, Katherine Brown, Bridget Dickson, Miriam Grotowski, Eva Jackson, Kathy Petoumenos, Phillip Read, Timothy Read, Darren Russell, David J. Smith, David J. Templeton, Christopher K. Fairley, Matthew G. Law. (2014) High rates of sexually transmissible infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. *Sexual Health* **11**:4, 291

[CrossRef](#)

-
- 170 Morenike Folayan, Megan Gottemoeller, Rosemary Mburu, Brandon Brown. (2014) Getting to zero the biomedical way in Africa: outcomes of deliberation at the 2013 Biomedical HIV Prevention Forum in Abuja, Nigeria. *BMC Proceedings* **8**:Suppl 3, S1

[CrossRef](#)

-
- 171 Lee M Ashton, Melinda J Hutchesson, Megan E Rollo, Philip J Morgan, Clare E Collins. (2014) A scoping review of risk behaviour interventions in young men. *BMC Public Health* **14**:1, 957

[CrossRef](#)

-
- 172 Noah Kiwanuka, Juliet Mpendo, Annet Nalutaaya, Matthias Wambizi, Annet Nanvubya, Paul K Kitandwe, Enoch Muyanja, Julius Ssemperiira, Apolo Balyegisawa, Ali Ssetala, . (2014) An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study. *BMC Public Health* **14**:1, 986

[CrossRef](#)

-
- 173 Marta Boffito, Akil Jackson, Andrew Owen, Stephen Becker. (2013) New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. *Drugs*

[CrossRef](#)

-
- 174 Eric Chun-Hin Tang, Magdalena E Sobieszczyk, Eileen Shu, Pedro Gonzales, Jorge Sanchez, Javier R. Lama. (2013) Provider Attitudes toward Oral Pre-Exposure Prophylaxis for HIV Prevention among High-Risk MSM in Lima, Peru. *AIDS Research and Human Retroviruses* 131210031612006

[CrossRef](#)

-
- 175 Kathleen M. Morrow, Joseph L. Fava, Rochelle K. Rosen, Sara Vargas, Julia G. Shaw, E. Milu Kojic, Patrick F. Kiser, David R. Friend, David F. Katz. (2013) Designing Preclinical Perceptibility Measures to Evaluate Topical Vaginal Gel Formulations: Relating User Sensory Perceptions and Experiences to Formulation Properties. *AIDS Research and Human Retroviruses* 131209064802009

[CrossRef](#)

-
- 176 Iryna Zablotska. (2013) Ending the pandemic: reducing new HIV infections to zero. *Journal of the International AIDS Society* **16**:1,

[CrossRef](#)

- 177 Jennifer Koen, Zaynab Essack, Catherine Slack, Graham Lindegger, Peter A. Newman. (2013) 'It Looks Like You Just Want Them When Things Get Rough': Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in HIV Prevention Trials. *Developing World Bioethics* **13**:3, 138-148
[CrossRef](#)
- 178 D. Alcaix. (2013) Manifestaciones reumatólogicas de la infección por el virus de la inmunodeficiencia humana. *EMC - Aparato Locomotor* **46**:4, 1-16
[CrossRef](#)
- 179 Takamitsu Matsuzawa, Tatsuyoshi Kawamura, Youichi Ogawa, Masaaki Takahashi, Rui Aoki, Kohji Moriishi, Yoshio Koyanagi, Hiroyuki Gatanaga, Andrew Blauvelt, Shinji Shimada. (2013) Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium. *Journal of Investigative Dermatology* **133**:12, 2803-2805
[CrossRef](#)
- 180 Jonathan Baker. (2013) Stay current with options for HIV prevention. *Journal of the American Academy of Physician Assistants* **26**:12, 14-20
[CrossRef](#)
- 181 S. Verguet, M. Stalcup, J. A. Walsh. (2013) Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?. *Sexually Transmitted Infections* **89**:8, 628-634
[CrossRef](#)
- 182 M. A. Ott, A. B. Alexander, M. Lally, J. B. Steever, G. D. Zimet, . (2013) Preventive misconception and adolescents' knowledge about HIV vaccine trials. *Journal of Medical Ethics* **39**:12, 765-771
[CrossRef](#)
- 183 H. Frickmann, B. Wulff, U. Loderstaedt, R. M. Hagen, D. Sturm, S. Polywka. (2013) From IEDs to AIDS? Detection of HIV in human corpses by rapid screening tests after suspected intentional transmission in terrorist attacks. *Journal of the Royal Army Medical Corps* **159**:4, 278-282
[CrossRef](#)
- 184 Joe Romano, Judy Manning, Anke Hemmerling, Elizabeth McGrory, Bethany Young Holt. (2013) Prioritizing multipurpose prevention technology development and investments using a target product profile. *Antiviral Research* **100**, S32-S38
[CrossRef](#)
- 185 Lisa C. Rohan, Haitao Yang, Lin Wang. (2013) Rectal pre-exposure prophylaxis (PrEP). *Antiviral Research* **100**, S17-S24
[CrossRef](#)
- 186 Britt Livak, Stuart Michaels, Keith Green, Charles Nelson, Montre Westbrook, Yaa Simpson, Nikhil G. Prachand, Nanette Benbow, John A. Schneider. (2013) Estimating the Number of Young Black Men who have Sex with Men (YBMSM) on the South Side of Chicago: Towards HIV Elimination within US Urban Communities. *Journal of Urban Health* **90**:6, 1205-1213
[CrossRef](#)
- 187 Fred J. Hellinger. (2013) Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US. *PharmacoEconomics* **31**:12, 1091-1104
[CrossRef](#)

- 188 Ruanne V Barnabas, Heidi van Rooyen, Connie Celum. Diagnosis and promotion of serostatus awareness in sub-Saharan Africa. In: HIV prevention. Future Medicine Ltd, 2013:5-20.
[CrossRef](#)
- 189 Audrey Pettifor, Molly Rosenberg, Sinead Delany-Moretlwe. Prevention of sexual transmission of HIV in adolescents. In: HIV prevention. Future Medicine Ltd, 2013:103-118.
[CrossRef](#)
- 190 Kevin Brian Rebe, James McIntyre. The ART of pre- and post-exposure prophylaxis. In: HIV prevention. Future Medicine Ltd, 2013:29-47.
[CrossRef](#)
- 191 Gita Ramjee. Microbicides for HIV prevention: theory and future prospects. In: HIV prevention. Future Medicine Ltd, 2013:49-69.
[CrossRef](#)
- 192 John Imrie, Geoffrey Jobson, Jerome Galea, Glenn de Swardt. HIV prevention and men: general population and vulnerable subgroups. In: HIV prevention. Future Medicine Ltd, 2013:71-88.
[CrossRef](#)
- 193 Steven Shoptaw. (2013) HIV prevention for people who use substances: Evidence-based strategies. *Journal of Food and Drug Analysis* **21**:4, S91-S94
[CrossRef](#)
- 194 Lynn A Paxton. (2013) Tenofovir-based HIV pre-exposure prophylaxis. *Future Virology* **8**:12, 1207-1218
[CrossRef](#)
- 195 Chantae S Sullivan-Pyke, Sahadat K Nurudeen, Lisa C Grossman, Mark V Sauer, Nataki C Douglas. (2013) Fertility treatment options for HIV-infected individuals. *Future Virology* **8**:12, 1219-1231
[CrossRef](#)
- 196 Kenneth K Mugwanya, Deborah Donnell, Connie Celum, Katherine K Thomas, Patrick Ndase, Nelly Mugo, Elly Katabira, Kenneth Ngure, Jared M Baeten. (2013) Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. *The Lancet Infectious Diseases* **13**:12, 1021-1028
[CrossRef](#)
- 197 Kristen Underhill, Kenneth H Mayer. (2013) Sexual behaviour among users of antiretroviral pre-exposure prophylaxis. *The Lancet Infectious Diseases* **13**:12, 996-997
[CrossRef](#)
- 198 Fatou Maria Dramé, Sarah Peitzmeier, Magda Lopes, Marième Ndaw, Abdoulaye Sow, Daouda Diouf, Stefan Baral. (2013) Gay men and other men who have sex with men in West Africa: evidence from the field. *Culture, Health & Sexuality* **15**:sup1, 7-21
[CrossRef](#)
- 199 Hammer , Scott M. , Sobieszczyk , Magdalena E. , Janes , Holly , Karuna , Shelly T. , Mulligan , Mark J. , Grove , Doug , Koblin , Beryl A. , Buchbinder , Susan P. , Keefer , Michael C. , Tomaras , Georgia D. , Frahm , Nicole , Hural , John , Anude , Chuka , Graham , Barney S. , Enama , Mary E. , Adams , Elizabeth , DeJesus , Edwin , Novak , Richard M. , Frank , Ian , Bentley , Carter , Ramirez , Shelly , Fu , Rong , Koup , Richard A. , Mascola , John R. , Nabel , Gary J. , Montefiori , David C. , Kublin , James , McElrath

, M. Juliana , Corey , Lawrence , Gilbert , Peter B. , . (2013) Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. *New England Journal of Medicine* **369**:22, 2083-2092

[Free Full Text](#)

- 200 M Rosinska, J Janiec, M Niedzwiedzka-Stadnik. (2013) Increase of new HIV diagnoses among men who have sex with men in Poland, 2000 to 2011. *Eurosurveillance* **18**:48, 20642
[CrossRef](#)
- 201 Jacob J. Berg, Rochelle K. Rosen, Dana E. Bregman, Lara A. Thompson, Kathleen M. Jensen, Patrick F. Kiser, David F. Katz, Karen Buckheit, Robert W. Buckheit, Kathleen M. Morrow. (2013) "Set it and Forget it": Women's Perceptions and Opinions of Long-Acting Topical Vaginal Gels. *AIDS and Behavior*
[CrossRef](#)
- 202 Matthew J. Mimiaga, Elizabeth F. Closson, Vishesh Kothary, Jennifer A. Mitty. (2013) Sexual Partnerships and Considerations for HIV Antiretroviral Pre-Exposure Prophylaxis Utilization Among High-Risk Substance Using Men Who Have Sex with Men. *Archives of Sexual Behavior*
[CrossRef](#)
- 203 J. M. Fogel, L. Wang, T. L. Parsons, S.-S. Ou, E. Piwowar-Manning, Y. Chen, V. O. Mudhune, M. C. Hosseiniipour, J. Kumwenda, J. G. Hakim, S. Chariyalertsak, R. Panchia, I. Sanne, N. Kumarasamy, B. Grinsztejn, J. Makhema, J. Pilotto, B. R. Santos, K. H. Mayer, M. McCauley, T. Gamble, N. N. Bumpus, C. W. Hendrix, M. S. Cohen, S. H. Eshleman. (2013) Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052). *Journal of Infectious Diseases* **208**:10, 1624-1628
[CrossRef](#)
- 204 Patrick S. Sullivan, Kristin M. Wall, Brandon O'Hara, Jeb Jones, Jasper Barnes, Ralph DiClemente, Colleen Hoff, Lamont Scales, Laura F. Salazar, Travis Sanchez, Darcy White, Gina Wingood, Susan Allen, Rob Stephenson. (2013) The Prevalence of Undiagnosed HIV Serodiscordance Among Male Couples Presenting for HIV Testing. *Archives of Sexual Behavior*
[CrossRef](#)
- 205 David W. Purcell, Yuko Mizuno, Dawn K. Smith, Kristina Grabbe, Cari Courtenay-Quirk, Hank Tomlinson, Jonathan Mermin. (2013) Incorporating Couples-Based Approaches into HIV Prevention for Gay and Bisexual Men: Opportunities and Challenges. *Archives of Sexual Behavior*
[CrossRef](#)
- 206 Francisco J. Leyva, Rahul P. Bakshi, Edward J. Fuchs, Liye Li, Brian S. Caffo, Arthur J. Goldsmith, Ana Ventuneac, Alex Carballo-Diéguez, Yong Du, Jeffrey P. Leal, Linda A. Lee, Michael S. Torbenson, Craig W. Hendrix. (2013) Isoosmolar Enemas Demonstrate Preferential Gastrointestinal Distribution, Safety, and Acceptability Compared with Hyperosmolar and Hypoosmolar Enemas as a Potential Delivery Vehicle for Rectal Microbicides. *AIDS Research and Human Retroviruses* **29**:11, 1487-1495
[CrossRef](#)
- 207 Chris Beyrer, Patrick Sullivan, Jorge Sanchez, Stefan D. Baral, Chris Collins, Andrea L. Wirtz, Dennis Altman, Gift Trapence, Kenneth Mayer. (2013) The increase in global HIV epidemics in MSM. *AIDS* **27**:17, 2665-2678
[CrossRef](#)
- 208 David A.M.C. van de Vijver, Brooke E. Nichols, Ume L. Abbas, Charles A.B. Boucher, Valentina Cambiano, Jeffrey W. Eaton, Robert Glaubius, Katrina Lythgoe, John Mellors,

Andrew Phillips, Kim C. Sigaloff, Timothy B. Hallett. (2013) Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. *AIDS* **27**:18, 2943-2951

[CrossRef](#)

- 209 Lindsay B. Avery, Melissa A. Zarr, Rahul P. Bakshi, Robert F. Siliciano, Craig W. Hendrix. (2013) Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. *AIDS Research and Human Retroviruses* **29**:11, 1434-1442

[CrossRef](#)

- 210 (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). *Enfermedades Infecciosas y Microbiología Clínica* **31**:9, 602.e1-602.e98

[CrossRef](#)

- 211 Holly Janes, Peter Gilbert, Susan Buchbinder, James Kublin, Magdalena E. Sobieszczyk, Scott M. Hammer. (2013) In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. *AIDS Research and Human Retroviruses* **29**:11, 1513-1523

[CrossRef](#)

- 212 Moupali Das, Katerina A. Christopoulos, Dara Geckeler, Emalie Huriaux, Stephanie E. Cohen, Susan Philip, Starley Shade, Nicholas J. Moss, Stephen F. Morin, Edwin D. Charlebois. (2013) Linkage to HIV Care in San Francisco. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **64**, S27-S32

[CrossRef](#)

- 213 Joseph Romano, Angela Kashuba, Stephen Becker, James Cummins, Jim Turpin, Fulvia Veronese, on Behalf of the Antiretr. (2013) Pharmacokinetics and Pharmacodynamics in HIV Prevention; Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention. *AIDS Research and Human Retroviruses* **29**:11, 1418-1427

[CrossRef](#)

- 214 Gerrit Koopman, Niels Beenhakker, Ivonne Nieuwenhuis, Gaby Doxiadis, Petra Mooij, Jan W. Drijfhout, Josef Koestler, Tomas Hanke, Zahra Fagrouch, Ernst J. Verschoor, Ronald E. Bontrop, Ralf Wagner, Willy M.J.M. Bogers, Cornelis J.M. Melief. (2013) DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. *AIDS* **27**:18, 2841-2851

[CrossRef](#)

- 215 Derrick Louz, Hans E. Bergmans, Birgit P. Loos, Rob C. Hoeben. (2013) Animal models in virus research: their utility and limitations. *Critical Reviews in Microbiology* **39**:4, 325-361

[CrossRef](#)

- 216 Alan E. Greenberg, David W. Purcell, Christopher M. Gordon, Stephen Flores, Cynthia Grossman, Holly H. Fisher, Rebecca J. Barasky. (2013) NIH Support of Centers for AIDS Research and Department of Health Collaborative Public Health Research. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **64**, S1-S6

[CrossRef](#)

- 217 Johanna Hanefeld, Virginia Bond, Janet Seeley, Shelley Lees, Nicola Desmond. (2013) Considerations for a Human Rights Impact Assessment of a Population Wide Treatment for HIV Prevention Intervention. *Developing World Bioethics* n/a-n/a

[CrossRef](#)

- 218 Nicolette A. Louissaint, Ying-Jun Cao, Paul L. Skipper, Rosa G. Liberman, Steven R. Tannenbaum, Sridhar Nimmagadda, Jean R. Anderson, Stephanie Everts, Rahul Bakshi, Edward J. Fuchs, Craig W. Hendrix. (2013) Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. *AIDS Research and Human Retroviruses* **29**:11, 1443-1450
[CrossRef](#)
- 219 Allan E. Rodríguez, Amanda D. Castel, Carrigan L. Parish, Sarah Willis, Daniel J. Feaster, Michael Kharfen, Gabriel A. Cardenas, Kira Villamizar, Michael Kolber, Liliana Vázquez-Rivera, Lisa R. Metsch. (2013) HIV Medical Providers' Perceptions of the Use of Antiretroviral Therapy as Nonoccupational Postexposure Prophylaxis in 2 Major Metropolitan Areas. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **64**, S68-S79
[CrossRef](#)
- 220 Bridget Haire, Christopher Jordens. (2013) Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials. *Developing World Bioethics* n/a
[CrossRef](#)
- 221 Ayyappa Chaturvedula, Michael J. Fossler, Craig W. Hendrix. (2013) Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. *The Journal of Clinical Pharmacology* n/a
[CrossRef](#)
- 222 Kenneth H Mayer. (2013) Thinking about an AIDS end game. *The Lancet* **382**:9903, 1462-1464
[CrossRef](#)
- 223 Lauren A Seserko, Joshua F Emory, Craig W Hendrix, Mark A Marzinke. (2013) The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. *Bioanalysis* **5**:22, 2771-2783
[CrossRef](#)
- 224 Françoise Barré-Sinoussi, Anna Laura Ross, Jean-François Delfraissy. (2013) Past, present and future: 30 years of HIV research. *Nature Reviews Microbiology*
[CrossRef](#)
- 225 Pamina M. Gorbach, Clifton W. Kelly, Joleen A. Borgerding, Gita Ramjee, Tchangani Tembo, Newton Kumwenda, Petina Musara, Sarah Roberts, Lisa Maslankowski. (2013) Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035). *AIDS and Behavior*
[CrossRef](#)
- 226 Tanuja N. Gengiah, Atika Moosa, Anushka Naidoo, Leila E. Mansoor. (2013) Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. *International Journal of Clinical Pharmacy*
[CrossRef](#)
- 227 Sarah L. Braunstein, Chi-Chi Udeagu, Angelica Bocour, Tamar Renaud, Colin W. Shepard. (2013) Identifying the Correlates of Membership in HIV-Serodiscordant Partnerships in New York City. *Sexually Transmitted Diseases* **40**:10, 784-791
[CrossRef](#)
- 228 Avnish Tripathi, Y. Omar Whiteside, Wayne A. Duffus. (2013) Perceptions and Attitudes About Preexposure Prophylaxis Among Seronegative Partners and the Potential of Sexual Disinhibition. *Southern Medical Journal* **106**:10, 558-564

[CrossRef](#)

- 229 Elisa F. Long, Robert R. Stavert. (2013) Portfolios of Biomedical HIV Interventions in South Africa: A Cost-Effectiveness Analysis. *Journal of General Internal Medicine* **28**:10, 1294-1301
[CrossRef](#)
- 230 Bridget Haire, Christopher Jordens. (2013) Standard of Prevention in the Real World: A Qualitative Study of Principal Investigators in HIV Biomedical Prevention Trials. *AJOB Primary Research* **4**:4, 14-25
[CrossRef](#)
- 231 David Tellalian, Khalid Maznavi, U. Fritz Bredeek, W. David Hardy. (2013) Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and Prescribing Practices. *AIDS Patient Care and STDs* **27**:10, 553-559
[CrossRef](#)
- 232 Hailey J. Gilmore, Albert Liu, Kimberly Ann Koester, K. Rivet Amico, Vanessa McMahan, Pedro Goicochea, Lorena Vargas, David Lubensky, Susan Buchbinder, Robert Grant. (2013) Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. *AIDS Patient Care and STDs* **27**:10, 560-566
[CrossRef](#)
- 233 Craig W. Hendrix. (2013) Exploring Concentration Response in HIV Pre-Exposure Prophylaxis to Optimize Clinical Care and Trial Design. *Cell* **155**:3, 515-518
[CrossRef](#)
- 234 Mark W. Hull, Julio S.G. Montaner. (2013) HIV treatment as prevention: The key to an AIDS-free generation. *Journal of Food and Drug Analysis*
[CrossRef](#)
- 235 Kristen Underhill. (2013) Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and research ethics. *Social Science & Medicine* **94**, 115-123
[CrossRef](#)
- 236 S. Wade Taylor, Kenneth H. Mayer, Steven M. Elsesser, Matthew J. Mimiaga, Conall O'Cleirigh, Steven A. Safren. (2013) Optimizing Content for Pre-exposure Prophylaxis (PrEP) Counseling for Men Who Have Sex with Men: Perspectives of PrEP Users and High-Risk PrEP Naïve Men. *AIDS and Behavior*
[CrossRef](#)
- 237 Aranka Anema, Thomas Kerr, M.-J. Milloy, Cindy Feng, Julio S.G. Montaner, Evan Wood. (2013) Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting. *AIDS Care* **1-7**
[CrossRef](#)
- 238 Jarrett K. Sell. (2013) Management of Human Immunodeficiency Virus in Primary Care. *Primary Care: Clinics in Office Practice* **40**:3, 589-617
[CrossRef](#)
- 239 Lisa A. Grohskopf, Kata L. Chillag, Roman Gvetadze, Albert Y. Liu, Melanie Thompson, Kenneth H. Mayer, Brandi M. Collins, Sonal R. Pathak, Brandon O'Hara, Marta L. Ackers, Charles E. Rose, Robert M. Grant, Lynn A. Paxton, Susan P. Buchbinder. (2013) Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among

HIV-Uninfected Men Who Have Sex With Men in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **64**:1, 79-86
[CrossRef](#)

- 240 Albert Y. Liu, Eric Vittinghoff, Kata Chillag, Kenneth Mayer, Melanie Thompson, Lisa Grohskopf, Grant Colfax, Sonal Pathak, Roman Gvetadze, Brandon O'Hara, Brandi Collins, Marta Ackers, Lynn Paxton, Susan P. Buchbinder. (2013) Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **64**:1, 87-94
[CrossRef](#)
- 241 Alan B. Stone, Polly F. Harrison, Manjula Lusti-Narasimhan. (2013) Microbicides from a regulatory perspective. *AIDS* **27**:14, 2261-2269
[CrossRef](#)
- 242 Irving F. Hoffman, Carl A. Latkin, Polina V. Kukhareva, Sergey V. Malov, Julia V. Batluk, Alla V. Shaboltas, Roman V. Skochilov, Nicolay V. Sokolov, Sergei V. Verevochkin, Michael G. Hudgens, Andrei P. Kozlov. (2013) A Peer-Educator Network HIV Prevention Intervention Among Injection Drug Users: Results of a Randomized Controlled Trial in St. Petersburg, Russia. *AIDS and Behavior* **17**:7, 2510-2520
[CrossRef](#)
- 243 Zoe Moodie, Holly Janes, Yunda Huang. (2013) New clinical trial designs for HIV vaccine evaluation. *Current Opinion in HIV and AIDS* **8**:5, 436-441
[CrossRef](#)
- 244 Christian Grov, H. Jonathon Rendina, Ana Ventuneac, Jeffrey T. Parsons. (2013) HIV Risk in Group Sexual Encounters: An Event-Level Analysis from a National Online Survey of MSM in the U.S.. *The Journal of Sexual Medicine* **10**:9, 2285-2294
[CrossRef](#)
- 245 Sten H. Vermund. (2013) Safety and Tolerability of Tenofovir for Preexposure Prophylaxis Among Men Who Have Sex With Men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **64**:1, 3-6
[CrossRef](#)
- 246 Jill Blumenthal, Richard Haubrich. (2013) Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. *Expert Opinion on Pharmacotherapy* **14**:13, 1777-1785
[CrossRef](#)
- 247 Rochelle P. Walensky. (2013) Combination HIV Prevention: The Value and Interpretation of Mathematical Models. *Current HIV/AIDS Reports* **10**:3, 195-198
[CrossRef](#)
- 248 Ethan A. Cowan, Ruth Macklin. (2013) Is preexposure prophylaxis ready for prime time use in HIV prevention research?. *AIDS*
[CrossRef](#)
- 249 Kachit Choopanya, Michael Martin, Suphak Vanichseni, Philip A Mock, Pravan Suntharasamai, Udomsak Sangkum. (2013) HIV antiretroviral prophylaxis for injecting drug users – Authors' reply. *The Lancet* **382**:9895, 855
[CrossRef](#)
- 250 Punnee Pitisuttithum, Supachai Rerks-Ngarm, Robert O'Connell, Jerome Kim, Jean-Louis Excler. (2013) An HIV Vaccine for South-East Asia—Opportunities and Challenges.

Vaccines 1:3, 348-366

[CrossRef](#)

- 251 María Fabiana De Rosa, Kevin R. Robillard, Connie J. Kim, Md. Tozammel Hoque, Gabor Kandel, Colin Kovacs, Rupert Kaul, Reina Bendayan. (2013) Expression of Membrane Drug Efflux Transporters in the Sigmoid Colon of HIV-Infected and Uninfected Men. *The Journal of Clinical Pharmacology* **53**:9, 934-945

[CrossRef](#)

- 252 Ryan P. Westergaard, Mary Catherine Beach, Somnath Saha, Elizabeth A. Jacobs. (2013) Racial/Ethnic Differences in Trust in Health Care: HIV Conspiracy Beliefs and Vaccine Research Participation. *Journal of General Internal Medicine*

[CrossRef](#)

- 253 Sarah E. Woolf-King, Thomas M. Rice, Hong-Ha M. Truong, William J. Woods, Roy C. Jerome, Adam W. Carrico. (2013) Substance Use and HIV Risk Behavior among Men Who Have Sex with Men: The Role of Sexual Compulsivity. *Journal of Urban Health*

[CrossRef](#)

- 254 Christina Knussen, Paul Flowers, Lisa M. McDaid. (2013) Factors associated with recency of HIV testing amongst men residing in Scotland who have sex with men. *AIDS Care* 1-7

[CrossRef](#)

- 255 C. S. Pace, R. Song, C. Ochsenbauer, C. D. Andrews, D. Franco, J. Yu, D. A. Oren, M. S. Seaman, D. D. Ho. (2013) Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. *Proceedings of the National Academy of Sciences* **110**:33, 13540-13545

[CrossRef](#)

- 256 Pamela M. Murnane, Connie Celum, Nelly Mugo, James D. Campbell, Deborah Donnell, Elizabeth Bukusi, Andrew Mujugira, Jordan Tappero, Erin M. Kahle, Katherine K. Thomas, Jared M. Baeten. (2013) Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. *AIDS* **27**:13, 2155-2160

[CrossRef](#)

- 257 Oyewole C. Durojaiye, Andrew Freedman. (2013) HIV prevention strategies. *Medicine* **41**:8, 466-469

[CrossRef](#)

- 258 M.-e. Cong, J. Mitchell, E. Sweeney, S. Bachman, D. L. Hanson, W. Heneine, J. G. Garcia-Lerma. (2013) Prophylactic Efficacy of Oral Emtricitabine and Tenofovir Disoproxil Fumarate Combination Therapy Against a Tenofovir-Resistant Simian/Human Immunodeficiency Virus Containing the K65R Mutation in Macaques. *Journal of Infectious Diseases* **208**:3, 463-467

[CrossRef](#)

- 259 Arunrat Tangmunkongvorakul, Suwat Chariyalertsak, K. Rivet Amico, Pongpun Saokhieo, Vorawan Wannalak, Thirayut Sangangamsakun, Pedro Goicochea, Robert Grant. (2013) Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. *AIDS Care* **25**:8, 961-967

[CrossRef](#)

- 260 M. Desai, S. Desai, A. K. Sullivan, M. Mohabeer, D. Mercey, M. A. Kingston, C. Thng, S. McCormack, O. N. Gill, A. Nardone, , A. McOwan, L. Samer, G. Dean, C. Rae, G. Wildman, S. Zubayr, M. Nathan, L. Greene, M. Tenant-Flowers, S. Schoeman, T. Balachandran, A. Sukthankar, D. Mercey, N. Sankar, T. McManus, L. Riddell, C. Bignell,

S. Murphy, C. Bowman, P. Hay, T. Anjum, J. Russell, K. Mclean, C. Hardwick, E. Savage, C. Lowndes. (2013) Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England. *Sexually Transmitted Infections* **89**:5, 404-408

[CrossRef](#)

- 261 Stuart Rennie. (2013) Ethical Use of Antiretroviral Resources for HIV Prevention in Resource Poor Settings. *Developing World Bioethics* **13**:2, 79-86
[CrossRef](#)
- 262 Quarasha Abdool Karim, Ronald Bayer. (2013) Anti-retrovirals for treatment and prevention - time for new paradigms in our response to the HIV/AIDS epidemic?. *Developing World Bioethics* **13**:2, ii-iii
[CrossRef](#)
- 263 Bridget Haire, John M. Kaldor. (2013) Ethics of ARV Based Prevention: Treatment-as-Prevention and PrEP. *Developing World Bioethics* **13**:2, 63-69
[CrossRef](#)
- 264 Bridget Haire, Morenike Oluwatoyin Folayan, Catherine Hankins, Jeremy Sugarman, Sheena McCormack, Gita Ramjee, Mitchell Warren. (2013) Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining PrEP. *Developing World Bioethics* **13**:2, 87-94
[CrossRef](#)
- 265 Nora J. Kenworthy, Nicola Bulled. (2013) From modeling to morals: Imagining the future of HIV PREP in Lesotho. *Developing World Bioethics* **13**:2, 70-78
[CrossRef](#)
- 266 Peter A Newman, Surachet Roungprakhon, Suchon Tepjan. (2013) A social ecology of rectal microbicide acceptability among young men who have sex with men and transgender women in Thailand. *Journal of the International AIDS Society* **16**:0,
[CrossRef](#)
- 267 J. Whetham, S. Taylor, L. Charlwood, T. Keith, R. Howell, C. McInnes, E. Payne, J. Home, D. White, Y. Gilleece. (2013) Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. *AIDS Care* **1**-5
[CrossRef](#)
- 268 H. Janes, D. P. Friedrich, A. Krambrink, R. J. Smith, E. G. Kallas, H. Horton, D. R. Casimiro, M. Carrington, D. E. Geraghty, P. B. Gilbert, M. J. McElrath, N. Frahm. (2013) Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. *Journal of Infectious Diseases*
[CrossRef](#)
- 269 Tonya N. Taylor, Joanne E. Mantell, Ntobeko Nywagi, Nomazize Cishe, Diane Cooper. (2013) 'He lacks his fatherhood': safer conception technologies and the biological imperative for fatherhood among recently-diagnosed Xhosa-speaking men living with HIV in South Africa. *Culture, Health & Sexuality* **1**-14
[CrossRef](#)
- 270 C. Celum, T. B. Hallett, J. M. Baeten. (2013) HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact. *Journal of Infectious Diseases* **208**:2, 189-191
[CrossRef](#)
- 271 U. L. Abbas, R. Glaubius, A. Mubayi, G. Hood, J. W. Mellors. (2013) Antiretroviral Therapy

and Pre-exposure Prophylaxis: Combined Impact on HIV Transmission and Drug Resistance in South Africa. *Journal of Infectious Diseases* **208**:2, 224-234
[CrossRef](#)

- 272 Sook-Kyung Lee, Nancy Cheng, Emily Hull-Ryde, Marc Potempa, Celia A. Schiffer, William Janzen, Ronald Swanstrom. (2013) A Sensitive Assay Using a Native Protein Substrate for Screening HIV-1 Maturation Inhibitors Targeting the Protease Cleavage Site between the Matrix and Capsid. *Biochemistry* 130711092930000
[CrossRef](#)
- 273 K. J. Metzner, A. U. Scherrer, B. Preiswerk, B. Joos, V. von Wyl, C. Leemann, P. Rieder, D. Braun, C. Grube, H. Kuster, J. Boni, S. Yerly, T. Klimkait, V. Aubert, H. Furrer, M. Battegay, P. L. Vernazza, M. Cavassini, A. Calmy, E. Bernasconi, R. Weber, H. F. Gunthard, , V. Aubert, J. Barth, M. Battegay, E. Bernasconi, J. Boni, H. C. Bucher, C. Burton-Jeangros, A. Calmy, M. Cavassini, M. Egger, L. Elzi, J. Fehr, J. Fellay, H. Furrer, C. A. Fux, M. Gorgievski, H. Gunthard, D. Haerry, B. Hasse, H. H. Hirsch, I. Hosli, C. Kahlert, L. Kaiser, O. Keiser, H. Kovari, R. Kouyos, B. Ledergerber, G. Martinetti, B. Martinez de Tejada, K. Metzner, N. Muller, D. Nadal, G. Pantaleo, A. Rauch, S. Regenass, M. Rickenbach, C. Rudin, P. Schmid, D. Schultze, F. Schoni-Affolter, J. Schupbach, R. Speck, P. Taffe, P. Tarr, A. Telenti, A. Trkola. (2013) Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. *Journal of Infectious Diseases*
[CrossRef](#)
- 274 Deborah Donnell, James P. Hughes, Lei Wang, Ying Q. Chen, Thomas R. Fleming. (2013) Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S130-S134
[CrossRef](#)
- 275 Beryl A. Koblin, Michele Andrasik, Judy Austin. (2013) Preparing for the Unexpected. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S183-S186
[CrossRef](#)
- 276 Wafaa M. El-Sadr, David M. Serwadda, Nirupama Sista, Myron S. Cohen. (2013) HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S115-S116
[CrossRef](#)
- 277 Jonathan D. Fuchs, Magdalena E. Sobieszczyk, Tamra Madenwald, Doug Grove, Shelly T. Karuna, Michele Andrasik, Adam Sherwat, Gail Broder, Kenneth Mayer, Beryl Koblin, Scott Hammer. (2013) Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**:3, 259-262
[CrossRef](#)
- 278 Kenneth H. Mayer, Darrell P. Wheeler, Linda-Gail Bekker, Beatriz Grinsztejn, Robert H. Remien, Theodorus G. M. Sandfort, Chris Beyrer. (2013) Overcoming Biological, Behavioral, and Structural Vulnerabilities. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S161-S167
[CrossRef](#)
- 279 Niels van Doorn. (2013) Treatment is Prevention. *Cultural Studies* **27**:6, 901-932
[CrossRef](#)
- 280 Steve Shoptaw, Brooke Montgomery, Chyvette T. Williams, Nabila El-Bassel, Apinun Aramrattana, Lisa Metsch, David S. Metzger, Irene Kuo, Francisco I. Bastos, Steffanie A. Strathdee. (2013) Not Just the Needle. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S174-S178
[CrossRef](#)

- 281 Corbin G. Thompson, Myron S. Cohen, Angela D.M. Kashuba. (2013) Antiretroviral Pharmacology in Mucosal Tissues. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S240-S247
[CrossRef](#)
- 282 Elisabeth Maria Elst, Judie Mbogua, Don Operario, Gaudensia Mutua, Caroline Kuo, Peter Mugo, Jennifer Kanungi, Sagri Singh, Jessica Haberer, Frances Priddy, Eduard Joachim Sanders. (2013) High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya. *AIDS and Behavior* **17**:6, 2162-2172
[CrossRef](#)
- 283 Martin Holt, Dean Murphy, Denton Callander, Jeanne Ellard, Marsha Rosengarten, Susan Kippax, John Wit. (2013) HIV-Negative and HIV-Positive Gay Men's Attitudes to Medicines, HIV Treatments and Antiretroviral-based Prevention. *AIDS and Behavior* **17**:6, 2156-2161
[CrossRef](#)
- 284 Audrey Pettifor, Linda-Gail Bekker, Sybil Hosek, Ralph DiClemente, Molly Rosenberg, Sheana S. Bull, Susannah Allison, Sinead Delany-Moretlwe, Bill G. Kapogiannis, Frances Cowan. (2013) Preventing HIV Among Young People. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S155-S160
[CrossRef](#)
- 285 Margaret L. McNairy, Andrea A. Howard, Wafaa M. El-Sadr. (2013) Antiretroviral Therapy for Prevention of HIV and Tuberculosis. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S200-S207
[CrossRef](#)
- 286 Jeremy Sugarman, Kenneth H. Mayer. (2013) Ethics and Pre-exposure Prophylaxis for HIV Infection. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S135-S139
[CrossRef](#)
- 287 K. Rivet Amico, Leila E. Mansoor, Amy Corneli, Kristine Torjesen, Ariane Straten. (2013) Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials. *AIDS and Behavior* **17**:6, 2143-2155
[CrossRef](#)
- 288 Hong-Van Tieu, Morgane Rolland, Scott M. Hammer, Magdalena E. Sobieszczyc. (2013) Translational Research Insights From Completed HIV Vaccine Efficacy Trials. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S150-S154
[CrossRef](#)
- 289 Sten H. Vermund, Sarah J. Fidler, Helen Ayles, Nulda Beyers, Richard J. Hayes. (2013) Can Combination Prevention Strategies Reduce HIV Transmission in Generalized Epidemic Settings in Africa? The HPTN 071 (PopART) Study Plan in South Africa and Zambia. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S221-S227
[CrossRef](#)
- 290 Bluma G. Brenner, Mark A. Wainberg. (2013) Future of Phylogeny in HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S248-S254
[CrossRef](#)
- 291 Katherine B. Rucinski, Nana P. Mensah, Kent A. Sepkowitz, Blayne H. Cutler, M. Monica Sweeney, Julie E. Myers. (2013) Knowledge and Use of Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in New York City. *AIDS and*

Behavior 17:6, 2180-2184

[CrossRef](#)

- 292 Ralph J. DiClemente. (2013) Turning the Corner on the HIV Epidemic Among Adolescents: Prioritizing Directions for Future Prevention Research. *Journal of HIV/AIDS & Social Services* 12:3-4, 258-265

[CrossRef](#)

- 293 Jared M. Baeten, Jessica E. Haberer, Albert Y. Liu, Nirupama Sista. (2013) Preexposure Prophylaxis for HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 63, S122-S129

[CrossRef](#)

- 294 Mitchell J. Warren, Emily S. Bass. (2013) Perspectives on HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 63, S255-S259

[CrossRef](#)

- 295 Brian Mustanski, Amy K. Johnson, Robert Garofalo, Daniel Ryan, Michelle Birkett. (2013) Perceived Likelihood of Using HIV Pre-exposure Prophylaxis Medications Among Young Men Who Have Sex with Men. *AIDS and Behavior* 17:6, 2173-2179

[CrossRef](#)

- 296 Connie Celum, Jared M. Baeten, James P. Hughes, Ruanne Barnabas, Albert Liu, Heidi Van Rooyen, Susan Buchbinder. (2013) Integrated Strategies for Combination HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 63, S213-S220

[CrossRef](#)

- 297 Richard H. Beigi, Lisa Noguchi, Gina Brown, Jeanna Piper, D. Heather Watts. (2013) Performing Drug Safety Research During Pregnancy and Lactation: Biomedical HIV Prevention Research as a Template. *Journal of Women's Health* 130629064740008

[CrossRef](#)

- 298 Sybil G. Hosek, Keith R. Green, George Siberry, Michelle Lally, Christopher Balthazar, Pedro A. Serrano, Bill Kapogiannis, The Adolescent Medicine Trials Netw. (2013) Integrating Behavioral HIV Interventions into Biomedical Prevention Trials with Youth: Lessons from Chicago's Project PrEPare. *Journal of HIV/AIDS & Social Services* 130627122928003

[CrossRef](#)

- 299 P. Pathela, S. L. Braunstein, S. Blank, J. A. Schillinger. (2013) HIV Incidence Among Men With and Those Without Sexually Transmitted Rectal Infections: Estimates From Matching Against an HIV Case Registry. *Clinical Infectious Diseases*

[CrossRef](#)

- 300 Heather Senn, James Wilton, Malika Sharma, Shawn Fowler, Darrell H.S. Tan. (2013) Knowledge of and Opinions on HIV Preexposure Prophylaxis Among Front-Line Service Providers at Canadian AIDS Service Organizations. *AIDS Research and Human Retroviruses* 130622051337000

[CrossRef](#)

- 301 A. B. Jena. (2013) Editorial Commentary: Balancing Disease Eradication With the Emergence of Multidrug-Resistant HIV in Test-and-Treat Policies. *Clinical Infectious Diseases* 56:12, 1797-1799

[CrossRef](#)

- 302 H. Gatanaga, T. Hayashida, J. Tanuma, S. Oka. (2013) Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. *Clinical Infectious Diseases* 56:12, 1812-1819

[CrossRef](#)

- 303 R. K. Gupta, M. A. Wainberg, F. Brun-Vezinet, J. M. Gatell, J. Albert, A. Sonnerborg, J. B. Nacheaga. (2013) Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. *Journal of Infectious Diseases* **207**:suppl 2, S101-S106
[CrossRef](#)
- 304 E. Rosenthal, L. Piroth, E. Cua, A. Joulié, I. Ravaux, M. Chauveau, K. Lacombe, L. Cotte, P. Bonnard, L. Weiss, M. Longuet, C. Pradier, P. Cacoub, . (2013) Preexposure prophylaxis (PrEP) of HIV infection in France: A nationwide cross-sectional study (PREVIC study). *AIDS Care* 1-10
[CrossRef](#)
- 305 Piot , Peter , Quinn , Thomas C . . (2013) Response to the AIDS Pandemic — A Global Health Model. *New England Journal of Medicine* **368**:23, 2210-2218
[Free Full Text](#)
- 306 Lung Vu, Sylvia Adebajo, Waimar Tun, Meredith Sheehy, Andrew Karlyn, Jean Njab, Aderemi Azeez, Babatunde Ahonsi. (2013) High HIV Prevalence Among Men Who Have Sex With Men in Nigeria. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**:2, 221-227
[CrossRef](#)
- 307 Sten H. Vermund, Richard J. Hayes. (2013) Combination Prevention: New Hope for Stopping the Epidemic. *Current HIV/AIDS Reports* **10**:2, 169-186
[CrossRef](#)
- 308 Conall O'Clearigh, Michael E. Newcomb, Kenneth H. Mayer, Margie Skeer, Lara Traeger, Steven A. Safren. (2013) Moderate Levels of Depression Predict Sexual Transmission Risk in HIV-Infected MSM: A Longitudinal Analysis of Data From Six Sites Involved in a "Prevention for Positives" Study. *AIDS and Behavior* **17**:5, 1764-1769
[CrossRef](#)
- 309 Sten H. Vermund, José A. Tique, Holly M. Cassell, Megan E. Pask, Philip J. Ciampa, Carolyn M. Audet. (2013) Translation of Biomedical Prevention Strategies for HIV. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S12-S25
[CrossRef](#)
- 310 Jared M. Baeten, Robert Grant. (2013) Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know?. *Current HIV/AIDS Reports* **10**:2, 142-151
[CrossRef](#)
- 311 John F. Murray. (2013) Epidemiology of Human Immunodeficiency Virus–Associated Pulmonary Disease. *Clinics in Chest Medicine* **34**:2, 165-179
[CrossRef](#)
- 312 Dianne M. Rausch, Cynthia I. Grossman, Emily J. Erbelding. (2013) Integrating Behavioral and Biomedical Research in HIV Interventions. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S6-S11
[CrossRef](#)
- 313 J. E. Myers, K. A. Sepkowitz. (2013) A Pill for HIV Prevention: Deja Vu All Over Again?. *Clinical Infectious Diseases* **56**:11, 1604-1612
[CrossRef](#)
- 314 Gina M. Wingood, Kristin Dunkle, Christina Camp, Shilpa Patel, Julia E. Painter, Anna Rubtsova, Ralph J. DiClemente. (2013) Racial Differences and Correlates of Potential

Adoption of Preexposure Prophylaxis. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**, S95-S101
[CrossRef](#)

- 315 Sandra I. McCoy, Karen Shiu, Tyler E. Martz, Carla Dillard Smith, Loris Mattox, Dale R. Gluth, Neena Murgai, Marsha Martin, Nancy S. Padian. (2013) Improving the Efficiency of HIV Testing With Peer Recruitment, Financial Incentives, and the Involvement of Persons Living With HIV Infection. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**:2, e56-e63
[CrossRef](#)
- 316 Susan Kasedde, Chewe Luo, Craig McClure, Upjeet Chandan. (2013) Reducing HIV and AIDS in Adolescents: Opportunities and Challenges. *Current HIV/AIDS Reports* **10**:2, 159-168
[CrossRef](#)
- 317 Peter Cherutich, Rebecca Bunnell, Jonathan Mermin. (2013) HIV Testing: Current Practice and Future Directions. *Current HIV/AIDS Reports* **10**:2, 134-141
[CrossRef](#)
- 318 Margaret L. McNairy, Myron Cohen, Wafaa M. El-Sadr. (2013) Antiretroviral Therapy for Prevention Is a Combination Strategy. *Current HIV/AIDS Reports* **10**:2, 152-158
[CrossRef](#)
- 319 Beryl A. Koblin, Barbara Metch, Richard M. Novak, Cecilia Morgan, Debbie Lucy, Debora Dunbar, Parrie Graham, Edith Swann, Tamra Madenwald, Gina Escamilla, Ian Frank. (2013) Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **63**:2, 239-244
[CrossRef](#)
- 320 Kachit Choopanya, Michael Martin, Pravan Suntharasamai, Udomsak Sangkum, Philip A Mock, Manoj Leethochawalit, Sithisat Chiamwongpaet, Praphan Kitisin, Pitinan Natrujirote, Somyot Kittimunkong, Rutt Chuachoowong, Roman J Gvetadze, Janet M McNicholl, Lynn A Paxton, Marcel E Curlin, Craig W Hendrix, Suphak Vanichseni. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *The Lancet*
[CrossRef](#)
- 321 , Panagiotis Vagenas, Kaysia T. Ludford, Pedro Gonzales, Jesus Peinado, Cesar Cabezas, Fernando Gonzales, Javier R. Lama, Jorge Sanchez, Frederick L. Altice. (2013) Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. *AIDS and Behavior*
[CrossRef](#)
- 322 Kristina Rodriguez, Delivette Castor, Timothy L. Mah, Stephanie H. Cook, Lex M. Augiste, Perry N. Halkitis, Marty Markowitz. (2013) Participation in research involving novel sampling and study designs to identify acute HIV-1 infection among minority men who have sex with men. *AIDS Care* **25**:7, 828-834
[CrossRef](#)
- 323 Kaja-Triin Laisaar, Anneli Uusküla, Anjali Sharma, Jack A. DeHovitz, K. Rivet Amico. (2013) Developing an adherence support intervention for patients on antiretroviral therapy in the context of the recent IDU-driven HIV/AIDS epidemic in Estonia. *AIDS Care* **25**:7, 863-873
[CrossRef](#)

- 324 Lisa A. Eaton, Seth C. Kalichman, David A. Kenny, Ofer Harel. (2013) A reanalysis of a behavioral intervention to prevent incident HIV infections: Including indirect effects in modeling outcomes of Project EXPLORE. *AIDS Care* **25**:7, 805-811
[CrossRef](#)
- 325 Sung-Jae Lee, Ronald Brooks, Robert K. Bolan, Risa Flynn. (2013) Assessing willingness to test for HIV among men who have sex with men using conjoint analysis, evidence for uptake of the FDA-approved at-home HIV test. *AIDS Care* **1**-7
[CrossRef](#)
- 326 Annemarie Shibata, Emily McMullen, Alex Pham, Michael Belshan, Bridget Sanford, You Zhou, Michael Goede, Abhijit A. Date, Christopher J. Destache. (2013) Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment. *AIDS Research and Human Retroviruses* **29**:5, 746-754
[CrossRef](#)
- 327 Faiza Yasin, Altanchimeg Delegchoimbol, Naranchimeg Jamiyanjamts, Tugsdelger Sovd, Krystal Mason, Stefan Baral. (2013) A Cross-Sectional Evaluation of Correlates of HIV Testing Practices Among Men Who Have Sex with Men (MSM) in Mongolia. *AIDS and Behavior* **17**:4, 1378-1385
[CrossRef](#)
- 328 Deborah Mindry, Glenn Wagner, Jordan Lake, Amber Smith, Sebastian Linnemann, Molly Quinn, Risa Hoffman. (2013) Fertility Desires Among HIV-Infected Men and Women in Los Angeles County: Client Needs and Provider Perspectives. *Maternal and Child Health Journal* **17**:4, 593-600
[CrossRef](#)
- 329 Darrel H. Higa, Nicole Crepaz, Khiya J. Marshall, Linda Kay, H. Waverly Vosburgh, Pilgrim Spikes, Cynthia M. Lyles, David W. Purcell. (2013) A Systematic Review to Identify Challenges of Demonstrating Efficacy of HIV Behavioral Interventions for Gay, Bisexual, and Other Men Who Have Sex with Men (MSM). *AIDS and Behavior* **17**:4, 1231-1244
[CrossRef](#)
- 330 Aimee N. C. Campbell, Susan Tross, Donald A. Calsyn. (2013) Substance Use Disorders and HIV/AIDS Prevention and Treatment Intervention: Research and Practice Considerations. *Social Work in Public Health* **28**:3-4, 333-348
[CrossRef](#)
- 331 , Douglas Bruce, Gary W. Harper, Katie Suleta. (2013) Sexual Risk Behavior and Risk Reduction Beliefs Among HIV-Positive Young Men Who have Sex with Men. *AIDS and Behavior* **17**:4, 1515-1523
[CrossRef](#)
- 332 Garrett Prestage, Graham Brown, Ian Alan Down, Fengyi Jin, Michael Hurley. (2013) "It's Hard to Know What is a Risky or not a Risky Decision": Gay Men's Beliefs About Risk During Sex. *AIDS and Behavior* **17**:4, 1352-1361
[CrossRef](#)
- 333 Yea-Hung Chen, H. Fisher Raymond, Michael Grasso, Binh Nguyen, Tyler Robertson, Willi McFarland. (2013) Prevalence and Predictors of Conscious Risk Behavior Among San Franciscan Men who have Sex with Men. *AIDS and Behavior* **17**:4, 1338-1343
[CrossRef](#)
- 334 Stefan Baral, Andrew Scheibe, Patrick Sullivan, Gift Trapence, Andrew Lambert, Linda-Gail Bekker, Chris Beyrer. (2013) Assessing Priorities for Combination HIV Prevention Research for Men Who have Sex with Men (MSM) in Africa. *AIDS and Behavior* **17**:S1, 60-

69

[CrossRef](#)

- 335 Enrique Vacas Córdoba, Eduardo Arnaiz, Miguel Relloso, Carlos Sánchez-Torres, Federico García, Lucía Pérez-Álvarez, Rafael Gómez, Francisco J. de la Mata, Marjorie Pion, Ma Ángeles Muñoz-Fernández. (2013) Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. *AIDS* **27**:8, 1219-1229
[CrossRef](#)
- 336 Jessica M. Conway, Bernhard P. Konrad, Daniel Coombs. (2013) Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection. *SIAM Journal on Applied Mathematics* **73**:2, 904-928
[CrossRef](#)
- 337 L. Kuhn, H.-Y. Kim, J. Walter, D. M. Thea, M. Sinkala, M. Mwiya, C. Kankasa, D. Decker, G. M. Aldrovandi. (2013) HIV-1 Concentrations in Human Breast Milk Before and After Weaning. *Science Translational Medicine* **5**:181, 181ra51-181ra51
[CrossRef](#)
- 338 K. H. Mayer, B. C. Zanoni. (2013) Editorial Commentary: HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet. *Clinical Infectious Diseases* **56**:8, 1156-1158
[CrossRef](#)
- 339 S. Rerks-Ngarm, R. M. Paris, S. Chunsutthiwat, N. Premsri, C. Namwat, C. Bowonwatanuwong, S. S. Li, J. Kaewkungkal, R. Trichavaroj, N. Churikanont, M. S. de Souza, C. Andrews, D. Francis, E. Adams, J. Flores, S. Gurunathan, J. Tartaglia, R. J. O'Connell, C. Eamsila, S. Nitayaphan, V. Ngauy, P. Thongcharoen, P. Kunasol, N. L. Michael, M. L. Robb, P. B. Gilbert, J. H. Kim. (2013) Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. *Journal of Infectious Diseases* **207**:8, 1195-1205
[CrossRef](#)
- 340 J. E. Pace, G. K. Siberry, R. Hazra, B. G. Kapogiannis. (2013) Preexposure Prophylaxis for Adolescents and Young Adults at Risk for HIV Infection: Is an Ounce of Prevention Worth a Pound of Cure?. *Clinical Infectious Diseases* **56**:8, 1149-1155
[CrossRef](#)
- 341 Sybil G. Hosek, George Siberry, Margo Bell, Michelle Lally, Bill Kapogiannis, Keith Green, M. Isabel Fernandez, Brandy Rutledge, Jaime Martinez, Robert Garofalo, Craig M. Wilson. (2013) The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:4, 447-456
[CrossRef](#)
- 342 Virginie Supervie. (2013) Les moyens de prévention de l'infection à VIH à base d'antirétroviraux. *médecine/sciences* **29**:4, 373-382
[CrossRef](#)
- 343 Bluma Brenner, Mark A. Wainberg, Michel Roger. (2013) Phylogenetic inferences on HIV-1 transmission. *AIDS* **27**:7, 1045-1057
[CrossRef](#)
- 344 Sarit A. Golub, Kristi E. Gamarel, H. Jonathon Rendina, Anthony Surace, Corina L. Lelutiu-Weinberger. (2013) From Efficacy to Effectiveness: Facilitators and Barriers to PrEP

Acceptability and Motivations for Adherence Among MSM and Transgender Women in New York City. *AIDS Patient Care and STDs* **27**:4, 248-254

[CrossRef](#)

- 345 Emma Torres, Jean-Luc Meynard. (2013) Zoom sur la prophylaxie préexposition. *La Revue de l'Infirmière* **62**:190, 28

[CrossRef](#)

- 346 Lori A. Nacius, Judy Levison, Charles G. Minard, Carl Fasser, Jessica A. Davila. (2013) Serodiscordance and Disclosure Among HIV-Positive Pregnant Women in the Southwestern United States. *AIDS Patient Care and STDs* **27**:4, 242-247

[CrossRef](#)

- 347 Paige Etter, Raphael Landovitz, Sengeziwe Sibeko, Magdalena E. Sobieszczyk, Sharon A. Riddler, Carissa Karg, Athe Tsibiris, Jeffrey Schouten. (2013) Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. *AIDS* **27**:7, 1119-1128

[CrossRef](#)

- 348 Jean-François Delfraissy. (2013) Quels enjeux de recherche trente ans après l'identification du virus VIH ?. *médecine/sciences* **29**:4, 339-340

[CrossRef](#)

- 349 Erik De Clercq. (2013) The Acyclic Nucleoside Phosphonates (ANPs): Antonín Holý's Legacy. *Medicinal Research Reviews*n/a-n/a

[CrossRef](#)

- 350 John M. Luce. (2013) A Strange New Disease in San Francisco. A Brief History of the City and Its Response to the HIV/AIDS Epidemic. *Annals of the American Thoracic Society* **10**:2, 143-147

[CrossRef](#)

- 351 G.E. Gray, B. Metch, G. Churchyard, K. Mlisana, M. Nchabeleng, M. Allen, Z. Moodie, J. Kublin, L.-G. Bekker. (2013) Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?. *Vaccine* **31**:16, 2089-2096

[CrossRef](#)

- 352 Richard A. Crosby. (2013) State of Condom Use in HIV Prevention Science and Practice. *Current HIV/AIDS Reports* **10**:1, 59-64

[CrossRef](#)

- 353 Iryna B. Zablotska, Garrett Prestage, John de Wit, Andrew E. Grulich, Limin Mao, Martin Holt. (2013) The Informal Use of Antiretrovirals for Preexposure Prophylaxis of HIV Infection Among Gay Men in Australia. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:3, 334-338

[CrossRef](#)

- 354 W. Kromdijk, S.A. Pereira, H. Rosing, J.W. Mulder, J.H. Beijnen, A.D.R. Huitema. (2013) Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B* **919-920**, 43-51

[CrossRef](#)

- 355 V. Savasi, L. Mandia, A. Laoreti, I. Cetin. (2013) Reproductive assistance in HIV serodiscordant couples. *Human Reproduction Update* **19**:2, 136-150

[CrossRef](#)

- 356 Yan Zhang, Bin Peng, Ying She, Hao Liang, Hong-Bin Peng, Han-Zhu Qian, Sten H.

Vermund, Xiao-Ni Zhong, Ailong Huang. (2013) Attitudes Toward HIV Pre-Exposure Prophylaxis Among Men Who Have Sex with Men in Western China. *AIDS Patient Care and STDs* **27**:3, 137-141

[CrossRef](#)

- 357 Jessica L. Adams, Craig Sykes, Prema Menezes, Heather M.A. Prince, Kristine B. Patterson, Katrien Fransen, Tania Crucitti, Irith De Baetselier, Lut Van Damme, Angela D.M. Kashuba. (2013) Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared With Isolated Peripheral Blood Mononuclear Cells. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:3, 260-266

[CrossRef](#)

- 358 Stephanie L. Combes, Asfawesen G-Yohannes, Altaye Kidane, Pai-Lien Chen, Abraham Aseffa, Paul J. Feldblum, Dominick Shattuck. (2013) HIV Prevalence and Incidence Among Women at Higher Risk of Infection in Addis Ababa, Ethiopia. *AIDS Research and Human Retroviruses* **29**:3, 535-540

[CrossRef](#)

- 359 Ariane Straten, Elizabeth T. Montgomery, Miriam Hartmann, Alexandra Minnis. (2013) Methodological Lessons from Clinical Trials and the Future of Microbicide Research. *Current HIV/AIDS Reports* **10**:1, 89-102

[CrossRef](#)

- 360 Allan R. Tenorio, Alan L. Landay. (2013) HIV: So Near and Yet So Far. *Current HIV/AIDS Reports* **10**:1, 1-2

[CrossRef](#)

- 361 Frits van Griensven, Warunee Thienkrua, Janet McNicholl, Wipas Wimonsate, Supaporn Chaikummao, Wannee Chonwattana, Anchalee Varangrat, Pachara Sirivongrangson, Philip A. Mock, Pasakorn Akarasewi, Jordan W. Tappero. (2013) Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand. *AIDS* **27**:5, 825-832

[CrossRef](#)

- 362 Greg L. Plosker. (2013) Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis. *Drugs* **73**:3, 279-291

[CrossRef](#)

- 363 Akil Jackson, Graeme Moyle, Victoria Watson, John Tjia, Alieu Ammara, David Back, Malika Mohabeer, Brian Gazzard, Marta Boffito. (2013) Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:3, 275-281

[CrossRef](#)

- 364 Shu-Hsing Cheng, Chin-Hui Yang, Yu-Mei Hsueh. (2013) Highly Active Antiretroviral Therapy is Associated with Decreased Incidence of Sexually Transmitted Diseases in a Taiwanese HIV-Positive Population. *AIDS Patient Care and STDs* **27**:3, 155-162

[CrossRef](#)

- 365 Susan A. Adakun, Mark J. Siedner, Conrad Muzoora, Jessica E. Haberer, Alexander C. Tsai, Peter W. Hunt, Jeff N. Martin, David R. Bangsberg. (2013) Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:3, 317-321

[CrossRef](#)

- 366 Stefan D Baral, Tonia Poteat, Susanne Strömdahl, Andrea L Wirtz, Thomas E Guadalupe, Chris Beyrer. (2013) Worldwide burden of HIV in transgender women: a systematic review

and meta-analysis. *The Lancet Infectious Diseases* **13**:3, 214-222

[CrossRef](#)

- 367 Melanie R Nicol, Jessica L Adams, Angela DM Kashuba. (2013) HIV pre-exposure prophylaxis trials: the road to success. *Clinical Investigation* **3**:3, 295-308
[CrossRef](#)
- 368 Yuqin Zhao, Dobromir T. Dimitrov, Hao Liu, Yang Kuang. (2013) Mathematical Insights in Evaluating State Dependent Effectiveness of HIV Prevention Interventions. *Bulletin of Mathematical Biology*
[CrossRef](#)
- 369 Timothy Frasca, Gary W. Dowsett, Alex Carballo-Diéguéz. (2013) The ethics of barebacking: Implications of gay men's concepts of right and wrong in the context of HIV. *International Journal of Sexual Health* **13**:206090536008
[CrossRef](#)
- 370 Deborah J. Donnell, Jared M. Baeten, Ting Hong, Jairam R. Lingappa, Andrew Mujugira, Edith Nakku-Joloba, David Bangsberg, Connie Celum. (2013) Correlation Between Pill Counts and Biologic Effects in an HIV-1 Prevention Clinical Trial: Implications for Measuring Adherence. *AIDS and Behavior* **17**:2, 632-639
[CrossRef](#)
- 371 J. Y. Dai, P. B. Gilbert, J. P. Hughes, E. R. Brown. (2013) Estimating the Efficacy of Preexposure Prophylaxis for HIV Prevention Among Participants With a Threshold Level of Drug Concentration. *American Journal of Epidemiology* **177**:3, 256-263
[CrossRef](#)
- 372 Preston Izulla, Lyle R. McKinnon, Julius Munyao, Sarah Karanja, Winnie Koima, Joshua Parmeres, Solomon Kamuti, Rosalia Kioko, Nico Nagelkerke, Gloria Gakii, Charles Wachihi, Nicholas Muraguri, Helgar Musyoki, Lawrence Gelmon, Rupert Kaul, Joshua Kimani. (2013) HIV Postexposure Prophylaxis in an Urban Population of Female Sex Workers in Nairobi, Kenya. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:2, 220-225
[CrossRef](#)
- 373 Sengeziwe Sibeko, Shokouh Makvandi-Nejad. (2013) From the Laboratory to Clinical Trials and Back Again: Lessons Learned from HIV Prevention Trials. *American Journal of Reproductive Immunology* **69**, 106-115
[CrossRef](#)
- 374 Lynn T. Matthews, Tamaryn Crankshaw, Janet Giddy, Angela Kaida, Jennifer A. Smit, Norma C. Ware, David R. Bangsberg. (2013) Reproductive Decision-Making and Periconception Practices Among HIV-Positive Men and Women Attending HIV Services in Durban, South Africa. *AIDS and Behavior* **17**:2, 461-470
[CrossRef](#)
- 375 Barbara S. Mensch, Barbara A. Friedland, Sharon A. Abbott, Lauren L. Katzen, Waimar Tun, Christine A. Kelly, Avina Sarna, Aylur K. Srikrishnan, Suniti Solomon. (2013) Characteristics of Female Sex Workers in Southern India Willing and Unwilling to Participate in a Placebo Gel Trial. *AIDS and Behavior* **17**:2, 585-597
[CrossRef](#)
- 376 Susan M. Fetherston, Peter Boyd, Clare F. McCoy, Marcella C. McBride, Karen-Leigh Edwards, Stephen Ampofo, R. Karl Malcolm. (2013) A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. *European Journal of Pharmaceutical Sciences* **48**:3, 406-415

[CrossRef](#)

- 377 Pamina M. Gorbach, Barbara S. Mensch, Marla Husnik, Astou Coly, Benoit Mâsse, Bonus Makanani, Chiwawa Nkhoma, Lameck Chinula, Tchangani Tembo, Stan Mierzwa, Kimberly Reynolds, Stacey Hurst, Anne Coletti, Andrew Forsyth. (2013) Effect of Computer-Assisted Interviewing on Self-Reported Sexual Behavior Data in a Microbicide Clinical Trial. *AIDS and Behavior* **17**:2, 790-800
[CrossRef](#)
- 378 Beatrice "Bean" E. Robinson, Jennifer S. Galbraith, Rebecca E. Swinburne Romine, Qing Zhang, Jeffrey H. Herbst. (2013) Differences Between HIV-Positive and HIV-Negative African American Men Who Have Sex with Men in Two Major U.S. Metropolitan Areas. *Archives of Sexual Behavior* **42**:2, 267-278
[CrossRef](#)
- 379 P Flowers, C Knussen, J Li, L McDaid. (2013) Has testing been normalized? An analysis of changes in barriers to HIV testing among men who have sex with men between 2000 and 2010 in Scotland, UK. *HIV Medicine* **14**:2, 92-98
[CrossRef](#)
- 380 Iván C. Balán, Alex Carballo-Díéguez, Ana Ventuneac, Robert H. Remien, Curtis Dolezal, Jordan Ford. (2013) Are HIV-Negative Men Who Have Sex with Men and Who Bareback Concerned About HIV Infection? Implications for HIV Risk Reduction Interventions. *Archives of Sexual Behavior* **42**:2, 279-289
[CrossRef](#)
- 381 Amy L. Herrick, Ron Stall, Hilary Goldhammer, James E. Egan, Kenneth H. Mayer. (2013) Resilience as a Research Framework and as a Cornerstone of Prevention Research for Gay and Bisexual Men: Theory and Evidence. *AIDS and Behavior*
[CrossRef](#)
- 382 Ronald H. Gray, Maria J. Wawer. (2013) Infection in 2012: Mixed results of pre-exposure prophylaxis for HIV prevention. *Nature Reviews Urology* **10**:2, 74-75
[CrossRef](#)
- 383 Jared Baeten, Connie Celum. (2013) Systemic and Topical Drugs for the Prevention of HIV Infection: Antiretroviral Pre-exposure Prophylaxis. *Annual Review of Medicine* **64**:1, 219-232
[CrossRef](#)
- 384 Rena Greifinger, Michelle Batchelor, Cynthia Fair. (2013) Improving Engagement and Retention in Adult Care Settings for Lesbian, Gay, Bisexual, Transgender and Questioning (LGBTQ) Youth Living with HIV: Recommendations for Health Care Providers. *Journal of Gay & Lesbian Mental Health* **17**:1, 80-95
[CrossRef](#)
- 385 E. Jennifer Edelman, David A. Fiellin. (2013) Moving HIV Pre-Exposure Prophylaxis Into Clinical Settings. *American Journal of Preventive Medicine* **44**:1, S86-S90
[CrossRef](#)
- 386 Sean Philpott. (2013) Social Justice, Public Health Ethics, and the Use of HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* **44**:1, S137-S140
[CrossRef](#)
- 387 Vincenzo Puro, Antonio Palummieri, Gabriella De Carli, Pierluca Piselli, Giuseppe Ippolito. (2013) Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. *BMC Infectious Diseases* **13**:1, 217

[CrossRef](#)

- 388 Lindsay Culp, Lisa Caucci. (2013) State Adolescent Consent Laws and Implications for HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* **44**:1, S119-S124
[CrossRef](#)
- 389 Mark A Wainberg, Andrew Lever. (2013) World AIDS Day: together we will stop HIV transmission and conquer AIDS. *Retrovirology* **10**:1, 129
[CrossRef](#)
- 390 Craig S. Pace, Marshall W. Fordyce, David Franco, Chia-Ying Kao, Michael S. Seaman, David D. Ho. (2013) Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:1, 1-9
[CrossRef](#)
- 391 Mohan J. Dutta. (2013) Disseminating HIV Pre-Exposure Prophylaxis Information in Underserved Communities. *American Journal of Preventive Medicine* **44**:1, S133-S136
[CrossRef](#)
- 392 Janet M. Blair, Lynn A. Paxton, Mary L. Kamb. HIV and AIDS in Women. In: Women and Health. Elsevier, 2013:505-522.
[CrossRef](#)
- 393 Timothy E. Morey, Matthew Booth, Scott Wasdo, Judith Wishin, Brian Quinn, Daniel Gonzalez, Hartmut Derendorf, Susan P. McGorray, Jane Simoni, Richard J. Melker, Donn M. Dennis. (2013) Oral Adherence Monitoring Using a Breath Test to Supplement Highly Active Antiretroviral Therapy. *AIDS and Behavior* **17**:1, 298-306
[CrossRef](#)
- 394 Linda J. Koenig, Cynthia Lyles, Dawn K. Smith. (2013) Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* **44**:1, S91-S98
[CrossRef](#)
- 395 Dobromir T. Dimitrov, Benoît R. Mâsse, Marie-Claude Boily. (2013) Beating the Placebo in HIV Prevention Efficacy Trials. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **62**:1, 95-101
[CrossRef](#)
- 396 Pedro MM Mesquita, Priya Srinivasan, Todd J Johnson, Rachna Rastogi, Tammy Evans-Strickfaden, Michael S Kay, Karen W Buckheit, Robert W Buckheit, James M Smith, Patrick F Kiser, Betsy C Herold. (2013) Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. *Retrovirology* **10**:1, 113
[CrossRef](#)
- 397 Catherine A. Hankins, Mark R. Dybul. (2013) The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission. *Current Opinion in HIV and AIDS* **8**:1, 50-58
[CrossRef](#)
- 398 James D. Campbell, Jeffrey H. Herbst, Robert T. Koppenhaver, Dawn K. Smith. (2013) Antiretroviral Prophylaxis for Sexual and Injection Drug Use Acquisition of HIV. *American Journal of Preventive Medicine* **44**:1, S63-S69
[CrossRef](#)
- 399 Mitchell H. Katz. (2013) Pre-Exposure Prophylaxis for HIV. *American Journal of Preventive*

Medicine 44:1, S161-S162

[CrossRef](#)

- 400 Deborah Kacanek, Alan Bostrom, Elizabeth T. Montgomery, Gita Ramjee, Guy de Bruyn, Kelly Blanchard, Amelia Rock, Sibongile Mtetwa, Ariane van der Straten. (2013) Intimate Partner Violence and Condom and Diaphragm Nonadherence Among Women in an HIV Prevention Trial in Southern Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 64:4, 400
[CrossRef](#)
- 401 James W. Dearing, Dawn K. Smith, R. Sam Larson, Carole A. Estabrooks. (2013) Designing for Diffusion of a Biomedical Intervention. *American Journal of Preventive Medicine* 44:1, S70-S76
[CrossRef](#)
- 402 Stefan Rowniak, Carmen Portillo. (2013) Pre-Exposure Prophylaxis: An Ethical Discussion. *Journal of the Association of Nurses in AIDS Care* 24:1, 6-10
[CrossRef](#)
- 403 Stephen J O'Brien, Sher L Hendrickson. (2013) Host genomic influences on HIV/AIDS. *Genome Biology* 14:1, 201
[CrossRef](#)
- 404 Sylvia Trent-Adams, Laura W. Cheever. (2013) Providing HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* 44:1, S147-S150
[CrossRef](#)
- 405 Marc P. Girard, Wayne C. Koff. Human immunodeficiency virus vaccines. In: *Vaccines*. Elsevier, 2013:1097-1121.
[CrossRef](#)
- 406 Stephanie E. Cohen, Albert Y. Liu, Kyle T. Bernstein, Susan Philip. (2013) Preparing for HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* 44:1, S80-S85
[CrossRef](#)
- 407 Ide Cremin, Ramzi Alsallaq, Mark Dybul, Peter Piot, Geoffrey Garnett, Timothy B. Hallett. (2013) The new role of antiretrovirals in combination HIV prevention. *AIDS* 27:3, 447-458
[CrossRef](#)
- 408 Kristine Torjesen, Jeanne M. Marrazzo, Sharon L. Hillier, Willard Cates. Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention. In: *Sexually Transmitted Diseases*. Elsevier, 2013:213-227.
[CrossRef](#)
- 409 Mark W. Thrun. (2013) Provider-Initiated HIV–Risk Behavior Counseling in the Context of HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* 44:1, S108
[CrossRef](#)
- 410 Susie Hoffman. (2013) The Female Condom in the Age of Antiretroviral-Based HIV Prevention. *Journal of Women's Health* 22:1, 7-8
[CrossRef](#)
- 411 John A. Davis. (2013) HIV and the LGBT Community: A Medical Update. *Journal of Gay & Lesbian Mental Health* 17:1, 64-79
[CrossRef](#)
- 412 Erik De Clercq. The Holy Trinity. Elsevier, 2013:293-316.
[CrossRef](#)

- 413 Dawn K. Smith, John Beltrami. (2013) A Proposed Framework to Monitor Daily Oral Antiretroviral Pre-Exposure Prophylaxis in the U.S. *American Journal of Preventive Medicine* **44**:1, S141-S146
[CrossRef](#)
- 414 Philip J Peters, Barbara J Marston, Paul J Weidle, John T Brooks. Human Immunodeficiency Virus Infection. In: Hunter's Tropical Medicine and Emerging Infectious Disease. Elsevier, 2013:217-247.
[CrossRef](#)
- 415 Kathy Baisley, Jared M. Baeten, James P. Hughes, Deborah J. Donnell, Jing Wang, Richard Hayes, Deborah Watson Jones, Connie Celum. (2013) Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting. *AIDS and Behavior* **17**:9, 3108
[CrossRef](#)
- 416 S. Shah, R. K. Lie. (2013) Aiming at a moving target: research ethics in the context of evolving standards of care and prevention. *Journal of Medical Ethics* **39**:11, 699
[CrossRef](#)
- 417 H. In: Ferri's Clinical Advisor 2013. Elsevier, 2013:447-566.
[CrossRef](#)
- 418 Erik De Clercq. The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS). Elsevier, 2013:317-358.
[CrossRef](#)
- 419 C. William Wester, Sophie Limou, Cheryl A. Winkler. HIV Pharmacogenetics and Pharmacogenomics. In: Genomic and Personalized Medicine. Elsevier, 2013:1211-1229.
[CrossRef](#)
- 420 Raph L. Hamers, Kim C.E. Sigaloff, Cissy Kityo, Peter Mugenyi, Tobias F. Rinke de Wit. (2013) Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. *Current Opinion in HIV and AIDS* **8**:1, 19-26
[CrossRef](#)
- 421 James W. Curran, Richard A. Crosby. (2013) Pre-Exposure Prophylaxis for HIV. *American Journal of Preventive Medicine* **44**:1, S163-S166
[CrossRef](#)
- 422 Ravindra K Gupta, David A M C Van de Vijver, Sheetal Manicklal, Mark A Wainberg. (2013) Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. *Retrovirology* **10**:1, 82
[CrossRef](#)
- 423 C. Kevin Malotte. (2013) Brief Risk-Reduction Counseling in Clinical Settings for HIV Pre-Exposure Prophylaxis. *American Journal of Preventive Medicine* **44**:1, S112-S118
[CrossRef](#)
- 424 Mitchell J. Warren, Emily S. Bass. (2013) From Efficacy to Impact. *American Journal of Preventive Medicine* **44**:1, S167-S170
[CrossRef](#)
- 425 Adam Bourne, Gary Hammond, Ford Hickson, David Reid, Axel J Schmidt, Peter Weatherburn, . (2013) What constitutes the best sex life for gay and bisexual men? Implications for HIV prevention. *BMC Public Health* **13**:1, 1083

[CrossRef](#)

- 426 Nina Derby, Thomas Zydowsky, Melissa Robbiani. (2013) In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?. *Expert Review of Anti-infective Therapy* 11:1, 5-8
[CrossRef](#)
- 427 Quarraisha Abdoel Karim, Cheryl Baxter. (2013) Microbicides for the prevention of sexually transmitted HIV infection. *Expert Review of Anti-infective Therapy* 11:1, 13-23
[CrossRef](#)
- 428 Nicolas Lorente, Karen Champenois, Jérôme Blanche, Marie Préau, Marie Suzan-Monti, Marion Mora, Lionel Fugon, Maria Patrizia Carrieri, Luis Sagaon-Teyssier, Jean-Marie Le Gall, Bruno Spire, Yazdan Yazdanpanah. (2013) Investigating Recent Testing among MSM: Results from Community-Based HIV Rapid Testing Attendees in France. *Journal of Sexually Transmitted Diseases* 2013, 1-8
[CrossRef](#)
- 429 George Ayala, Keletso Makofane, Glenn-Milo Santos, Jack Beck, Tri D. Do, Pato Hebert, Patrick A. Wilson, Thomas Pyun, Sonya Arreola. (2013) Access to Basic HIV-Related Services and PrEP Acceptability among Men Who Have sex with Men Worldwide: Barriers, Facilitators, and Implications for Combination Prevention. *Journal of Sexually Transmitted Diseases* 2013, 1-11
[CrossRef](#)
- 430 Adi Moseri, Subramanyam Tantry, Fa-Xiang Ding, Fred Naider, Jacob Anglister. (2012) Synergism Between a CD4-Mimic Peptide and Antibodies Elicited by a Constrained V3 Peptide. *AIDS Research and Human Retroviruses* 121226065029006
[CrossRef](#)
- 431 Tamaryn L. Crankshaw, Lynn T. Matthews, Janet Giddy, Angela Kaida, Norma C. Ware, Jennifer A. Smit, David R. Bangsberg. (2012) A conceptual framework for understanding HIV risk behavior in the context of supporting fertility goals among HIV-serodiscordant couples. *Reproductive Health Matters* 20:39, 50-60
[CrossRef](#)
- 432 Wiriya Rutvisuttinunt, Sunee Sirivichayakul, Sineenart Oota, Vatcharin Assawadarachai, Kultida Poltavee, Hathairat Savadsuk, Supanit Pattanachaiwit, Suwittra Chaemchuen, Miguel A. Arroyo, Robert M. Paris, Nelson L. Michael, Jerome H. Kim, Kiat Ruxrungtham, Mark de Souza, Praphan Phanuphak, Sodsai Tovanabutra. (2012) Two Unique Recombinant Forms Identified in Incident HIV Type 1 Infections in Thai Blood Donors. *AIDS Research and Human Retroviruses* 28:12, 1703-1711
[CrossRef](#)
- 433 KEVIN MICHAEL O'HARA. (2012) Pre-exposure prophylaxis: Where HIV prevention and responsibility intersect. *Journal of the American Academy of Physician Assistants* 25:12, 61-62
[CrossRef](#)
- 434 Susanne Strömdahl, Abimbola Onigbanjo Williams, Bede Eziefule, Godwin Emmanuel, Stella Iwuagwu, Oliver Anene, Ifeanyi Orazulike, Chris Beyrer, Stefan Baral. (2012) Associations of Consistent Condom Use Among Men Who Have Sex with Men in Abuja, Nigeria. *AIDS Research and Human Retroviruses* 28:12, 1756-1762
[CrossRef](#)
- 435 Edith Jasny, Suzanne Geer, Ines Frank, Panagiotis Vagenas, Meropi Aravantinou, Andres M. Salazar, Jeffrey D. Lifson, Michael Piatak, Agegnehu Gettie, James L. Blanchard,

Melissa Robbiani. (2012) Characterization of Peripheral and Mucosal Immune Responses In Rhesus Macaques on Long-Term Tenofovir and Emtricitabine Combination Antiretroviral Therapy. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **61**:4, 425-435
[CrossRef](#)

-
- 436 Felix M. Muchomba, Robin E. Gearing, Jane M. Simoni, Nabila El-Bassel. (2012) State of The Science of Adherence in Pre-Exposure Prophylaxis and Microbicide Trials. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **61**:4, 490-498
[CrossRef](#)

-
- 437 Patrick Lacor. (2012) Preparing for PrEP. *The European Journal of Contraception and Reproductive Health Care* **17**:6, 482-486
[CrossRef](#)

-
- 438 Christine Bruno, Parya Saberi. (2012) Pharmacists as providers of HIV pre-exposure prophylaxis. *International Journal of Clinical Pharmacy* **34**:6, 803-806
[CrossRef](#)

-
- 439 Christina Psaros, Jennifer Barinas, Gregory K. Robbins, C. Andres Bedoya, Steven A. Safren, Elyse R. Park. (2012) Intimacy and Sexual Decision Making: Exploring the Perspective of HIV Positive Women Over 50. *AIDS Patient Care and STDs* **26**:12, 755-760
[CrossRef](#)

-
- 440 Laura M. Castellano, James Shorter. (2012) The Surprising Role of Amyloid Fibrils in HIV Infection. *Biology* **1**:3, 58-80
[CrossRef](#)

-
- 441 Alexander C. Tsai. (2012) A typology of structural approaches to HIV prevention: A commentary on Roberts and Matthews. *Social Science & Medicine* **75**:9, 1562-1567
[CrossRef](#)

-
- 442 Douglas Krakower, Kenneth H. Mayer. (2012) Engaging healthcare providers to implement HIV pre-exposure prophylaxis. *Current Opinion in HIV and AIDS* **7**:6, 593-599
[CrossRef](#)

-
- 443 Hela Saidi, Mohammad-Ali Jenabian, Laurent Belec. (2012) Understanding Factors That Modulate HIV Infection at the Female Genital Tract Mucosae for the Rationale Design of Microbicides. *AIDS Research and Human Retroviruses* **28**:11, 1485-1497
[CrossRef](#)

-
- 444 Simi Gunaseelan, Philippe A. Gallay, Michael D. Bobardt, Charlene S. Dezzutti, Timothy Esch, Richard Maskiewicz. (2012) Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices. *Pharmaceutical Research* **29**:11, 3156-3168
[CrossRef](#)

-
- 445 Meropi Aravantinou, Rachel Singer, Nina Derby, Giulia Calenda, Paul Mawson, Ciby J. Abraham, Radhika Menon, Samantha Seidor, Daniel Goldman, Jessica Kenney, Guillermo Villegas, Agegnehu Gettie, James Blanchard, Jeffrey D. Lifson, Michael Piatak, José A. Fernández-Romero, Thomas M. Zydowsky, Natalia Teleshova, Melissa Robbiani. (2012) The Nonnucleoside Reverse Transcription Inhibitor MIV-160 Delivered from an Intravaginal Ring, But Not from a Carrageenan Gel, Protects Against Simian/Human Immunodeficiency Virus-RT Infection. *AIDS Research and Human Retroviruses* **28**:11, 1467-1475
[CrossRef](#)

-
- 446 Peter A. Anton, Ross D. Cranston, Angela Kashuba, Craig W. Hendrix, Namandjé N. Bumpus, Nicola Richardson-Harman, Julie Elliott, Laura Janocko, Elena Khanukhova,

Robert Dennis, William G. Cumberland, Chuan Ju, Alex Carballo-Díéguez, Christine Mauck, Ian McGowan. (2012) RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. *AIDS Research and Human Retroviruses* **28**:11, 1412-1421
[CrossRef](#)

-
- 447 Eric T. Roberts, Derrick D. Matthews. (2012) HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. *Social Science & Medicine* **75**:9, 1555-1561

[CrossRef](#)

-
- 448 Lynn T. Matthews, Jennifer A. Smit, Susan Cu-Uvin, Deborah Cohan. (2012) Antiretrovirals and safer conception for HIV-serodiscordant couples. *Current Opinion in HIV and AIDS* **7**:6, 569-578

[CrossRef](#)

-
- 449 Justin J. O'Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Reply to 'Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial'. *AIDS* **26**:17, 2262-2263

[CrossRef](#)

-
- 450 Lynn A. Paxton. (2012) Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings. *Current Opinion in HIV and AIDS* **7**:6, 557-562

[CrossRef](#)

-
- 451 Jared Baeten, Connie Celum. (2012) Oral antiretroviral chemoprophylaxis. *Current Opinion in HIV and AIDS* **7**:6, 514-519

[CrossRef](#)

-
- 452 Bisrat K. Abraham, Roy Gulick. (2012) Next-generation oral preexposure prophylaxis. *Current Opinion in HIV and AIDS* **7**:6, 600-606

[CrossRef](#)

-
- 453 Ian McGowan. (2012) Rectal microbicide development. *Current Opinion in HIV and AIDS* **7**:6, 526-533

[CrossRef](#)

-
- 454 Randall Tressler, Catherine Godfrey. (2012) NRTI Backbone in HIV Treatment. *Drugs* **72**:16, 2051-2062

[CrossRef](#)

-
- 455 Stefan D. Baral, Susanne Strömdahl, Chris Beyrer. (2012) The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. *Current Opinion in HIV and AIDS* **7**:6, 563-568

[CrossRef](#)

-
- 456 J. Gerardo García-Lerma, Walid Heneine. (2012) Animal models of antiretroviral prophylaxis for HIV prevention. *Current Opinion in HIV and AIDS* **7**:6, 505-513

[CrossRef](#)

-
- 457 I. Mary Poynten, Iryna Zablotska, Andrew E. Grulich. (2012) Considerations regarding antiretroviral chemoprophylaxis in MSM. *Current Opinion in HIV and AIDS* **7**:6, 549-556

[CrossRef](#)

-
- 458 Mandana Mehta, Fred Semitala, Lutgarde Lynen, Robert Colebunders. (2012) Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?. *Expert Review of Anti-infective Therapy* **10**:11, 1287-1296

[CrossRef](#)

- 459 Charlene S. Dezzutti, Cory Shetler, Alamelu Mahalingam, Shweta R. Ugaonkar, Garry Gwozdz, Karen W. Buckheit, Robert W. Buckheit. (2012) Safety and efficacy of tenofovir/IQP-0528 combination gels – A dual compartment microbicide for HIV-1 prevention. *Antiviral Research* **96**:2, 221-225
[CrossRef](#)
- 460 Jose R. Castillo-Mancilla, Jia-Hua Zheng, Joseph E. Rower, Amie Meditz, Edward M. Gardner, Julie Predhomme, Caitlin Fernandez, Jacob Langness, Jennifer J. Kiser, Lane R. Bushman, Peter L. Anderson. (2012) Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. *AIDS Research and Human Retroviruses* **12**1010062750004
[CrossRef](#)
- 461 John Schneider, Rupali Kumar, Rakhi Dandona, Prem Kumar, Anil Kumar, Vemu Lakshmi, Edward Laumann, Kenneth Mayer, Lalit Dandona. (2012) Social Network and Risk-Taking Behavior Most Associated with Rapid HIV Testing, Circumcision, and Preexposure Prophylaxis Acceptability Among High-Risk Indian Men. *AIDS Patient Care and STDs* **26**:10, 631-640
[CrossRef](#)
- 462 Jason W. Mitchell, Luis Garcia, Donna Champeau, S. Marie Harvey, Andrew E. Petroll. (2012) HIV-Negative Seroconcordant Gay Male Couples' Attitudes, Intentions, and Perceived Behavioral Control for Planned Condom Use Within and Outside of Their Relationships. *International Journal of Sexual Health* **24**:4, 239-253
[CrossRef](#)
- 463 Peter A. Newman, Surachet Roungrakhon, Suchon Tepjan, Suzy Yim, Rachael Walisser. (2012) A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. *Global Public Health* **7**:9, 1009-1024
[CrossRef](#)
- 464 Peter A. Newman, Sung-Jae Lee, Surachet Roungrakhon, Suchon Tepjan. (2012) Demographic and Behavioral Correlates of HIV Risk among Men and Transgender Women Recruited from Gay Entertainment Venues and Community-based Organizations in Thailand: Implications for HIV Prevention. *Prevention Science* **13**:5, 483-492
[CrossRef](#)
- 465 Stephen Frausto, Emily Lee, Hengli Tang. (2012) Targeting host cofactors to inhibit viral infection. *Frontiers in Biology* **7**:5, 445-458
[CrossRef](#)
- 466 Dawn K. Smith, Lauren Toledo, Donna Jo Smith, Mary Anne Adams, Richard Rothenberg. (2012) Attitudes and Program Preferences of African-American Urban Young Adults About Pre-Exposure Prophylaxis (PrEP). *AIDS Education and Prevention* **24**:5, 408-421
[CrossRef](#)
- 467 Mark I. Ryder, Wipawee Nittayananta, Maeve Coogan, Deborah Greenspan, John S. Greenspan. (2012) Periodontal disease in HIV/AIDS. *Periodontology 2000* **60**:1, 78-97
[CrossRef](#)
- 468 Erik De Clercq. (2012) Human viral diseases: what is next for antiviral drug discovery?. *Current Opinion in Virology* **2**:5, 572-579
[CrossRef](#)
- 469 Zabrina L Brumme, Denis R Chopera, Mark A Brockman. (2012) Modulation of HIV

reservoirs by host HLA: bridging the gap between vaccine and cure. *Current Opinion in Virology* 2:5, 599-605
[CrossRef](#)

- 470 Ranajit Pal, Lindsey Galmin, Lara E. Pereira, Bin Li, Jining Zhang, Daniel Li, Jesse Francis, Janet M. McNicholl, Deborah E. Weiss, James M. Smith. (2012) Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. *Virology* 432:1, 173-183
[CrossRef](#)
- 471 Michael P. Carey, Lori A. J. Scott-Sheldon, Peter A. Venable. HIV/AIDS. In: *Handbook of Psychology*, Second Edition. John Wiley & Sons, Inc., 2012.
[CrossRef](#)
- 472 Lisa A. Eaton, Tania B. Huedo-Medina, Seth C. Kalichman, Jennifer A. Pellowski, Michael J. Sagherian, Michelle Warren, Blair T. Johnson, Ami R. Popat. (2012) Meta-Analysis of Single-Session Behavioral Interventions to Prevent Sexually Transmitted Infections: Implications for Bundling Prevention Packages. *American Journal of Public Health* 102:1-e11
[CrossRef](#)
- 473 Mitzy Gafos, Misiwe A. Mzimela, Hlengiwe B. Ndlovu, Sheena McCormack, Nuala McGrath. (2012) How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community. *AIDS Care* 1-6
[CrossRef](#)
- 474 P. L. Anderson, D. V. Glidden, A. Liu, S. Buchbinder, J. R. Lama, J. V. Guanira, V. McMahan, L. R. Bushman, M. Casapia, O. Montoya-Herrera, V. G. Veloso, K. H. Mayer, S. Chariyalartsak, M. Schechter, L.-G. Bekker, E. G. Kallas, R. M. Grant, . (2012) Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. *Science Translational Medicine* 4:151, 151ra125-151ra125
[CrossRef](#)
- 475 Virginia A Fonner, Julie Denison, Caitlin E Kennedy, Kevin O'Reilly, Michael Sweat, Virginia A Fonner. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, 2012.
[CrossRef](#)
- 476 Perry N. Halkitis. (2012) Obama, Marriage Equality, and the Health of Gay Men. *American Journal of Public Health* 102:9, 1628-1629
[CrossRef](#)
- 477 E. N. Kersh, W. Luo, Q. Zheng, D. R. Adams, D. Hanson, A. S. Youngpairoj, M.-e. Cong, K. Butler, R. M. Hendry, J. M. McNicholl, W. Heneine, J. G. Garcia-Lerma. (2012) Reduced Inflammation and CD4 Loss in Acute SHIV Infection During Oral Pre-Exposure Prophylaxis. *Journal of Infectious Diseases* 206:5, 770-779
[CrossRef](#)
- 478 K. Rebe, P. Semugoma, J. A. McIntyre. (2012) New HIV prevention technologies and their relevance to MARPS in African epidemics. *SAHARA-J: Journal of Social Aspects of HIV/AIDS* 9:3, 164-166
[CrossRef](#)
- 479 Cindy Patton, Hye Jin Kim. (2012) The Cost of Science. *Journal of Bioethical Inquiry* 9:3, 295-310
[CrossRef](#)

- 480 Nicholas Muraguri, Marleen Temmerman, Scott Geibel. (2012) A decade of research involving men who have sex with men in sub-Saharan Africa: Current knowledge and future directions. *SAHARA-J: Journal of Social Aspects of HIV/AIDS* 9:3, 137-147
[CrossRef](#)
- 481 Havlir , Diane , Beyer , Chris , . (2012) The Beginning of the End of AIDS?. *New England Journal of Medicine* 367:8, 685-687
[Free Full Text](#)
- 482 Alex Carballo-Díéguez, Timothy Frasca, Ivan Balan, Mobolaji Ibitoye, Curtis Dolezal. (2012) Use of a Rapid HIV Home Test Prevents HIV Exposure in a High Risk Sample of Men Who Have Sex With Men. *AIDS and Behavior*
[CrossRef](#)
- 483 Van Damme , Lut , Cornelis , Amy , Ahmed , Khatija , Agot , Kawango , Lombaard , Johan , Kapiga , Saidi , Malahleha , Mookho , Owino , Fredrick , Manongi , Rachel , Onyango , Jacob , Temu , Lucky , Monedi , Modie Constance , Mak'Oketch , Paul , Makanda , Mankalimeng , Reblin , Ilse , Makatu , Shumani Elsie , Saylor , Lisa , Kieman , Haddie , Kirkendale , Stella , Wong , Christina , Grant , Robert , Kashuba , Angela , Nanda , Kavita , Mandala , Justin , Fransen , Katrien , Deese , Jennifer , Crucitti , Tania , Mastro , Timothy D. , Taylor , Douglas , . (2012) Preexposure Prophylaxis for HIV Infection among African Women. *New England Journal of Medicine* 367:5, 411-422
[Free Full Text](#)
- 484 Cohen , Myron S. , Baden , Lindsey R. , . (2012) Preexposure Prophylaxis for HIV — Where Do We Go from Here?. *New England Journal of Medicine* 367:5, 459-461
[Free Full Text](#)
- 485 (2012) Preexposure Prophylaxis for HIV Prevention. *New England Journal of Medicine* 367:5, 462-465
[Free Full Text](#)
- 486 Baeten , Jared M. , Donnell , Deborah , Ndase , Patrick , Mugo , Nelly R. , Campbell , James D. , Wangisi , Jonathan , Tappero , Jordan W. , Bukusi , Elizabeth A. , Cohen , Craig R. , Katabira , Elly , Ronald , Allan , Tumwesigye , Elioda , Were , Edwin , Fife , Kenneth H. , Kiarie , James , Farquhar , Carey , John-Stewart , Grace , Kakia , Aloysious , Odoyo , Josephine , Mucunguzi , Akasiima , Nakku-Joloba , Edith , Twesigye , Rogers , Ngure , Kenneth , Apaka , Cosmas , Tamoooh , Harrison , Gabona , Fridah , Mujugira , Andrew , Panteleeff , Dana , Thomas , Katherine K. , Kidoguchi , Lara , Krows , Meighan , Revall , Jennifer , Morrison , Susan , Haugen , Harald , Emmanuel-Ogier , Mira , Ondrejcek , Lisa , Coombs , Robert W. , Frenkel , Lisa , Hendrix , Craig , Bumpus , Namandjé N. , Bangsberg , David , Haberer , Jessica E. , Stevens , Wendy S. , Lingappa , Jairam R. , Celum , Connie , . (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. *New England Journal of Medicine* 367:5, 399-410
[Free Full Text](#)
- 487 Thigpen , Michael C. , Kebaabetswe , Poloko M. , Paxton , Lynn A. , Smith , Dawn K. , Rose , Charles E. , Segolodi , Tebogo M. , Henderson , Faith L. , Pathak , Sonal R. , Soud , Fatma A. , Chillag , Kata L. , Mutanhaurwa , Rodreck , Chirwa , Lovemore Ian , Kasonde , Michael , Abebe , Daniel , Buliva , Evans , Gvetadze , Roman J. , Johnson , Sandra , Sukalac , Thom Thomas , Vasavi T. , Hart , Clyde , Johnson , Jeffrey A. , Malotte , C. Kevin , Hendrix , Craig W. , Brooks , John T. , . (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. *New England Journal of Medicine* 367:5, 423-434
[Free Full Text](#)
- 488 Connie J. Sexton, Elizabeth C. Costenbader, Dang Thi Nhat Vinh, Pai Lien Chen, Tran Vu

Hoang, Nguyen Thi Hoang Lan, Paul Feldblum, Andrea Kim, Le Truong Giang. (2012) Correlation of Prospective and Cross-Sectional Measures of HIV Type 1 Incidence in a Higher-Risk Cohort in Ho Chi Minh City, Vietnam. *AIDS Research and Human Retroviruses* **28**:8, 866-873

[CrossRef](#)

- 489 M. Juliana McElrath, Bruce D. Walker. (2012) Is an HIV Vaccine Possible?. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**, S41-S43

[CrossRef](#)

- 490 Vagish Hemmige, Rachel McFadden, Scott Cook, Hui Tang, John A. Schneider. (2012) HIV Prevention Interventions to Reduce Racial Disparities in the United States: A Systematic Review. *Journal of General Internal Medicine* **27**:8, 1047-1067

[CrossRef](#)

- 491 Nancy S. Padian, Michael T. Isbell, Elizabeth S. Russell, M. Essex. (2012) The Future of HIV Prevention. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**, S22-S26

[CrossRef](#)

- 492 Richard Needle, Joe Fu, Chris Beyrer, Virginia Loo, Abu S. Abdul-Quader, James A. McIntyre, Zhijun Li, Jessie K. K. Mbwambo, Mercy Muthui, Billy Pick. (2012) PEPFAR's Evolving HIV Prevention Approaches for Key Populations—People Who Inject Drugs, Men Who Have Sex With Men, and Sex Workers. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**, S145-S151

[CrossRef](#)

- 493 Eric Goosby, Mark Dybul, Anthony A. Fauci, Joe Fu, Thomas Walsh, Richard Needle, Paul Bouey. (2012) The United States President's Emergency Plan for AIDS Relief. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**, S51-S56

[CrossRef](#)

- 494 Caroline A. Ryan, Shanti R. Conly, David L. Stanton, Nina S. Hasen. (2012) Prevention of Sexually Transmitted HIV Infections Through the President's Emergency Plan for AIDS Relief. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**, S70-S77

[CrossRef](#)

- 495 Beryl A. Koblin, Kenneth H. Mayer, Elizabeth Noonan, Ching-Yun Wang, Michael Marmor, Jorge Sanchez, Stephen J. Brown, Michael N. Robertson, Susan P. Buchbinder. (2012) Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**:4, 405-413

[CrossRef](#)

- 496 Sandhya Vasan, Nelson L Michael. (2012) Improved outlook on HIV-1 prevention and vaccine development. *Expert Opinion on Biological Therapy* **12**:8, 983-994

[CrossRef](#)

- 497 John T. Brooks, Kate Buchacz, Kelly A. Gebo, Jonathan Mermin. (2012) HIV Infection and Older Americans: The Public Health Perspective. *American Journal of Public Health* **102**:8, 1516-1526

[CrossRef](#)

- 498 Dawn K. Smith, Sherri L. Pals, Jeffrey H. Herbst, Sanjyot Shinde, James W. Carey. (2012) Development of a Clinical Screening Index Predictive of Incident HIV Infection Among Men Who Have Sex With Men in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**:4, 421-427

[CrossRef](#)

- 499 Guido Antonelli, Ombretta Turziani. (2012) Antiviral therapy: old and current issues. *International Journal of Antimicrobial Agents* **40**:2, 95-102
[CrossRef](#)
- 500 L. Chonco, M. Pion, E. Vacas, B. Rasines, M. Maly, M.J. Serramía, L. López-Fernández, J. De la Mata, S. Alvarez, R. Gómez, M.A. Muñoz-Fernández. (2012) Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. *Journal of Controlled Release* **161**:3, 949-958
[CrossRef](#)
- 501 Christophe Vanpouille, Anush Arakelyan, Leonid Margolis. (2012) Microbicides: still a long road to success. *Trends in Microbiology* **20**:8, 369-375
[CrossRef](#)
- 502 Myron S. Cohen, Kathryn E. Muessig, M. Kumi Smith, Kimberly A. Powers, Angela D.M. Kashuba. (2012) Antiviral agents and HIV prevention. *AIDS* **26**:13, 1585-1598
[CrossRef](#)
- 503 Alex Sigal, David Baltimore. (2012) As Good As It Gets? The Problem of HIV Persistence despite Antiretroviral Drugs. *Cell Host & Microbe* **12**:2, 132-138
[CrossRef](#)
- 504 Benjamin H. Chi, Michelle R. Adler, Omotayo Bolu, Dorothy Mburi-Ngacha, Didier K. Ekouevi, Anna Gieselman, Tsungai Chipato, Chewe Luo, B. Ryan Phelps, Craig McClure, Lynne M. Mofenson, Jeffrey S. A. Stringer. (2012) Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US President's Emergency Plan for AIDS Relief. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **60**, S78-S87
[CrossRef](#)
- 505 Janni J. Kinsler, William E. Cunningham, César R. Nureña, Carsten Nadat-Haiem, Beatriz Grinsztejn, Martin Casapia, Orlando Montoya-Herrera, Jorge Sánchez, Jerome T. Galea. (2012) Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities. *AIDS and Behavior* **16**:6, 1436-1447
[CrossRef](#)
- 506 Stefan Baral, Frangiscos Sifakis, Alena Peryskina, Vladimir Mogilnii, Nicole F. Masenior, Boris Sergeyev, Irina Deobald, Andrea L. Wirtz, Chris Beyrer. (2012) Risks for HIV Infection Among Gay, Bisexual, and Other Men Who Have Sex with Men in Moscow and St. Petersburg, Russia. *AIDS Research and Human Retroviruses* **28**:8, 874-879
[CrossRef](#)
- 507 K. Mulligan, D. R. Harris, P. Emmanuel, R. A. Fielding, C. Worrell, B. G. Kapogiannis, D. Monte, J. Slesman, C. M. Wilson, G. M. Aldrovandi, . (2012) Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B. *Clinical Infectious Diseases* **55**:3, 461-468
[CrossRef](#)
- 508 Salim S. Abdoor Karim, Cheryl Baxter. (2012) Overview of microbicides for the prevention of human immunodeficiency virus. *Best Practice & Research Clinical Obstetrics & Gynaecology* **26**:4, 427-439
[CrossRef](#)
- 509 Michael S. MacVeigh, Maria K. Kosmetatos, James E. McDonald, Joan L. Reeder, Debby A. Parrish, Thomas P. Young. (2012) Prevalence of Drug-Resistant HIV Type 1 at the Time of Initiation of Antiretroviral Therapy in Portland, Oregon. *AIDS Research and Human*

Retroviruses 120718112500009

[CrossRef](#)

- 510 U. M. Parikh, J. W. Mellors. (2012) HIV-1 Drug Resistance Resulting from Antiretroviral Therapy Far Exceeds That From Pre-exposure Prophylaxis. *Clinical Infectious Diseases* **55**:2, 303-304
[CrossRef](#)
- 511 C. B. Hurt, J. J. Eron, M. S. Cohen. (2012) Reply to Parikh and Mellors. *Clinical Infectious Diseases* **55**:2, 304-304
[CrossRef](#)
- 512 Elizabeth T. Montgomery, A. Straten, H. Cheng, L. Wegner, G. Masenga, C. Mollendorf, L. Bekker, S. Ganesh, K. Young, J. Romano, A. Nel, C. Woodsong. (2012) Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use. *AIDS and Behavior*
[CrossRef](#)
- 513 Charles I Okwundu, Olalekan A Uthman, Christy AN Okoromah, Charles I Okwundu. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
[CrossRef](#)
- 514 Audrey Pettifor, Catherine MacPhail, Nadia Nguyen, Molly Rosenberg. (2012) Can Money Prevent the Spread of HIV? A Review of Cash Payments for HIV Prevention. *AIDS and Behavior*
[CrossRef](#)
- 515 Alex Carballo-Díéguez, Timothy Frasca, Curtis Dolezal, Ivan Balan. (2012) Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. *Journal of Sex Research* **49**:4, 379-387
[CrossRef](#)
- 516 Wendy A. Burgers, Amapola Manrique, David Masopust, Lyle R. McKinnon, Matthew R. Reynolds, Morgane Rolland, Catherine Blish, Gerald K. Chege, Rhonda Curran, William Fischer, Carolina Herrera, D. Noah Sather. (2012) Measurements of Immune Responses for Establishing Correlates of Vaccine Protection Against HIV. *AIDS Research and Human Retroviruses* **28**:7, 641-648
[CrossRef](#)
- 517 William A. Fisher. (2012) "I Think Having the Option Available is a No-Brainer": Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. *Journal of Sex Research* **49**:4, 388-389
[CrossRef](#)
- 518 Erik De Clercq. (2012) Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?. *Medicinal Research Reviews* **32**:4, 765-785
[CrossRef](#)
- 519 Alain Giami, Christophe Perrey. (2012) Transformations in the Medicalization of Sex: HIV Prevention between Discipline and Biopolitics. *Journal of Sex Research* **49**:4, 353-361
[CrossRef](#)
- 520 Sorachai Nitayaphan, Viseth Ngauy, Robert O'Connell, Jean-Louis Excler. (2012) HIV epidemic in Asia: optimizing and expanding vaccine development. *Expert Review of Vaccines* **11**:7, 805-819
[CrossRef](#)

- 521 Gift Trapence, Chris Collins, Sam Avrett, Robert Carr, Hugo Sanchez, George Ayala, Daouda Diouf, Chris Beyer, Stefan D Baral. (2012) From personal survival to public health: community leadership by men who have sex with men in the response to HIV. *The Lancet* **380**:9839, 400-410
[CrossRef](#)
- 522 Chris Beyer, Patrick S Sullivan, Jorge Sanchez, David Dowdy, Dennis Altman, Gift Trapence, Chris Collins, Elly Katabira, Michel Kazatchkine, Michel Sidibe, Kenneth H Mayer. (2012) A call to action for comprehensive HIV services for men who have sex with men. *The Lancet* **380**:9839, 424-438
[CrossRef](#)
- 523 Patrick S Sullivan, Alex Carballo-Díéguez, Thomas Coates, Steven M Goodreau, Ian McGowan, Eduard J Sanders, Adrian Smith, Prabuddhagopal Goswami, Jorge Sanchez. (2012) Successes and challenges of HIV prevention in men who have sex with men. *The Lancet* **380**:9839, 388-399
[CrossRef](#)
- 524 Jaclyn M. White, Matthew J. Mimiaga, Douglas S. Krakower, Kenneth H. Mayer. (2012) Evolution of Massachusetts Physician Attitudes, Knowledge, and Experience Regarding the Use of Antiretrovirals for HIV Prevention. *AIDS Patient Care and STDs* 120613073450003
[CrossRef](#)
- 525 Róbert Sendula, Erika Orbán, Ferenc Hudecz, Gyula Sági, István Jablonkai. (2012) Synthesis and Cytotoxic Activity of Novel 5-Substituted-1-(β -L-Arabinofuranosyl) Pyrimidine Nucleosides. *Nucleosides, Nucleotides and Nucleic Acids* **31**:6, 482-500
[CrossRef](#)
- 526 Kathryn Curran, Jared M. Baeten, Thomas J. Coates, Ann Kurth, Nelly R. Mugo, Connie Celum. (2012) HIV-1 Prevention for HIV-1 Serodiscordant Couples. *Current HIV/AIDS Reports* **9**:2, 160-170
[CrossRef](#)
- 527 Marie Laga, Peter Piot. (2012) Prevention of sexual transmission of HIV. *AIDS* **26**:10, 1223-1229
[CrossRef](#)
- 528 Louise Kuhn, Marc Bulterys. (2012) Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?. *AIDS* **26**:9, 1167-1169
[CrossRef](#)
- 529 (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). *Enfermedades Infecciosas y Microbiología Clínica* **30**:6, e1-e89
[CrossRef](#)
- 530 Paul W. Denton, J. Victor Garcia. (2012) Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. *Trends in Microbiology* **20**:6, 268-274
[CrossRef](#)
- 531 Kevin O. Saunders, Rebecca S. Rudicell, Gary J. Nabel. (2012) The design and evaluation of HIV-1 vaccines. *AIDS* **26**:10, 1293-1302
[CrossRef](#)
- 532 Salim S Abdoel Karim, Quarraisha Abdoel Karim. (2012) Antiretroviral prophylaxis for HIV

prevention reaches a key milestone. *The Lancet* **379**:9831, 2047-2048

[CrossRef](#)

- 533 Virginie Supervie, Sally Blower. (2012) Predicting effect of pre-exposure prophylaxis on HIV epidemics. *The Lancet* **379**:9835, 2423
[CrossRef](#)

- 534 Angela DM Kashuba, Kristine B Patterson, Julie B Dumond, Myron S Cohen. (2012) Pre-exposure prophylaxis for HIV prevention: how to predict success. *The Lancet* **379**:9835, 2409-2411
[CrossRef](#)

- 535 Hong Shang, Junjie Xu, Xiaoxu Han, Jessica Spero Li, Kelly C. Arledge, Linqi Zhang. (2012) HIV prevention: Bring safe sex to China. *Nature* **485**:7400, 576-577
[CrossRef](#)

- 536 D. H. Barouch, P. J. Klasse, J. Dufour, R. S. Veazey, J. P. Moore. (2012) Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. *Proceedings of the National Academy of Sciences* **109**:22, 8694-8698
[CrossRef](#)

- 537 A. Straten, E. T. Montgomery, H. Cheng, L. Wegner, G. Masenga, C. Mollendorf, L. Bekker, S. Ganesh, K. Young, J. Romano, A. Nel, C. Woodsong. (2012) High Acceptability of a Vaginal Ring Intended as a Microbicide Delivery Method for HIV Prevention in African Women. *AIDS and Behavior*
[CrossRef](#)

- 538 Quarraisha Abdoel Karim, Ayesha B. M. Kharsany, Janet A. Frohlich, Lise Werner, Mukelisiwe Mlotshwa, Bernadette T. Madlala, Salim S. Abdoel Karim. (2012) HIV Incidence in Young Girls in KwaZulu-Natal, South Africa—Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. *AIDS and Behavior*
[CrossRef](#)

- 539 R. P. Walensky, J.-E. Park, R. Wood, K. A. Freedberg, C. A. Scott, L.-G. Bekker, E. Losina, K. H. Mayer, G. R. Seage, A. D. Paltiel. (2012) The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. *Clinical Infectious Diseases* **54**:10, 1504-1513
[CrossRef](#)

- 540 D Dolling, AN Phillips, V Delpech, D Pillay, PA Cane, AM Crook, J Shepherd, E Fearnhill, T Hill, D Dunn, . (2012) Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infected population of men who have sex with men. *HIV Medicine* **13**:5, 309-314
[CrossRef](#)

- 541 Tanuja N Gengiah, Cheryl Baxter, Leila E Mansoor, Ayesha BM Kharsany, Salim. S Abdoel Karim. (2012) A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. *Expert Opinion on Investigational Drugs* **21**:5, 695-715
[CrossRef](#)

- 542 Erik De Clercq. (2012) Ten Paths to the Discovery of Antivirally Active Nucleoside and Nucleotide Analogues. *Nucleosides, Nucleotides and Nucleic Acids* **31**:4, 339-352
[CrossRef](#)

- 543 Jeffrey H. Herbst, Marlene Glassman, James W. Carey, Thomas M. Painter, Deborah J. Gelaude, Amy M. Fasula, Jerris L. Raiford, Arin E. Freeman, Camilla Harshbarger, Abigail

H. Viall, David W. Purcell. (2012) Operational Research to Improve HIV Prevention in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **59**:5, 530-536
[CrossRef](#)

- 544 Charlene Flash, Douglas Krakower, Kenneth H. Mayer. (2012) The Promise of Antiretrovirals for HIV Prevention. *Current Infectious Disease Reports* **14**:2, 185-193
[CrossRef](#)
- 545 Norma C. Ware, Monique A. Wyatt, Jessica E. Haberer, Jared M. Baeten, Alexander Kintu, Christina Psaros, Steven Safran, Elioda Tumwesigye, Connie L. Celum, David R. Bangsberg. (2012) What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **59**:5, 463-468
[CrossRef](#)
- 546 Kenneth H. Mayer, Matthew J. Mimiaga, Marcy Gelman, Chris Grasso. (2012) Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **59**:4, 354-359
[CrossRef](#)
- 547 Avnish Tripathi, Chinelo Ogbuanu, Mauda Monger, James J. Gibson, Wayne A. Duffus. (2012) Preexposure Prophylaxis for HIV Infection. *Southern Medical Journal* **105**:4, 199-206
[CrossRef](#)
- 548 Xuefeng Li, Hongyan Lu, Xiaoyan Ma, Yanming Sun, Xiong He, Chunmei Li, H. F. Raymond, Willi McFarland, Stephen W. Pan, Yiming Shao, Sten H. Vermund, Yan Xiao, Yuhua Ruan, Yujiang Jia. (2012) HIV/AIDS-Related Stigmatizing and Discriminatory Attitudes and Recent HIV Testing Among Men Who Have Sex With Men in Beijing. *AIDS and Behavior* **16**:3, 499-507
[CrossRef](#)
- 549 Ariane van der Straten, Lut Van Damme, Jessica E. Haberer, David R. Bangsberg. (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. *AIDS* **26**:7, F13-F19
[CrossRef](#)
- 550 Fatih M Uckun, Pedro Cahn, Sanjive Qazi, Osmond D'Cruz. (2012) Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. *Expert Opinion on Investigational Drugs* **21**:4, 489-500
[CrossRef](#)
- 551 Amanda Clarke, Denise Hsu, Stephen J Kerr, Reshmie Ramautarsing, Pirapon June Ohata, Nadia Kancheva Landolt, Anchalee Avihingsanon, Wirach Maek-a-nantawat, Thanyawee Puthanakit, Torsak Bunupuradah, Wasana Prasitsuebsai, Jintanat Ananworanich, Praphan Phanuphak, Kiat Ruxrungtham. (2012) The 15th Bangkok International Symposium on HIV Medicine. *Future Virology* **7**:4, 341-344
[CrossRef](#)
- 552 Thana Khawcharoenporn, Sabrina Kendrick, Kimberly Smith. (2012) HIV Risk Perception and Preexposure Prophylaxis Interest Among a Heterosexual Population Visiting a Sexually Transmitted Infection Clinic. *AIDS Patient Care and STDs* **120309093020005**
[CrossRef](#)
- 553 Anneke C. Grobler, Salim S. Abdoor Karim. (2012) Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. *AIDS* **26**:5, 529-532
[CrossRef](#)

- 554 Erik De Clercq. (2012) Pre-exposure chemoprophylaxis of HIV infection: Quo vadis?. *Biochemical Pharmacology* **83**:5, 567-573
[CrossRef](#)
- 555 Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate, Sheela V. Godbole. (2012) Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India. *Proceedings of the National Academy of Sciences, India Section B: Biological Sciences* **82**:1, 167-180
[CrossRef](#)
- 556 James Y. Dai, Peter B. Gilbert, Benoît R. Mâsse. (2012) Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials. *Journal of the American Statistical Association* **107**:497, 52-65
[CrossRef](#)
- 557 Jane Anderson. (2012) Women and HIV. *Current Opinion in Infectious Diseases* **25**:1, 58-65
[CrossRef](#)
- 558 Valerie E. Stone. (2012) HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S.. *Current Infectious Disease Reports* **14**:1, 53-60
[CrossRef](#)
- 559 Emilie Venables, Jonathan Stadler. (2012) 'The study has taught me to be supportive of her': empowering women and involving men in microbicide research. *Culture, Health & Sexuality* **14**:2, 181-194
[CrossRef](#)
- 560 Matthew A. Price, Wasima Rida, Mary Mwangome, Gaudensia Mutua, Keren Middelkoop, Surita Roux, Haile S. Okuku, Linda-Gail Bekker, Omu Anzala, Elizabeth Ngugi, Gwynn Stevens, Paramesh Chetty, Pauli N. Amornkul, Eduard J. Sanders. (2012) Identifying At-Risk Populations in Kenya and South Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **59**:2, 185-193
[CrossRef](#)
- 561 Kenneth H. Mayer, Robert Ducharme, Nickolas D. Zaller, Philip A. Chan, Patricia Case, David Abbott, Irma I. Rodriguez, Timothy Cavanaugh. (2012) Unprotected Sex, Underestimated Risk, Undiagnosed HIV and Sexually Transmitted Diseases Among Men Who Have Sex With Men Accessing Testing Services in a New England Bathhouse. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **59**:2, 194-198
[CrossRef](#)
- 562 Connie Celum, Jared M. Baeten. (2012) Tenofovir-based pre-exposure prophylaxis for HIV prevention. *Current Opinion in Infectious Diseases* **25**:1, 51-57
[CrossRef](#)
- 563 Ronald A. Brooks, Raphael J. Landovitz, Rachel L. Kaplan, Eli Lieber, Sung-Jae Lee, Thomas W. Barkley. (2012) Sexual Risk Behaviors and Acceptability of HIV Pre-Exposure Prophylaxis Among HIV-Negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study. *AIDS Patient Care and STDs* **26**:2, 87-94
[CrossRef](#)
- 564 Nelson L. Michael. (2012) Rare serotype adenoviral vectors for HIV vaccine development. *Journal of Clinical Investigation* **122**:1, 25-27
[CrossRef](#)
- 565 L. Mandelbrot. (2012) Désir d'enfant et VIH : le préservatif est-il dépassé ?. *Gynécologie Obstétrique & Fertilité* **40**:1, 58-61

[CrossRef](#)

- 566 Deborah Cohan, Shannon Weber, Ronald Goldschmidt. (2012) Safer conception options for HIV-serodiscordant couples. *American Journal of Obstetrics and Gynecology* **206**:1, e21
[CrossRef](#)
- 567 Qi Zheng, Susan Ruone, William M Switzer, Walid Heneine, J García-Lerma. (2012) Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. *Retrovirology* **9**:1, 40
[CrossRef](#)
- 568 G. Pialoux, J. Chas, P. Bonnard. (2012) PreP un nouvel outil de prévention contre le VIH. *Journal des Anti-infectieux* **14**:4, 175
[CrossRef](#)
- 569 Angela Kelly, Martha Kupul, Lisa Fitzgerald, Herick Aeno, James Neo, Richard Naketrum, Peter Siba, John M Kaldor, Andrew Vallely, . (2012) "Now we are in a different time; various bad diseases have come." understanding men's acceptability of male circumcision for HIV prevention in a moderate prevalence setting. *BMC Public Health* **12**:1, 67
[CrossRef](#)
- 570 S. E. Reid, S. M. Topp, E. R. Turnbull, S. Hatwiinda, J. B. Harris, K. R. Maggard, S. T. Roberts, A. Kruuner, J. C. Morse, N. Kapata. (2012) Tuberculosis and HIV Control in Sub-Saharan African Prisons: "Thinking Outside the Prison Cell". *The Journal of Infectious Diseases* **205**:suppl 2, S265
[CrossRef](#)
- 571 Girish N. Vyas, Cheryl A. Stoddart, M. Scott Killian, Todd V. Brennan, Tiffany Goldberg, Alyssa Ziman, Yvonne Bryson. (2012) Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies. *Biologicals* **40**:1, 15-20
[CrossRef](#)
- 572 G. Bocharov, V. Chereshnev, I. Gainova, S. Bazhan, B. Bachmetyev, J. Argilaguet, J. Martinez, A. Meyerhans. (2012) Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. *Mathematical Modelling of Natural Phenomena* **7**:5, 78-104
[CrossRef](#)
- 573 Marc M. Baum, Irina Butkyavichene, Joshua Gilman, Sean Kennedy, Etana Kopin, Amanda M. Malone, Cali Nguyen, Thomas J. Smith, David R. Friend, Meredith R. Clark, John A. Moss. (2012) An intravaginal ring for the simultaneous delivery of multiple drugs. *Journal of Pharmaceutical Sciences* n/a-n/a
[CrossRef](#)
- 574 Koen K.A. Van Rompay. (2012) The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. *AIDS Research and Human Retroviruses* **28**:1, 16-35
[CrossRef](#)
- 575 J.A. Stockman. (2012) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. *Yearbook of Pediatrics* **2012**, 271-272
[CrossRef](#)
- 576 Thomas R. Moench, Deirdre E. O'Hanlon, Richard A. Cone. (2012) Evaluation of Microbicide Gel Adherence Monitoring Methods. *Sexually Transmitted Diseases* **1**
[CrossRef](#)
- 577 Salim S. Abdoel Karim. HIV prevention. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:113-121.

[CrossRef](#)

- 578 Ruth M. Greenblatt, Monica Gandhi. Special issues regarding women with HIV infection. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:521-536.
[CrossRef](#)
- 579 Bruce R. Schackman, Ashley A. Eggman. (2012) Cost-effectiveness of pre-exposure prophylaxis for HIV. *Current Opinion in HIV and AIDS* 7:6, 587
[CrossRef](#)
- 580 Ayesha Mirza, Mobeen H. Rathore. (2012) Pediatric HIV Infection. *Advances in Pediatrics* 59:1, 9-26
[CrossRef](#)
- 581 Susa Coffey, Paul A. Volberding. Overview of antiretroviral therapy. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:133-153.
[CrossRef](#)
- 582 Justin J. O'Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Apparent declining efficacy in randomized trials. *AIDS* 26:2, 123-126
[CrossRef](#)
- 583 Gabriel R Galindo, Ja'Nina J Walker, Patrick Hazelton, Tim Lane, Wayne T Steward, Stephen F Morin, Emily A Arnold. (2012) Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. *Implementation Science* 7:1, 116
[CrossRef](#)
- 584 Shahin Lockman, Paul Sax. (2012) Treatment-for-prevention. *Current Opinion in HIV and AIDS* 1
[CrossRef](#)
- 585 S.M. Owen. (2012) Testing for acute HIV infection : implications for treatment as prevention. *Current Opinion in HIV and AIDS* 7:2, 125
[CrossRef](#)
- 586 Yelina Alvarez, Michael Tuen, Arthur Nàdas, Catarina E. Hioe. (2012) In Vitro Restoration of Th17 Response During HIV Infection with an Antiretroviral Drug and Th17 Differentiation Cytokines. *AIDS Research and Human Retroviruses* 28:8, 823
[CrossRef](#)
- 587 Richard A. Crosby, Willard Cates. (2012) Condom use: still a sexual health staple. *Sexual Health* 9:1, 1
[CrossRef](#)
- 588 L. T. Matthews. (2012) Reproductive Counseling by Clinic Healthcare Workers in Durban, South Africa: Perspectives from HIV-Infected Men and Women Reporting Serodiscordant Partners. *Infectious Diseases in Obstetrics and Gynecology* 2012, 1-9
[CrossRef](#)
- 589 Renee Heffron, Deborah Donnell, Helen Rees, Connie Celum, Nelly Mugo, Edwin Were, Guy de Bruyn, Edith Nakku-Joloba, Kenneth Ngure, James Kiarie, Robert W Coombs, Jared M Baeten. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. *The Lancet Infectious Diseases* 12:1, 19-26
[CrossRef](#)
- 590 Mark W Hull, Julio SG Montaner. (2012) Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime time?. *Clinical Investigation* 2:1, 1-4

[CrossRef](#)

- 591 Carlos Del Rio. Prevention of Human Immunodeficiency Virus Infection. In: Goldman's Cecil Medicine. Elsevier, 2012:2182-2185.
[CrossRef](#)
- 592 Thomas J. Ketas, Sophie Holuigue, Katie Matthews, John P. Moore, Per Johan Klasse. (2012) Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. *Virology* **422**:1, 22-36
[CrossRef](#)
- 593 Mary Jo Hoyt, Deborah S. Storm, Erika Aaron, Jean Anderson. (2012) Preconception and Contraceptive Care for Women Living with HIV. *Infectious Diseases in Obstetrics and Gynecology* **2012**, 1-14
[CrossRef](#)
- 594 J. D. Shelton. (2011) ARVs as HIV Prevention: A Tough Road to Wide Impact. *Science* **334**:6063, 1645-1646
[CrossRef](#)
- 595 C. B. Hurt, J. J. Eron, M. S. Cohen. (2011) Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. *Clinical Infectious Diseases* **53**:12, 1265-1270
[CrossRef](#)
- 596 J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. *Clinical Infectious Diseases* **53**:suppl 3, S64-S78
[CrossRef](#)
- 597 K. B. Patterson, H. A. Prince, E. Kraft, A. J. Jenkins, N. J. Shaheen, J. F. Rooney, M. S. Cohen, A. D. M. Kashuba. (2011) Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. *Science Translational Medicine* **3**:112, 112re4-112re4
[CrossRef](#)
- 598 M. Scott Killian, Jay A. Levy. (2011) HIV/AIDS: 30 Years of progress and future challenges. *European Journal of Immunology* **41**:12, 3401-3411
[CrossRef](#)
- 599 Ronald O. Valdiserri. (2011) Commentary: Thirty Years of AIDS in America: A Story of Infinite Hope. *AIDS Education and Prevention* **23**:6, 479-494
[CrossRef](#)
- 600 Roger Detels, Dean L. Winslow. (2011) Treatment as Prevention. *AIDS* **1**
[CrossRef](#)
- 601 Ming Li, Dorothy L. Patton, Yvonne Cosgrove-Sweeney, Deena Ratner, Lisa C. Rohan, Alexander M. Cole, Patrick M. Tarwater, Phalguni Gupta, Bharat Ramratnam. (2011) Incorporation of the HIV-1 Microbicide Cyanovirin-N in a Food Product. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **58**:4, 379-384
[CrossRef](#)
- 602 Jie Yang, Lin Li, Suiyi Tan, Hong Jin, Jiayin Qiu, Qinchao Mao, Runming Li, Chenglai Xia, Zhi-Hong Jiang, Shibo Jiang, Shuwen Liu. (2011) A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: Potential applications for preventing HIV-1 infection. *Fitoterapia*
[CrossRef](#)

- 603 Thomas C. Quinn. (2011) The 30-Year War on AIDS: Have We Reached the Tipping Point?. *Sexually Transmitted Diseases* **38**:12, 1089-1093
[CrossRef](#)
- 604 Stefano Rusconi. (2011) Investigators Involvement in the Care of HIV-Infected Individuals. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **58**:4, e118-e119
[CrossRef](#)
- 605 James A. McIntyre. (2011) Can Devices for Adult Male Circumcision Help Bridge the Implementation Gap for HIV Prevention Services?. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **58**:5, 506-508
[CrossRef](#)
- 606 Douglas Krakower, Kenneth H. Mayer. (2011) Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications. *Current HIV/AIDS Reports* **8**:4, 241-248
[CrossRef](#)
- 607 José Heuker, Gerard J.B. Sonder, Ineke Stolte, Ronald Geskus, Anneke Van Den Hoek. (2011) High HIV incidence among MSM prescribed postexposure prophylaxis in Amsterdam, 2000–2009. *AIDS* [CrossRef](#)
- 608 B. E. Nichols, C. A. B. Boucher, D. A. M. C. van de Vijver. (2011) HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. *Journal of Internal Medicine* **270**:6, 532-549
[CrossRef](#)
- 609 Iryna B. Zablotska, Garrett Prestage, Martin Holt, Mary Poynten, John de Wit, Rebecca Guy, Limin Mao, John McAllister, Andrew E. Grulich. (2011) Australian Gay Men Who Have Taken Nonoccupational Postexposure Prophylaxis for HIV Are in Need of Effective HIV Prevention Methods. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **58**:4, 424-428
[CrossRef](#)
- 610 Salim S Abdoool Karim, Quarraisha Abdoool Karim. (2011) Antiretroviral prophylaxis: a defining moment in HIV control. *The Lancet* **378**:9809, e23-e25
[CrossRef](#)
- 611 Lindsay M Ferguson, Lisa Cencia Rohan. (2011) The importance of the vaginal delivery route for antiretrovirals in HIV prevention. *Therapeutic Delivery* **2**:12, 1535-1550
[CrossRef](#)
- 612 Nirupama Deshmane Sista, Quarraisha Abdoool Karim, Kathy Hinson, Deborah Donnell, Susan H Eshleman, Sten H Vermund. (2011) Experience in international clinical research: the HIV Prevention Trials Network. *Clinical Investigation* **1**:12, 1609-1618
[CrossRef](#)
- 613 Nicolas Lorente, Lionel Fugon, Maria Patrizia Carrieri, Christian Andreo, Jean-Marie Le Gall, Emmanuel Cook, Jean-Pierre Aboulker, Catherine Capitant, Jean-Michel Molina, Bruno Spire. (2011) Acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. *AIDS Care* **1**:10
[CrossRef](#)
- 614 José das Neves, Johan Michiels, Kevin K. Ariën, Guido Vanham, Mansoor Amiji, Maria Fernanda Bahia, Bruno Sarmento. (2011) Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate

Dapivirine. *Pharmaceutical Research*[CrossRef](#)

- 615 Lauren L. Katzen, José A. Fernández-Romero, Avina Sarna, Kailapuri G. Murugavel, Daniel Gawarecki, Thomas M. Zydowsky, Barbara S. Mensch. (2011) Validation of a Dye Stain Assay for Vaginally Inserted Hydroxyethylcellulose-Filled Microbicide Applicators. *Sexually Transmitted Diseases* **38**:11, 1050-1055
[CrossRef](#)
- 616 P. Volberding. (2011) The impact of HIV research on health outcome and healthcare policy. *Annals of Oncology* **22**:Suppl 7, vii50-vii53
[CrossRef](#)
- 617 S. Daou, A. Calmy. (2011) Le traitement prophylactique de l'infection par le virus de l'immunodéficience humaine (VIH). *La Revue de Médecine Interne* **32**:11, 658-662
[CrossRef](#)
- 618 Beryl A. Koblin, Gordon Mansergh, Victoria Frye, Hong Van. Tieu, Donald R. Hoover, Sebastian Bonner, Stephen A. Flores, Sharon M. Hudson, Grant N. Colfax. (2011) Condom-Use Decision Making in the Context of Hypothetical Pre-Exposure Prophylaxis Efficacy Among Substance-Using Men Who Have Sex With Men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **58**:3, 319-327
[CrossRef](#)
- 619 Samuel B. Keller, Davey M. Smith. (2011) The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. *AIDS* **25**:18, 2308-2310
[CrossRef](#)
- 620 Felicity Daly. (2011) The introduction of new antiretroviral-based HIV prevention methods into health systems: key issues. *Reproductive Health Matters* **19**:38, 208-212
[CrossRef](#)
- 621 A. J. Leigh Brown, S. J. Lycett, L. Weinert, G. J. Hughes, E. Fearnhill, D. T. Dunn, . (2011) Transmission Network Parameters Estimated From HIV Sequences for a Nationwide Epidemic. *Journal of Infectious Diseases* **204**:9, 1463-1469
[CrossRef](#)
- 622 John Stover. (2011) 30 years after HIV identification: where to from here?. *Expert Review of Anti-infective Therapy* **9**:11, 947-949
[CrossRef](#)
- 623 Rúbia Marília de Medeiros, Dennis Maletich Junqueira, Maria Cristina Cotta Matte, Nêmora Tregnago Barcellos, José Artur Bogo Chies, Sabrina Esteves Matos Almeida. (2011) Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: Analysis of primary resistance mutations. *Journal of Medical Virology* **83**:10, 1682-1688
[CrossRef](#)
- 624 Pietro L. Vernazza, Irma Graf, Ulrike Sonnenberg-Schwan, Maria Geit, Anja Meurer. (2011) Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. *AIDS* **25**:16, 2005-2008
[CrossRef](#)
- 625 Robert T Koppenhaver, Stephen W Sorensen, Paul G Farnham, Stephanie L Sansom. (2011) The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex With Men in the United States: An Epidemic Model. *JAIDS Journal of Acquired Immune*

Deficiency Syndromes **58**:2, e51-e52[CrossRef](#)

- 626 Graciela Andrei, Andrea Lisco, Christophe Vanpouille, Andrea Introini, Emanuela Balestra, Joost van den Oord, Tomas Cihlar, Carlo-Federico Perno, Robert Snoeck, Leonid Margolis, Jan Balzarini. (2011) Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication. *Cell Host & Microbe* **10**:4, 379-389
[CrossRef](#)
- 627 Harkaitz Azkune, Maialen Ibarguren, Xabier Camino, José Antonio Iribarren. (2011) Prevención de la transmisión del VIH (vertical, ocupacional y no ocupacional). *Enfermedades Infecciosas y Microbiología Clínica* **29**:8, 615-625
[CrossRef](#)
- 628 José Vicente Fernández-Montero, Vicente Soriano. (2011) Profilaxis preexposición en la prevención de la infección por virus de la inmunodeficiencia humana. *Medicina Clínica* **137**:10, 446-448
[CrossRef](#)
- 629 Rewa Kohli, Sharon Tsui, Sanjay Mehendale, Elizabeth Tolley. (2011) Indian married men's interest in microbicide use. *AIDS Care* **23**:10, 1344-1349
[CrossRef](#)
- 630 Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen E. Gómez, Beatriz Perdiguero, Jose L. Nájera, Victoria Jiménez, Juan García-Arraiza, Alberto C. Guardo, Iñaki Pérez, Vicens Díaz-Brito, Matilde Sánchez Conde, Nuria González, Amparo Alvarez, José Alcamí, José Luis Jiménez, Judit Pich, Joan Albert Arnaiz, María J. Maleno, Agathe León, María Angeles Muñoz-Fernández, Peter Liljeström, Jonathan Weber, Giuseppe Pantaleo, José M. Gatell, Montserrat Plana, Mariano Esteban. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). *Vaccine* **29**:46, 8309-8316
[CrossRef](#)
- 631 Vitaly A. Kushnir, William Lewis. (2011) Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. *Fertility and Sterility* **96**:3, 546-553
[CrossRef](#)
- 632 Leolin Katsidzira, James G. Hakim. (2011) HIV prevention in southern Africa: why we must reassess our strategies?. *Tropical Medicine & International Health* **16**:9, 1120-1130
[CrossRef](#)
- 633 Nicole Stolte-Leeb, Roberta Loddo, Sophia Antimisiaris, Tina Schultheiss, Ulrike Sauermann, Monika Franz, Spyridon Mourtas, Christophe Parsy, Richard Storer, Paolo La Colla, Christiane Stahl-Hennig. (2011) Topical Nonnucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of Macaques. *AIDS Research and Human Retroviruses* **27**:9, 933-943
[CrossRef](#)
- 634 Lane R. Bushman, Jennifer J. Kiser, Joseph E. Rower, Brandon Klein, Jia-Hua Zheng, Michelle L. Ray, Peter L. Anderson. (2011) Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. *Journal of Pharmaceutical and Biomedical Analysis* **56**:2, 390-401
[CrossRef](#)
- 635 S. A. Springer, A. C. Spaulding, J. P. Meyer, F. L. Altice. (2011) Public Health Implications

for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components.

Clinical Infectious Diseases **53**:5, 469-479

[CrossRef](#)

- 636 Hammer , Scott M. , . (2011) Antiretroviral Treatment as Prevention. *New England Journal of Medicine* **365**:6, 561-562

[Free Full Text](#)

- 637 Andrew Anglemyer, George W Rutherford, Rachel C Baggaley, Matthias Egger, Nandi Siegfried, George W Rutherford. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.

[CrossRef](#)

- 638 Gerard van den Aardweg. (2011) On the Psychogenesis of Homosexuality. *The Linacre Quarterly* **78**:3, 330-354

[CrossRef](#)

- 639 Nico J.D. Nagelkerke, Jan A.C. Hontelez, Sake J. de Vlas. (2011) The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study.

Vaccine **29**:36, 6079-6085

[CrossRef](#)

- 640 Richard T. Gray, Mohammad H. Ghaus, Alexander Hoare, David P. Wilson. (2011) Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. *Vaccine* **29**:36, 6125-6129

[CrossRef](#)

- 641 Kevin M De Cock, Wafaa M El-Sadr, Tedros A Ghebreyesus. (2011) Game Changers: Why Did the Scale-Up of HIV Treatment Work Despite Weak Health Systems?. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **57**, S61-S63

[CrossRef](#)

- 642 Gerard van den Aardweg. (2011) Abuse by Priests, Homosexuality, <i>Humanae vitae</i>, and a Crisis of Masculinity in the Church. *The Linacre Quarterly* **78**:3, 274-293

[CrossRef](#)

- 643 Paula M. Frew, Matthew Archibald, Brooke Hixson, Carlos del Rio. (2011) Socioecological influences on community involvement in HIV vaccine research. *Vaccine* **29**:36, 6136-6143

[CrossRef](#)

- 644 Kyean M. Andersson, John Stover. (2011) The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. *Vaccine* **29**:36, 6092-6099

[CrossRef](#)

- 645 Sten H Vermund. (2011) Modeling interventions to assess HIV epidemic impact in Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **1**

[CrossRef](#)

- 646 Kelly A Curtis, M Susan Kennedy, Amara Luckay, Mian-er Cong, Ae S Youngpairoj, Qi Zheng, James Smith, Debra Hanson, Walid Heneine, S Michele Owen, J Gerardo García-Lerma. (2011) Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis. *JAIDS Journal of Acquired Immune Deficiency Syndromes* **57**:5, 355-362

[CrossRef](#)

- 647 AR Giuliano, MF Schim van der Loeff, AG Nyitray. (2011) Circumcised HIV-infected men

and HPV transmission. *The Lancet Infectious Diseases* **11**:8, 581-582

[CrossRef](#)

- 648 Gita Ramjee. (2011) Antiretroviral-based microbicides and oral pre-exposure prophylaxis for HIV prevention. *Future Virology* **6**:8, 997-1014

[CrossRef](#)

- 649 Marc P. Girard, Saladin Osmanov, Olga M. Assossou, Marie-Paule Kieny. (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. *Vaccine* **29**:37, 6191-6218

[CrossRef](#)

- 650 Reinhard H. Dennin, Michael Lafrenz, Arndt Sinn, Lan-juan Li. (2011) Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights. *Journal of Zhejiang University SCIENCE B* **12**:7, 591-610

[CrossRef](#)

- 651 R. J. Shattock, M. Warren, S. McCormack, C. A. Hankins. (2011) Turning the Tide Against HIV. *Science* **333**:6038, 42-43

[CrossRef](#)

- 652 Erik De Clercq. (2011) The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. *Biochemical Pharmacology* **82**:2, 99-109

[CrossRef](#)

- 653 Sheldon R Morris, Susan J Little. (2011) MSM: resurgent epidemics. *Current Opinion in HIV and AIDS* **6**:4, 326-332

[CrossRef](#)

- 654 Merlin Robb. (2011) HIV vaccine development: a new beginning. *Expert Review of Vaccines* **10**:7, 925-927

[CrossRef](#)

- 655 Kenneth H Mayer. (2011) Antiretrovirals for HIV prevention: translating promise into praxis. *The Lancet* **378**:9787, 206-208

[CrossRef](#)

- 656 Louise Kuhn, Ida Susser, Zena Stein. (2011) Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified?. *The Lancet* **378**:9787, 285-287

[CrossRef](#)

- 657 Nancy S Padian, Sandra I McCoy, Salim S Abdool Karim, Nina Hasen, Julia Kim, Michael Bartos, Elly Katabira, Stefano M Bertozi, Bernhard Schwartländer, Myron S Cohen. (2011) HIV prevention transformed: the new prevention research agenda. *The Lancet* **378**:9787, 269-278

[CrossRef](#)

- 658 Salim S Abdool Karim, Angela DM Kashuba, Lise Werner, Quarasha Abdool Karim. (2011) Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. *The Lancet* **378**:9787, 279-281

[CrossRef](#)

- 659 Laurent Bélec, Mohammad-Ali Jenabian, Charlotte Charpentier, Hela Saïdi. (2011) Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. *Future Microbiology* **6**:7, 731-737

[CrossRef](#)

- 660 John Imrie, Frank Tanser. (2011) Targeting strategies and behavior change to combat the HIV epidemic in southern Africa. *Future Virology* **6**:7, 793-800
[CrossRef](#)
- 661 Salim S. Abdool Karim. (2011) Stigma impedes AIDS prevention. *Nature* **474**:7349, 29-31
[CrossRef](#)
- 662 (2011) A big disease with a little name. *Nature* **474**:7349, 5-5
[CrossRef](#)
- 663 Meredith R. Clark, Patrick F. Kiser, Andrew Loxley, Christopher McConville, R. Karl Malcolm, David R. Friend. (2011) Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. *Drug Delivery and Translational Research* **1**:3, 238-246
[CrossRef](#)
- 664 Arleen A. Leibowitz, Karen Byrnes Parker, Mary Jane Rotheram-Borus. (2011) A US Policy Perspective on Oral Preexposure Prophylaxis for HIV. *American Journal of Public Health* **101**:6, 982-985
[CrossRef](#)
- 665 Margaret A. Lampe, Dawn K. Smith, Gillian J.E. Anderson, Ashley E. Edwards, Steven R. Nesheim. (2011) Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. *American Journal of Obstetrics and Gynecology* **204**:6, 488.e1-488.e8
[CrossRef](#)
- 666 Kumi Smith, Kimberly A Powers, Angela DM Kashuba, Myron S Cohen. (2011) HIV-1 treatment as prevention: the good, the bad, and the challenges. *Current Opinion in HIV and AIDS* **1**
[CrossRef](#)
- 667 Theodoros Kelesidis, Raphael J. Landovitz. (2011) Preexposure Prophylaxis for HIV Prevention. *Current HIV/AIDS Reports* **8**:2, 94-103
[CrossRef](#)
- 668 Natasha A. Verma, Anna C. Lee, Betsy C. Herold, Marla J. Keller. (2011) Topical Prophylaxis for HIV Prevention in Women: Becoming a Reality. *Current HIV/AIDS Reports* **8**:2, 104-113
[CrossRef](#)
- 669 Y. Omar Whiteside, Tammy Harris, Christopher Scanlon, Stephen Clarkson, Wayne Duffus. (2011) Self-Perceived Risk of HIV Infection and Attitudes About Preexposure Prophylaxis Among Sexually Transmitted Disease Clinic Attendees in South Carolina. *AIDS Patient Care and STDs* **25**:6, 365-370
[CrossRef](#)
- 670 J. B. F. de Wit, P. Aggleton, T. Myers, M. Crewe. (2011) The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. *Health Education Research* **26**:3, 381-392
[CrossRef](#)
- 671 Cohen , Myron S. , Shaw , George M. , McMichael , Andrew J. , Haynes , Barton F. , . (2011) Acute HIV-1 Infection. *New England Journal of Medicine* **364**:20, 1943-1954
[Full Text](#)
- 672 Jessica E. Price, Willard Cates. (2011) Sex Worker Studies: The Science, Semantics, and

Politics of Targeting Our HIV Prevention Response. *Sexually Transmitted Diseases* **38**:5, 395-397
[CrossRef](#)

- 673 HimaBindu Chunduri, Clyde Crumpacker, Prem L. Sharma. (2011) Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. *Virology* **414**:1, 34-41
[CrossRef](#)

- 674 Mark A Wainberg, Hugh J Field. (2011) Proof of principle: antiretroviral drugs can prevent sexual transmission of HIV-1. *Future Virology* **6**:5, 549-551
[CrossRef](#)

- 675 Barry R O'Keefe. (2011) Anti-HIV microbicide development: targeting the virus is the key. *Future Virology* **6**:5, 553-556
[CrossRef](#)

- 676 (2011) Preexposure Chemoprophylaxis for HIV Prevention. *New England Journal of Medicine* **364**:14, 1372-1375
[Free Full Text](#)

- 677 P. Anton, B. C. Herold. (2011) HIV Transmission: Time for Translational Studies to Bridge the Gap. *Science Translational Medicine* **3**:77, 77ps11-77ps11
[CrossRef](#)

- 678 Mian-er Cong, Ae S. Youngpaipoj, Wutyi Aung, Sunita Sharma, James Mitchell, Charles Dobard, Walid Heneine, J. Gerardo Garcia-Lerma. (2011) Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques. *Virology* **412**:2, 435-440
[CrossRef](#)

- 679 Elie Dolgin. (2011) Trial success spurs planning for rollout of HIV prevention pills. *Nature Medicine* **17**:4, 392-392
[CrossRef](#)

- 680 David Rey. (2011) Post-exposure prophylaxis for HIV infection. *Expert Review of Anti-infective Therapy* **9**:4, 431-442
[CrossRef](#)

- 681 Amanda Clarke, Reshmie Ramautarsing, Pirapon June Ohata, Denise Hsu, Nadia Kancheva Landolt, Stephen J Kerr, Anchalee Avihingsanon, Wirach Maek-a-nantawat, Thanyawee Puthanakit, Torsak Bunupuradah, Wasana Prasitsuebsai, Jintanat Ananworanich, Kiat Ruxrungtham. (2011) The 14th Bangkok International Symposium on HIV Medicine. *Future Virology* **6**:4, 409-412
[CrossRef](#)

- 682 Rebecca F Baggaley, Kimberly A Powers, Marie-Claude Boily. (2011) What do mathematical models tell us about the emergence and spread of drug-resistant HIV?. *Current Opinion in HIV and AIDS* **6**:2, 131-140
[CrossRef](#)

- 683 Kevin K. Ariën, Vicky Jespers, Guido Vanham. (2011) HIV sexual transmission and microbicides. *Reviews in Medical Virology* **21**:2, 110-133
[CrossRef](#)

- 684 Brian S. Mustanski, Michael E. Newcomb, Steve N. Du Bois, Steve C. Garcia, Christian Grov. (2011) HIV in Young Men Who Have Sex with Men: A Review of Epidemiology, Risk and Protective Factors, and Interventions. *Journal of Sex Research* **48**:2-3, 218-253

[CrossRef](#)

- 685 Gavin M. Myers, Kenneth H. Mayer. (2011) Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings. *AIDS Patient Care and STDs* **25**:2, 63-71
[CrossRef](#)
- 686 S. H. Vermund, L. Van Damme. (2011) HIV Prevention in Women: Next Steps. *Science* **331**:6015, 284-284
[CrossRef](#)
- 687 Mark A. Wainberg. (2011) AIDS: Drugs that prevent HIV infection. *Nature* **469**:7330, 306-307
[CrossRef](#)
- 688 Rony Zachariah, Wim Van Damme, Vic Arendt, Jean Schmit, Anthony D Harries. (2011) The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research. *Journal of the International AIDS Society* **14**:Suppl 1, S7
[CrossRef](#)
- 689 Robert Kalyesubula, Mark A. Perazella. (2011) Nephrotoxicity of HAART. *AIDS Research and Treatment* **2011**, 1-11
[CrossRef](#)
- 690 Lisa M. McDaid, Graham J. Hart. (2011) Willingness to Participate in Future HIV Prevention Studies Among Gay and Bisexual Men in Scotland, UK: A Challenge for Intervention Trials. *AIDS and Behavior* **16**:6, 1420
[CrossRef](#)
- 691 Kathleen M MacQueen. (2011) Framing the social in biomedical HIV prevention trials: a 20-year retrospective. *Journal of the International AIDS Society* **14**:Suppl 2, S3
[CrossRef](#)
- 692 Barry D Adam. (2011) Epistemic fault lines in biomedical and social approaches to HIV prevention. *Journal of the International AIDS Society* **14**:Suppl 2, S2
[CrossRef](#)
- 693 Andrew Anglemyer, George W Rutherford, Matthias Egger, Nandi Siegfried, George W Rutherford. Cochrane Database of Systematic Reviews Protocols. 2011.
[CrossRef](#)
- 694 Erik De Clercq. (2011) Acyclic nucleoside phosphonates: An unfinished story. *Collection of Czechoslovak Chemical Communications* **76**:7, 829-842
[CrossRef](#)
- 695 Bruce L. Gilliam, Devang Patel, Rohit Talwani, Zelalem Temesgen. (2011) HIV in Africa: Challenges and Directions for the Next Decade. *Current Infectious Disease Reports* **14**:1, 91
[CrossRef](#)
- 696 Richard G Wamai, Brian J Morris, Stefan A Bailis, David Sokal, Jeffrey D Klausner, Ross Appleton, Nelson Sewankambo, David A Cooper, John Bongaarts, Guy de Bruyn, Alex D Wodak, Joya Banerjee. (2011) Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. *Journal of the International AIDS Society* **14**:1, 49
[CrossRef](#)
- 697 Ram Yoge, Ellen Gould Chadwick. Acquired Immunodeficiency Syndrome (Human Immunodeficiency Virus). In: Nelson Textbook of Pediatrics. Elsevier, 2011:1157-1177.e1.

[CrossRef](#)

- 698 Brian Williams, Robin Wood, Victor Dukay, Wim Delva, David Ginsburg, John Hargrove, Martinus Stander, Robert Sheneberger, Julio Montaner, Alex Welte. (2011) Treatment as prevention: preparing the way. *Journal of the International AIDS Society* **14**:Suppl 1, S6
[CrossRef](#)

- 699 Michael , Nelson L. , . (2010) Oral Preexposure Prophylaxis for HIV — Another Arrow in the Quiver?. *New England Journal of Medicine* **363**:27, 2663-2665

[Free Full Text](#)[Comments \(8\)](#)[Newest](#) | [Oldest](#)

PAGE 1

Data by Profession and Location

[Newest](#) | [Oldest](#)

PAGE 1

[Letters](#)